<SEC-DOCUMENT>0001493152-21-024517.txt : 20211004
<SEC-HEADER>0001493152-21-024517.hdr.sgml : 20211004
<ACCEPTANCE-DATETIME>20211004164947
ACCESSION NUMBER:		0001493152-21-024517
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		32
CONFORMED PERIOD OF REPORT:	20210928
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211004
DATE AS OF CHANGE:		20211004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LifeMD, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39785
		FILM NUMBER:		211303561

	BUSINESS ADDRESS:	
		STREET 1:		800 THIRD AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(866) 351-5907

	MAIL ADDRESS:	
		STREET 1:		800 THIRD AVENUE, SUITE 2800
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CONVERSION LABS, INC.
		DATE OF NAME CHANGE:	20180622

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immudyne, Inc.
		DATE OF NAME CHANGE:	20120514

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:LFMD="http://lifemd.com/20210928">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_LFMD_lifemd.com_20210928 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20210928_20210928 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0000948320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityCentralIndexKey">0000948320</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lfmd-20210928.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-09-28to2021-09-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-28</xbrli:startDate>
        <xbrli:endDate>2021-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-28</xbrli:startDate>
        <xbrli:endDate>2021-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesPreferredStockStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-28</xbrli:startDate>
        <xbrli:endDate>2021-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_904_edei--DocumentType_c20210928__20210928_zkTdfgVUj8Ac"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of earliest event reported): <span id="xdx_900_edei--DocumentPeriodEndDate_c20210928__20210928_ziAmkdvLcuSl"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 28, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityRegistrantName_c20210928__20210928_zrFuEd6XFYC7"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityRegistrantName">LIFEMD,
INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210928__20210928_zWuP0PjeJAKj"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityFileNumber_c20210928__20210928_zIq5YU7BSd96"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityFileNumber">001-39785</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20210928__20210928_zCpPczYX7U67"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityTaxIdentificationNumber">76-0238453</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20210928__20210928_zQhdJkQJrnc2"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressAddressLine1">800
Third Avenue</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20210928__20210928_zm7ojJohJNqb"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressAddressLine2">Suite 2800</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityAddressCityOrTown_c20210928__20210928_zzuMIZAPqJSg"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20210928__20210928_zuou35rTf3j4"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20210928__20210928_zh4z9ULBh464"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:EntityAddressPostalZipCode">10022</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Address
of principal executive offices, including zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_901_edei--CityAreaCode_c20210928__20210928_zXqam08KjH5j"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:CityAreaCode">(866)</ix:nonNumeric></span>
<span id="xdx_905_edei--LocalPhoneNumber_c20210928__20210928_zTPFoyz5cOJ9"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" name="dei:LocalPhoneNumber">351-5907</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--WrittenCommunications_c20210928__20210928_z7lESr3lXhYl"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--SolicitingMaterial_c20210928__20210928_zWGU5HlDMpni"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementTenderOffer_c20210928__20210928_zYTkp8TL1709"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20210928__20210928_zTWbfKtsX3r9"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zn9q2f2MzJpa"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember" name="dei:Security12bTitle">Common
    Stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_z6lgdGyUpJ2e"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember" name="dei:TradingSymbol">LFMD</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_907_edei--SecurityExchangeName_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zvXOh4etwn21"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--Security12bTitle_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--SeriesPreferredStockStockParValue0.0001PerShareMember_zByRdW0rcred"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember" name="dei:Security12bTitle">Series
    A Preferred Stock Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--SeriesPreferredStockStockParValue0.0001PerShareMember_zL1hwCDmvbMl"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember" name="dei:TradingSymbol">LFMDP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_90B_edei--SecurityExchangeName_c20210928__20210928__us-gaap--StatementClassOfStockAxis__custom--SeriesPreferredStockStockParValue0.0001PerShareMember_z7s5qPUijD9a"><ix:nonNumeric contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Global Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20210928__20210928_zGEpJwFPklkk"><ix:nonNumeric contextRef="From2021-09-28to2021-09-28" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1.01 Entry Into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span>Common
Stock Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 28, 2021, LifeMD, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an underwriting agreement (the &#8220;Common
Underwriting Agreement&#8221;) with B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). Pursuant to the Common Underwriting Agreement,
the Company agreed to sell to B. Riley 3,833,334 shares of common stock (including 500,000 shares pursuant to B. Riley&#8217;s option) (the &#8220;Common Shares&#8221;), par value $0.01 per share, of the Company at a public offering price of $6.00
per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses (the &#8220;Common
Stock Offering&#8221;). The Common Shares in the Common Stock Offering were offered pursuant to a registration statement on Form S-3
(File No. 333-256911), which was declared effective by the Securities and Exchange Commission on June 22, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
net proceeds of the Common Stock Offering to the Company, after deducting the underwriting discounts and commissions, repayment of
debt and estimated offering expenses payable by the Company were approximately $16.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Common Underwriting Agreement also contains representations, warranties, indemnification and other provisions customary for transactions
of this nature. Pursuant to the Common Underwriting Agreement, the Company and its directors and executive officer have agreed, subject
to certain exceptions, not to offer, issue or sell any shares of common stock or securities convertible into or exercisable or exchangeable
for shares of common stock for a period of ninety (90) days following September 28, 2021 without the prior written consent of the B.
Riley.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing summary of the Common Underwriting Agreement does not purport to be complete and is subject to, and qualified in its entirety
by, such document, which is attached as Exhibit 1.1 hereto and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
copy of the opinion of Dorsey &amp; Whitney LLP relating to the legality of the issuance and sale of the Common Shares is attached as
Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i><span>Preferred
Stock Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 29, 2021, the Company entered into an underwriting agreement (the &#8220;Preferred Underwriting Agreement&#8221;) with B. Riley,
as representative of the several underwriters named therein (the &#8220;Representative&#8221;). Pursuant to the Preferred Underwriting
Agreement, the Company agreed to sell 1,400,000 shares of Series A Cumulative Perpetual Preferred Stock, (the &#8220;Preferred Shares&#8221;),
par value $0.0001 per share, of the Company (the &#8220;Series A Preferred Stock&#8221;) at a public offering price of $25.00 per share
of Series A Preferred Stock, prior to deducting underwriting discounts and commissions and estimated offering expenses (the &#8220;Preferred
Stock Offering&#8221;). In addition, the company granted the underwriters an option to purchase up to an additional 210,000 shares of
Series A Preferred Stock within 30 days following September 29, 2021. The Preferred Shares in the Preferred Stock Offering were offered
pursuant to a registration statement on Form S-3 (File No. 333-256911), which was declared effective by the Securities and Exchange Commission
on June 22, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
net proceeds of the Preferred Stock Offering to the Company, after deducting the underwriting discounts and commissions, the structuring
fee, repayment of debt and estimated offering expenses payable by the Company were approximately $22.9 million. This amends the
&#8220;Use of Proceeds&#8221; section of the Prospectus Supplement dated September 29, 2021 and filed October 1, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Preferred Underwriting Agreement also contains representations, warranties, indemnification and other provisions customary for transactions
of this nature. Pursuant to the Preferred Underwriting Agreement, the Company agreed, subject to certain exceptions, not to offer, issue
or sell any shares of Preferred Stock or securities convertible into or exercisable or exchangeable for shares of Series A Preferred
Stock for a period of thirty (30) days following September 29, 2021 without the prior written consent of the Representative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing summary of the Preferred Underwriting Agreement does not purport to be complete and is subject to, and qualified in its entirety
by, such document, which is attached as Exhibit 1.2 hereto and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
copy of the opinion of Dorsey &amp; Whitney LLP relating to the legality of the issuance and sale of the Preferred Shares is attached
as Exhibit 5.2 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor
shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
3.03 Material Modifications to Rights of Security Holders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the closing of the Preferred Stock Offering discussed in Item 1.01 above, on October 4, 2021, the
Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Cumulative Perpetual Preferred Stock
(the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware. The Certificate of Designation designated
a total of 1,610,000 shares of preferred stock as Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
set forth in the Certificate of Designation, the Series A Preferred Stock, as to dividend rights and rights upon the liquidation, dissolution
or winding-up of the Company, will rank (1) senior to all classes or series of the Corporation&#8217;s common stock and to all other
equity securities issued by the Corporation other than any equity securities issued with terms specifically providing that those equity
securities rank on a parity with the Series B Preferred Stock, (2) on parity with the Corporation&#8217;s Series B Preferred Stock, (3)
junior to all equity securities issued by the Corporation with terms specifically providing that those equity securities rank senior
to the Series A Preferred Stock with respect to the payment of dividends and the distribution of assets upon liquidation, dissolution
or winding up of the Corporation; and (4) effectively junior to all the Corporation&#8217;s existing and future indebtedness (including
indebtedness convertible into the Corporation&#8217;s common stock or preferred stock) and to the indebtedness and other liabilities
of (as well as any preferred equity interests held by others in) the Corporation&#8217;s existing or future subsidiaries. Holders of
Series A Preferred Stock, when and as authorized by the Company&#8217;s Board of Directors, are entitled to cumulative cash dividends
at the rate of 8.875% of the $25.00 liquidation preference per year (equivalent to $2.21875 per share per year). Dividends will be payable
quarterly in arrears, on or about the 15th of January, April, July and October, beginning on or about January 15, 2022. The Company,
at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time or from time to time, for cash, as follows:
(i) on and after October 15, 2022 but prior to October 15, 2023, at a redemption price of $25.75 per share, (ii) on and after October
15, 2023 but prior to October 15, 2024, at a redemption price of $25.50 per share, (iii) on and after October 15, 2024 but prior to October
15, 2025, at a redemption price of $25.25 per share, (iv) after October 15, 2025 at a redemption price of $25.00 per share, in each case,
plus any accrued and unpaid dividends. On and after October 15, 2025, the shares of Series A Preferred Stock will be redeemable at the
Company&#8217;s option, in whole or in part, at a redemption price equal to $25.00 per share, plus any accrued and unpaid dividends.
Furthermore, upon a change of control or delisting event (each as defined in the Certificate of Designation), the Company will have a
special option to redeem the Series A Preferred Stock at $25.00 per share, plus any accrued and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
description of the terms of the Series A Preferred Stock is qualified in its entirety by reference to the Certificate of Designation,
which is included as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
information relating to the Certificate of Designation set forth under Item 3.03 of this Current Report on Form 8-K is hereby incorporated
by reference into this Item 5.03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
7.01 Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 28, 2021, the Company issued a press release announcing the launch of the Common Stock Offering. A copy of the press release
is furnished as Exhibit 99.1 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 28, 2021, the Company issued a press release announcing the launch of the Preferred Stock Offering. A copy of the press release
is furnished as Exhibit 99.2 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 29, 2021, the Company issued a press release announcing the pricing of the Common Stock Offering. A copy of the press release
is furnished as Exhibit 99.3 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 30, 2021, the Company issued a press release announcing the pricing of the Preferred Stock Offering. A copy of the press release
is furnished as Exhibit 99.4 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 4, 2021, the Company issued a press release announcing the closing of the Common Stock Offering.
A copy of the press release is furnished as Exhibit 99.5 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 4, 2021, the Company issued a press release announcing the closing of the Preferred Stock Offering. A copy of the press release
is furnished as Exhibit 99.6 and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cautionary
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are
based on the Company&#8217;s current beliefs, assumptions and expectations regarding future events, which in turn are based on information
currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties.
Forward-looking statements include, without limitation, statements relating to projected industry growth rates, the Company&#8217;s current
growth rates and the Company&#8217;s present and future cash flow position. A variety of factors could cause actual events and results,
as well as the Company&#8217;s expectations, to differ materially from those expressed in or contemplated by the forward-looking statements.
Risk factors affecting the Company are discussed in detail in the Company&#8217;s filings with the SEC. The Company undertakes no obligation
to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except
to the extent required by applicable securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(d)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits<i>.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.05in; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex1-1.htm">Underwriting Agreement, dated as of September 28, 2021, by and between the Company and B. Riley Securities, Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">1.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex1-2.htm">Underwriting Agreement, dated as of September 29, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">1.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex1-3.htm">Certificate of Designation of Series A Preferred Stock</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm">Opinion of Dorsey &amp; Whitney LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-2.htm">Opinion of Dorsey &amp; Whitney LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Dorsey &amp; Whitney LLP to the filing of Exhibit 5.1 herewith (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">23.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Dorsey &amp; Whitney LLP to the filing of Exhibit 5.2 herewith (included in Exhibit 5.2)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm">Launch Press Release for Common Stock Offering dated September 28, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-2.htm">Launch Press Release for Preferred Stock Offering dated September 28, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-3.htm">Pricing Press Release for Common Stock Offering dated September 29, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-4.htm">Pricing Press Release for Preferred Stock Offering dated September 30, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-5.htm"><span style="font: 10pt Times New Roman, Times, Serif">Closing Press Release for Common Stock Offering dated October 4, 2021</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">99.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-6.htm">Closing Press Release for Preferred Stock Offering dated October 4, 2021</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIFEMD,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Dated:
    October 4, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Eric Yecies</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Eric
    Yecies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">General
    Counsel and Chief Compliance Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFkE1qwzAQhU+QOwymS+PILl3Uu9S0odQpJgmhW8WetCK2xoxktzlSb1lZ6g+EQIUYIWne954URXG0pAfVIsPL3bqELXZ9Ky3CGg/IqGt0HcXjUw5uXeOrMpaltn77IyzIadBpbpLbvTv3naMy2OSQirnI5lkKIsuvBVSraDbdF6QPqkFtlWxB6gYqpp4VWsmnQNjKD9LUnbzTDtko0g6XiHD9CZlIM3imUb4THw2UZRHNYj9m0ZJp6CebwVjq4L7FznmZIP2bPkrte/INOntT8fRsxmZjqT76UkneyXZAkQgh0gp58yYZV9jtkZ08FZlLsviOFSiwgF8QeEioMfSSYZxocBV40LsPNBPxQib3sR3p8xT/ZQiqy44X/L4A4LuZ3g== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,333,334
Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
28, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
28, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
                                            Riley Securities, Inc.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">299 Park Avenue, 21st Floor</TD></TR>
                                                                                   <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">New York, New York 100171</TD></TR>
                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several Underwriters named in Schedule
I hereto (the &ldquo;<B>Underwriters</B>&rdquo;) 3,333,334 shares of its common stock, par value $0.001 per share (the &ldquo;<B>Firm
Shares</B>&rdquo;). The Company also proposes to issue and sell to the several Underwriters not more than an additional 500,000 shares
of its common stock, par value $0.001 per share (the &ldquo;<B>Additional Shares</B>&rdquo;) if and to the extent that B. Riley Securities,
Inc. (&ldquo;<B>B. Riley Securities</B>&rdquo;), as representative of the Underwriters, shall have determined to exercise, on behalf
of the Underwriters, the right to purchase such Additional Shares granted to the Underwriters in Section 2 hereof. The Firm Shares and
the Additional Shares are hereinafter collectively referred to as the &ldquo;<B>Shares.</B>&rdquo; The shares of common stock, par value
$0.001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as
the &ldquo;<B>Common Stock.</B>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement on Form
S-3 (File No. 333-256911), including a preliminary prospectus supplement, relating to the Shares. The registration statement as amended
at the time it became effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness
pursuant to Rule 430A under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), is hereinafter referred
to as the &ldquo;<B>Registration Statement</B>&rdquo;. The prospectus in the form in which it was filed with the Commission in connection
with the initial filing of the Registration Statement is herein called the &ldquo;<B>Base Prospectus</B>.&rdquo; Each preliminary prospectus
supplement to the Base Prospectus (including the Base Prospectus as so supplemented) that described the Shares and omitted the Rule 430B
Information and that was used prior to the filing of the final prospectus supplement referred to in the following sentence is herein
called a &ldquo;<B>Preliminary Prospectus</B>.&rdquo; Promptly after the execution and delivery of this Agreement, the Company will prepare
and file with the Commission a final prospectus supplement to the Base Prospectus relating to the Shares in accordance with the provisions
of Rule 430B and Rule 424(b) of the Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so
supplemented), in the form filed with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the &ldquo;<B>Prospectus.</B>&rdquo;
If the Company has filed an abbreviated registration statement to register additional shares of Common Stock pursuant to Rule 462(b)
under the Securities Act (a &ldquo;<B>Rule 462 Registration Statement</B>&rdquo;), then any reference herein to the term &ldquo;<B>Registration
Statement</B>&rdquo; shall be deemed to include such Rule 462 Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule 405 under the Securities Act,
&ldquo;preliminary prospectus&rdquo; shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each
prospectus that omitted information pursuant to Rule 430A under the Securities Act that was used after such effectiveness and prior to
the execution and delivery of this Agreement, &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the preliminary prospectus contained
in the Registration Statement at the time of its effectiveness together with the documents and pricing information set forth in Schedule
II hereto, and &ldquo;<B>broadly available road show</B>&rdquo; means a &ldquo;bona fide electronic road show&rdquo; as defined in Rule
433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms &ldquo;Registration
Statement,&rdquo; &ldquo;preliminary prospectus,&rdquo; &ldquo;Time of Sale Prospectus&rdquo; and &ldquo;Prospectus&rdquo; shall include
the documents, if any, incorporated by reference therein as of the date hereof. The terms &ldquo;<B>supplement,</B>&rdquo; &ldquo;<B>amendment</B>&rdquo;
and &ldquo;<B>amend</B>&rdquo; as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus
or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange
Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), that are deemed to be incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Representations and Warranties. The Company represents and warrants to and agrees with each of the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and
no proceedings for such purpose or pursuant to Section 8A under the Securities Act are pending before or, to the Company&rsquo;s knowledge,
threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) (i)
Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus
or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations
of the Commission thereunder, (ii) the Registration Statement, when it became effective, did not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply and, as amended
or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations
of the Commission thereunder, (iv) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with
the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section 4), the
Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading, (v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading and (vi) the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties
set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the
Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through B. Riley
Securities expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Company is not an &ldquo;ineligible issuer&rdquo; in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities
Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will
be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the
Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for
the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to B. Riley
Securities before first use, the Company has not prepared, used or referred to, and will not, without B. Riley Securities&rsquo; prior
consent, prepare, use or refer to, any free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation,
has the corporate power and authority necessary to own or lease its property and to conduct its business as described in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing
in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except
to the extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Each
subsidiary of the Company has been duly incorporated, organized or formed, is validly existing as a corporation or other business entity
in good standing under the laws of the jurisdiction of its incorporation, organization or formation, has the corporate or other business
entity power and authority necessary to own or lease its property and to conduct its business as described in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the
extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse effect
on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary
of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly
by the Company, free and clear of all liens, encumbrances, equities or claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) This
Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) The
shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be validly
issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
any provision of applicable law or the Company&rsquo;s certificate of incorporation, as amended, or bylaws or any agreement or other
instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole,
or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and
no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required for the performance
by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various
states in connection with the offer and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) There
has not occurred any material adverse change, or any development that could reasonably be expected to result in a material adverse change,
in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a
whole, from that set forth in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) There
are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries
is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i) other than proceedings accurately
described in all material respects in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and proceedings
that would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or
on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated
by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii) that are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described; and there are no statutes, regulations,
contracts or other documents that are required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus
or to be filed as exhibits to the Registration Statement that are not described or filed as required, except, in each case, that would
not be reasonably expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) Each
preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed
pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable
rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) The
Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an &ldquo;investment
company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o) The
Company and each of its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations
relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(&ldquo;<B>Environmental Laws</B>&rdquo;), (ii) have received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit,
license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other
approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate,
have a material adverse effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p) There
are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints
on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q) There
are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company
to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to
include such securities with the Shares registered pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r) (i)
None of the Company or any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company&rsquo;s knowledge,
any agent, controlled affiliate or representative of the Company or of any of its subsidiaries, has taken any action in furtherance of
an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything
else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office) (&ldquo;<B>Government Official</B>&rdquo;)
in order to influence official action, or to any person in violation of any applicable anti-corruption laws; and (ii) the Company and
each of its subsidiaries have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained
policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties
contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s) The
operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with all applicable
financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and
the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit or proceeding by or before any court
or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t) (i)
None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company&rsquo;s knowledge, any
agent, controlled affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by one or more Persons that are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control,
the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively,
&ldquo;<B>Sanctions</B>&rdquo;), or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba,
Iran, North Korea and Syria).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions, except to the extent permitted for a Person required to comply with Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company and each of its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u) (i)
The Company and its subsidiaries own or have a valid license to all patents, inventions, copyrights, know how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and
trade names (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) reasonably necessary to the conduct of their businesses;
(ii) the Intellectual Property Rights owned by the Company and its subsidiaries and, to the Company&rsquo;s knowledge, the Intellectual
Property Rights licensed to the Company and its subsidiaries, are valid, subsisting and enforceable, and there is no pending or, to the
Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of
any such Intellectual Property Rights; (iii) neither the Company nor any of its subsidiaries has received any notice alleging any infringement,
misappropriation or other violation of Intellectual Property Rights which, singly or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole; (iv) to the
Company&rsquo;s knowledge, no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or
otherwise violated, any Intellectual Property Rights owned by the Company; (v) to the Company&rsquo;s knowledge, neither the Company
nor any of its subsidiaries infringes, misappropriates or otherwise violates, or has infringed, misappropriated or otherwise violated,
any Intellectual Property Rights; (vi) all employees or contractors engaged in the development of Intellectual Property Rights on behalf
of the Company or any subsidiary of the Company have executed an invention assignment agreement whereby such employees or contractors
presently assign all of their right, title and interest in and to such Intellectual Property Rights to the Company or the applicable
subsidiary, and to the Company&rsquo;s knowledge no such agreement has been breached or violated; and (vii) the Company and its subsidiaries
use, and have used, commercially reasonable efforts to appropriately maintain all information intended to be maintained as a trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) (i)
The Company and its subsidiaries use and have used, to the Company&rsquo;s knowledge, any and all software and other materials distributed
under a &ldquo;free,&rdquo; &ldquo;open source,&rdquo; or similar licensing model (including but not limited to the MIT License, Apache
License, GNU General Public License, GNU Lesser General Public License and GNU Affero General Public License) (&ldquo;<B>Open Source
Software</B>&rdquo;) in compliance with all license terms applicable to such Open Source Software; and (ii) to the Company&rsquo;s knowledge,
neither the Company nor any of its subsidiaries uses or distributes or has used or distributed any Open Source Software in any manner
that requires or has required (A) the Company or any of its subsidiaries to permit reverse engineering of any software code or other
technology owned by the Company or any of its subsidiaries or (B) any software code or other technology owned by the Company or any of
its subsidiaries to be (1) disclosed or distributed in source code form, (2) licensed for the purpose of making derivative works or (3)
redistributed at no charge, where such requirements would have a material adverse effect on the Company and its subsidiaries, taken as
a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w) (i)
The Company and each of its subsidiaries have complied and are presently in material compliance with all internal and external privacy
policies, contractual obligations, industry standards, applicable laws, statutes, judgments, orders, rules and regulations of any court
or arbitrator or other governmental or regulatory authority and any other legal obligations, in each case, relating to the collection,
use, transfer, import, export, storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personal, personally
identifiable, household, sensitive, confidential or regulated data (&ldquo;<B>Data Security Obligations</B>&rdquo;, and such data, &ldquo;<B>Data</B>&rdquo;);
(ii) the Company has not received any notification of or complaint regarding and is unaware of any other facts that, individually or
in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation; and (iii) there is no action, suit or proceeding
by or before any court or governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance
with any Data Security Obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) The
Company and each of its subsidiaries have taken all technical and organizational measures necessary to protect the information technology
systems and Data used in connection with the operation of the Company&rsquo;s and its subsidiaries&rsquo; businesses. Without limiting
the foregoing, the Company and its subsidiaries have used reasonable efforts to establish and maintain, and have established, maintained,
implemented and complied with, reasonable information technology, information security, cyber security and data protection controls,
policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster
recovery and security plans that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution, use,
access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any information technology system
or Data used in connection with the operation of the Company&rsquo;s and its subsidiaries&rsquo; businesses (&ldquo;<B>Breach</B>&rdquo;).
To the knowledge of the Company, there has been no such Breach except as would not reasonably be expected, singly or in the aggregate,
to have a Material Adverse Effect, and the Company and its subsidiaries have not been notified of and have no knowledge of any event
or condition that would reasonably be expected to result in, any such Breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y) The
Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date
of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, have
a material adverse effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon
(except for cases in which the failure to file or pay would not, singly or in the aggregate, have a material adverse effect on the Company
and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by generally
accepted accounting principles (&ldquo;<B>U.S. GAAP</B>&rdquo;) have been created in the financial statements of the Company), and no
tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor
does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to
be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect
on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z) The
financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting
requirements of the Securities Act and present fairly the consolidated financial position of the Company and its subsidiaries as of the
dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity
with U.S. GAAP applied on a consistent basis throughout the periods covered thereby except for any normal year-end adjustments in the
Company&rsquo;s quarterly financial statements. The other financial information included in each of the Registration Statement, the Time
of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and
presents fairly in all material respects the information shown thereby. The statistical, industry-related and market-related data included
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the
Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they
are derived, in each case in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa) Each
of Friedman LLP and BF Borgers CPA PC, who have certified certain financial statements of the Company and its subsidiaries and delivered
its report with respect to the audited consolidated financial statements and schedules filed with the Commission as part of the Registration
Statement and included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered
public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations
thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb) The
Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
is accurate. Since the end of the Company&rsquo;s most recent audited fiscal year, there has been (i) no material weakness in the Company&rsquo;s
internal control over financial reporting (whether or not remediated) and (ii) no change in the Company&rsquo;s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc) The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and
guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd) The
Company (i) has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications
with the consent of B. Riley Securities with entities that are reasonably believed to be qualified institutional buyers within the meaning
of Rule 144A under the Securities Act or institutions that are reasonably believed to be accredited investors within the meaning of Rule
501 under the Securities Act and (ii) has not authorized anyone other than B. Riley Securities to engage in Testing-the-Waters Communications.
The Company reconfirms that B. Riley Securities has been authorized to act on its behalf in undertaking Testing-the-Waters Communications.
The Company has not distributed any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under
the Securities Act. &ldquo;<B>Testing-the-Waters Communication</B>&rdquo; means any communication with potential investors undertaken
in reliance on Section 5(d) or Rule 163B of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee) As
of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers,
none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered together with the Time of Sale Prospectus,
and (C) any individual Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <I>Agreements
to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the
representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not
jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule I hereto opposite its name at $5.64
a share (the &ldquo;<B>Purchase Price</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees
to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly,
up to 500,000 Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional
Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not
payable on such Additional Shares. B. Riley Securities may exercise this right on behalf of the Underwriters in whole or from time to
time in part by giving written notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the
number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase
date must be at least one business day after the written notice is given and may not be earlier than the closing date for the Firm Shares
or later than ten business days after the date of such notice. Additional Shares may be purchased as provided in Section 4 hereof solely
for the purpose of covering sales of shares in excess of the number of the Firm Shares. On each day, if any, that Additional Shares are
to be purchased (an &ldquo;<B>Option Closing Date</B>&rdquo;), each Underwriter agrees, severally and not jointly, to purchase the number
of Additional Shares (subject to such adjustments to eliminate fractional shares as B. Riley Securities may determine) that bears the
same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set
forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <I>Terms
of Public Offering</I>. The Company is advised by B. Riley Securities that the Underwriters propose to make a public offering of their
respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in B. Riley Securities&rsquo;
judgment is advisable. The Company is further advised by B. Riley Securities that the Shares are to be offered to the public initially
at $6.00 a share (the &ldquo;<B>Public Offering Price</B>&rdquo;) and to certain dealers selected by B. Riley Securities at a price that
represents a concession not in excess of $0.216 a share under the Public Offering Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <I>Payment
and Delivery. </I>Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York
City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time,
on October 4, 2021, or at such other time on the same or such other date, not later than October 14, 2021, as shall be designated in
writing by B. Riley Securities. The time and date of such payment are hereinafter referred to as the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery
of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified
in the corresponding notice described in Section 2 or at such other time on the same or on such other date, in any event not later than
November 12, 2021, as shall be designated in writing by B. Riley Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Firm Shares and Additional Shares shall be registered in such names and in such denominations as B. Riley Securities shall request not
later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares
and Additional Shares shall be delivered to B. Riley Securities on the Closing Date or an Option Closing Date, as the case may be, for
the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to
the Underwriters duly paid, against payment of the Purchase Price therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <I>Conditions
to the Underwriters&rsquo; Obligations</I>. The several obligations of the Underwriters are subject to the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) no
order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to
Section 8A under the Securities Act shall be pending before or threatened by the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the
Company or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is defined
in Section 3(a)(62) of the Exchange Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Common Stock shall have been approved for listing on the Nasdaq Global Market; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) there
shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in
the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus
that, in B. Riley Securities&rsquo; judgment, is material and adverse and that makes it, in B. Riley Securities&rsquo; judgment, impracticable
to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the
Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties of
the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the
agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Dorsey &amp; Whitney LLP, outside counsel
for the Company, dated the Closing Date, each in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Duane Morris LLP, counsel for the Underwriters,
dated the Closing Date, with respect to the due authorization and valid issuance of the Common Stock, the Registration Statement, the
Prospectus and other related matters as B. Riley Securities may reasonably request, and such counsel shall have received such papers
and information as they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Underwriters, from each of Friedman LLP and BF Borgers CPA PC, independent
public accountants, containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the
Time of Sale Prospectus and the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a &ldquo;cut-off
date&rdquo; not earlier than the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The
Underwriters shall have received on the Closing Date such other documents as B. Riley Securities may reasonably request with respect
to the good standing of the Company, the due authorization and issuance of the Firm Shares and other matters related to the issuance
of the Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The
several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to B. Riley Securities on
the applicable Option Closing Date of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) an
opinion and negative assurance letter of Dorsey &amp; Whitney LLP, outside counsel for the Company, dated the Option Closing Date, relating
to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section
5(c) hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) an
opinion and negative assurance letter of Duane Morris LLP, counsel for the Underwriters, dated the Option Closing Date, relating to the
Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 5(d)
hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) a
letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from each of Friedman LLP and BF Borgers
CPA PC, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant
to Section 5(e) hereof; <I>provided</I> that the letter delivered on the Option Closing Date shall use a &ldquo;cut-off date&rdquo; not
earlier than two business days prior to such Option Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) such
other documents as B. Riley Securities may reasonably request with respect to the good standing of the Company, the due authorization
and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <I>Covenants
of the Company</I>. The Company covenants with each Underwriter as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) To
furnish or make available through EDGAR to B. Riley Securities, without charge, two signed copies of the Registration Statement (including
exhibits thereto and documents incorporated by reference) and for delivery to each other Underwriter a conformed copy of the Registration
Statement (without exhibits thereto but including documents incorporated by reference) and to furnish to B. Riley Securities in New York
City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during
the period mentioned in Section 6(e) below, as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated
by reference therein and any supplements and amendments thereto or to the Registration Statement as B. Riley Securities may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Before
amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to B. Riley Securities
a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which B. Riley Securities
reasonably objects, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) To
furnish to B. Riley Securities a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred
to by the Company and not to use or refer to any proposed free writing prospectus to which B. Riley Securities reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Not
to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d)
under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) If
the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective
purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or
condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement
then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus
to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and
to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to
a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) If,
during such period after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus
(or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with
sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel
for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses B. Riley Securities
will furnish to the Company) to which Shares may have been sold by B. Riley Securities on behalf of the Underwriters and to any other
dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented
will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities
Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) To
use its reasonable best efforts to list, effect and maintain, subject to notice of issuance, the Shares on the Nasdaq Global Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) To
endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as B. Riley Securities
shall reasonably request to the extent that exemptions from such qualification are not available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) To
make generally available to the Company&rsquo;s security holders and to B. Riley Securities as soon as practicable an earnings statement
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement
which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) Whether
or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all
expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of
the Company&rsquo;s counsel and the Company&rsquo;s accountants in connection with the registration and delivery of the Shares under
the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred
to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the
mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) all costs and
expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon,
(iii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares
under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities
laws as provided in Section 6(g) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters
in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all filing fees and the
reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering
of the Shares by the Financial Industry Regulatory Authority, (v) all costs and expenses incident to listing the Shares on the Nasdaq
Global Market, (vi) the cost of printing certificates representing the Shares, (vii) the costs and charges of any transfer agent, registrar
or depositary, (viii) the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken
in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation
or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses
of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging
expenses of the representatives and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection
with the road show, (ix) the reasonable fees and disbursements of counsel to the Underwriters in connection with the transactions contemplated
in this Agreement in an aggregate amount not to exceed $100,000 and (x) all other costs and expenses incident to the performance of the
obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that except
as provided in this Section, Section 8 entitled &ldquo;Indemnity and Contribution&rdquo; and the last paragraph of Section 10 below,
the Underwriters will pay all of their costs and expenses, including taxes payable on resale of any of the Common Stock by them and any
advertising expenses connected with any offers they may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) If
at any time following the distribution of any Testing-the-Waters Communication that is a written communication within the meaning of
Rule 405 under the Securities Act there occurred or occurs an event or development as a result of which such Testing-the-Waters Communication
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will
promptly notify B. Riley Securities and will promptly amend or supplement, at its own expense, such Testing-the-Waters Communication
to eliminate or correct such untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) The
Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed
Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company
undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification
of the foregoing Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also covenants with each Underwriter that, without the prior written consent of B. Riley Securities on behalf of the Underwriters,
it will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of the Prospectus (the &ldquo;<B>Restricted
Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or (2) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether
any such transaction described in clause 1 or 2 above is to be settled by delivery of Common Stock or such other securities, in cash
or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock. The restrictions contained in the foregoing sentence shall
not apply to (A) the Shares to be sold hereunder, (B) the issuance by the Company of shares of Common Stock upon the exercise of an option
or warrant or the conversion of a security outstanding on the date hereof as described in each of the Time of Sale Prospectus and Prospectus,
or (C) facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule
10b5-1 under the Exchange Act, for the transfer of shares of Common Stock, <I>provided</I> that (i) such plan does not provide for the
transfer of Common Stock during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act,
if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall
include a statement to the effect that no transfer of Common Stock may be made under such plan during the Restricted Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <I>Covenants
of the Underwriters</I>. Each Underwriter, severally and not jointly, covenants with the Company not to take any action that would result
in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <I>Indemnity
and Contribution.</I> (a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter
within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter
within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or
claim) that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any
issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed,
or is required to file, pursuant to Rule 433(d) under the Securities Act, any &ldquo;road show&rdquo; as defined in Rule 433(h) under
the Securities Act (a &ldquo;road show&rdquo;), the Prospectus or any amendment or supplement thereto, or any Testing-the-Waters Communication,
or arise out of, or are based upon, any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities arise out of,
or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity
with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through B. Riley Securities
expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters through B. Riley
Securities consists of the information described as such in paragraph (b) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section
20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to
information relating to such Underwriter furnished to the Company in writing by such Underwriter through B. Riley Securities expressly
for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road
show, or the Prospectus or any amendment or supplement thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 8(a) or 8(b), such person (the &ldquo;<B>indemnified party</B>&rdquo;) shall promptly notify the person
against whom such indemnity may be sought (the &ldquo;<B>indemnifying party</B>&rdquo;) in writing and the indemnifying party, upon request
of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and
any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have
mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include
both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due
to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in respect of the legal
expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the
fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such
fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by B. Riley Securities, in the case
of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The
indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from
and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated
by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any
proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying
party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such
request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party,
effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party
and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of
such indemnified party from all liability on claims that are the subject matter of such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) To
the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect
of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the allocation provided by clause 8(d)(i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with
the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares
(before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters,
in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares. The
relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Underwriters&rsquo; respective obligations to contribute pursuant
to this Section 8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined
by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any indemnified party at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The
indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of the Company
contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter
or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment
for any of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <I>Termination</I>.
The Underwriters may terminate this Agreement by notice given by B. Riley Securities to the Company, if after the execution and delivery
of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i) trading generally shall have
been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the Nasdaq
Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of
any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption
in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any moratorium on commercial banking
activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation
of hostilities, or any change in financial markets or any calamity or crisis that, in B. Riley Securities&rsquo; judgment, is material
and adverse and which, singly or together with any other event specified in this clause (v), makes it, in B. Riley Securities&rsquo;
judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated
in the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <I>Effectiveness;
Defaulting Underwriters</I>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase
Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased
on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite
their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting
Underwriters, or in such other proportions as B. Riley Securities may specify, to purchase the Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that
any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of
one-ninth of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more
than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to B. Riley Securities
and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate
without liability on the part of any non-defaulting Underwriter or the Company. In any such case either B. Riley Securities or the Company
shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if
any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be
effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate
number of Additional Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Additional Shares
to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their obligation
hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii) purchase not less than the number of Additional
Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default. Any action taken under
this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company
to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform
its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement
with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably
incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <I>Entire
Agreement</I>. (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent
not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and
the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct
of the offering, and the purchase and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Company acknowledges that in connection with the offering of the Shares: (i) the Underwriters have acted at arms length, are not agents
of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations
set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent not superseded by this
Agreement), if any, and (iii) the Underwriters may have interests that differ from those of the Company. The Company waives to the full
extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in
connection with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <I>Recognition
of the U.S. Special Resolution Regimes</I>. (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section a &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and
shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &ldquo;<B>Covered Entity</B>&rdquo; means any of the following: (i)
a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered
bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<B>Default Right</B>&rdquo; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.
&ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <I>Counterparts</I>.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <I>Applicable
Law</I>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <I>Headings</I>.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <I>Notices.
</I>All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to B. Riley Securities at 299 Park Avenue, 21<SUP>st</SUP> Floor, New York, New York 10171, Attention: General Counsel; and if
to the Company shall be delivered, mailed or sent to 800 Third Avenue, Suite 2800, New York, New York 10022, Attention: Justin Schreiber.
An electronic communication (&ldquo;Electronic Notice&rdquo;) shall be deemed written notice for purposes of this Section 16 if sent
to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the
time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party receiving Electronic Notice
may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;Nonelectronic Notice&rdquo;) which
shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
    INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Marc Benathen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Marc Benathen</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">CFO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
    as of the date hereof</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.
    RILEY SECURITIES, INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
    severally on behalf of themselves and the several Underwriters named in Schedule I hereto.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. Riley Securities,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Patrice McNicoll</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Patrice McNicoll</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Co-Head of Investment Banking</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to LifeMD, Inc. Common Stock Underwriting Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Firm Shares To Be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">B. Riley Securities, Inc.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">3,333,334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt">Total:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,333,334</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
of Sale Prospectus</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Firm
Shares: 3,333,334</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Option
Shares: 500,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Price
to Public: $6.00 per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Underwriters&rsquo;
Discount: $0.36 per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>ex1-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
1.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,400,000
Shares</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.875% Series A Cumulative Perpetual Preferred
Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
                                            Riley Securities, Inc.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">299 Park Avenue, 21st Floor</TD></TR>
                                                                                   <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">New York, New York 100171</TD></TR>
                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">LifeMD, Inc., a Delaware corporation (the
&ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several Underwriters named in Schedule&nbsp;I hereto (the &ldquo;<B>Underwriters</B>&rdquo;)
1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share and liquidation preference of
$25.00 per share (the &ldquo;<B>Firm Shares</B>&rdquo;). The Company also proposes to issue and sell to the several Underwriters not more
than an additional 210,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share and liquidation
preference of $25.00 per share (the &ldquo;<B>Additional Shares</B>&rdquo;) if and to the extent that B. Riley Securities, Inc. (&ldquo;<B>B.
Riley Securities</B>&rdquo;), as representative of the Underwriters, shall have determined to exercise, on behalf of the Underwriters,
the right to purchase such Additional Shares granted to the Underwriters in Section&nbsp;</FONT><FONT STYLE="font-size: 12pt">&lrm;</FONT><FONT STYLE="font-size: 10pt">2
hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &ldquo;<B>Shares.</B>&rdquo; The shares
of 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share and liquidation preference of $25.00 per share, of
the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &ldquo;<B>Preferred
Stock.</B>&rdquo; The shares of the Common Stock, par value $0.01 per share, of the Company are hereinafter referred to as the &ldquo;<B>Common
Stock</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a registration statement on Form
S-3 (File No. 333-256911), including a preliminary prospectus supplement, relating to the Shares. The registration statement as amended
at the time it became effective, including the information (if any) deemed to be part of the registration statement at the time of effectiveness
pursuant to Rule 430A under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), is hereinafter referred
to as the &ldquo;<B>Registration Statement</B>&rdquo;. The prospectus in the form in which it was filed with the Commission in connection
with the initial filing of the Registration Statement is herein called the &ldquo;<B>Base Prospectus</B>.&rdquo; Each preliminary prospectus
supplement to the Base Prospectus (including the Base Prospectus as so supplemented) that described the Shares and omitted the Rule 430B
Information and that was used prior to the filing of the final prospectus supplement referred to in the following sentence is herein
called a &ldquo;<B>Preliminary Prospectus</B>.&rdquo; Promptly after the execution and delivery of this Agreement, the Company will prepare
and file with the Commission a final prospectus supplement to the Base Prospectus relating to the Shares in accordance with the provisions
of Rule 430B and Rule 424(b) of the Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so
supplemented), in the form filed with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the &ldquo;<B>Prospectus.</B>&rdquo;
If the Company has filed an abbreviated registration statement to register additional shares of Preferred Stock pursuant to Rule 462(b)
under the Securities Act (a &ldquo;<B>Rule 462 Registration Statement</B>&rdquo;), then any reference herein to the term &ldquo;<B>Registration
Statement</B>&rdquo; shall be deemed to include such Rule 462 Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule 405 under the Securities Act,
&ldquo;preliminary prospectus&rdquo; shall mean each prospectus used prior to the effectiveness of the Registration Statement, and each
prospectus that omitted information pursuant to Rule 430A under the Securities Act that was used after such effectiveness and prior to
the execution and delivery of this Agreement, &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the preliminary prospectus contained
in the Registration Statement at the time of its effectiveness together with the documents and pricing information set forth in Schedule
II hereto, and &ldquo;<B>broadly available road show</B>&rdquo; means a &ldquo;bona fide electronic road show&rdquo; as defined in Rule
433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms &ldquo;Registration
Statement,&rdquo; &ldquo;preliminary prospectus,&rdquo; &ldquo;Time of Sale Prospectus&rdquo; and &ldquo;Prospectus&rdquo; shall include
the documents, if any, incorporated by reference therein as of the date hereof. The terms &ldquo;<B>supplement,</B>&rdquo; &ldquo;<B>amendment</B>&rdquo;
and &ldquo;<B>amend</B>&rdquo; as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus
or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange
Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), that are deemed to be incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Representations and Warranties. The Company represents and warrants to and agrees with each of the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Registration Statement has become effective; no stop order suspending the effectiveness of the Registration Statement is in effect, and
no proceedings for such purpose or pursuant to Section 8A under the Securities Act are pending before or, to the Company&rsquo;s knowledge,
threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) (i)
Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Time of Sale Prospectus
or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations
of the Commission thereunder, (ii) the Registration Statement, when it became effective, did not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (iii) the Registration Statement and the Prospectus comply and, as amended
or supplemented, if applicable, will comply in all material respects with the Securities Act and the applicable rules and regulations
of the Commission thereunder, (iv) the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with
the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in Section 4), the
Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading, (v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading and (vi) the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties
set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale Prospectus or the
Prospectus based upon information relating to any Underwriter furnished to the Company in writing by such Underwriter through B. Riley
Securities expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Company is not an &ldquo;ineligible issuer&rdquo; in connection with the offering pursuant to Rules 164, 405 and 433 under the Securities
Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will
be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the
Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for
the free writing prospectuses, if any, identified in Schedule II hereto, and electronic road shows, if any, each furnished to B. Riley
Securities before first use, the Company has not prepared, used or referred to, and will not, without B. Riley Securities&rsquo; prior
consent, prepare, use or refer to, any free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation,
has the corporate power and authority necessary to own or lease its property and to conduct its business as described in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing
in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except
to the extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Each
subsidiary of the Company has been duly incorporated, organized or formed, is validly existing as a corporation or other business entity
in good standing under the laws of the jurisdiction of its incorporation, organization or formation, has the corporate or other business
entity power and authority necessary to own or lease its property and to conduct its business as described in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus and is duly qualified to transact business and is in good standing in each
jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the
extent that the failure to be so qualified or be in good standing would not, singly or in the aggregate, have a material adverse effect
on the Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock or other equity interests of each subsidiary
of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly
by the Company, free and clear of all liens, encumbrances, equities or claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) This
Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) The
shares of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Shares have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will be
validly issued, fully paid and non-assessable, and the issuance of the Shares will not be subject to any preemptive or similar rights.
</FONT>The Shares, when issued, will conform in all material respects to the description thereof contained in each of the Registration
Statement, the Time of Sale Prospectus and the Prospectus, and will entitle the holders of the Shares to the rights and benefits provided
therein and in the Certificate of Designation of the 8.875% Series A Cumulative Perpetual Preferred Stock of LifeMD, Inc. (the &ldquo;<B>COD</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement will not contravene
any provision of applicable law or the Company&rsquo;s certificate of incorporation, as amended, or bylaws or any agreement or other
instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole,
or any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and
no consent, approval, authorization or order of, or qualification with, any governmental body, agency or court is required for the performance
by the Company of its obligations under this Agreement, except such as may be required by the securities or Blue Sky laws of the various
states in connection with the offer and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) There
has not occurred any material adverse change, or any development that could reasonably be expected to result in a material adverse change,
in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a
whole, from that set forth in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) There
are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries
is a party or to which any of the properties of the Company or any of its subsidiaries is subject (i) other than proceedings accurately
described in all material respects in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus and proceedings
that would not, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole, or
on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated
by each of the Registration Statement, the Time of Sale Prospectus and the Prospectus or (ii) that are required to be described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus and are not so described; and there are no statutes, regulations,
contracts or other documents that are required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus
or to be filed as exhibits to the Registration Statement that are not described or filed as required, except, in each case, that would
not be reasonably expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) Each
preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment thereto, or filed
pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities Act and the applicable
rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) The
Company is not, and after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register as an &ldquo;investment
company&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o) The
Company and each of its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations
relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(&ldquo;<B>Environmental Laws</B>&rdquo;), (ii) have received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit,
license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other
approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate,
have a material adverse effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p) There
are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints
on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a material adverse
effect on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q) There
are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company
to file a registration statement under the Securities Act with respect to any securities of the Company or to require the Company to
include such securities with the Shares registered pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r) (i)
None of the Company or any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company&rsquo;s knowledge,
any agent, controlled affiliate or representative of the Company or of any of its subsidiaries, has taken any action in furtherance of
an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything
else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned
or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office) (&ldquo;<B>Government Official</B>&rdquo;)
in order to influence official action, or to any person in violation of any applicable anti-corruption laws; and (ii) the Company and
each of its subsidiaries have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained
policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties
contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s) The
operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with all applicable
financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and
the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit or proceeding by or before any court
or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t) (i)
None of the Company, any of its subsidiaries, or any director, officer, or employee thereof, or, to the Company&rsquo;s knowledge, any
agent, controlled affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by one or more Persons that are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control,
the United Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively,
&ldquo;<B>Sanctions</B>&rdquo;), or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba,
Iran, North Korea and Syria).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding
or facilitation, is the subject of Sanctions, except to the extent permitted for a Person required to comply with Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company and each of its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u) (i)
The Company and its subsidiaries own or have a valid license to all patents, inventions, copyrights, know how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and
trade names (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;) reasonably necessary to the conduct of their businesses;
(ii) the Intellectual Property Rights owned by the Company and its subsidiaries and, to the Company&rsquo;s knowledge, the Intellectual
Property Rights licensed to the Company and its subsidiaries, are valid, subsisting and enforceable, and there is no pending or, to the
Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of
any such Intellectual Property Rights; (iii) neither the Company nor any of its subsidiaries has received any notice alleging any infringement,
misappropriation or other violation of Intellectual Property Rights which, singly or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would have a material adverse effect on the Company and its subsidiaries, taken as a whole; (iv) to the
Company&rsquo;s knowledge, no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or
otherwise violated, any Intellectual Property Rights owned by the Company; (v) to the Company&rsquo;s knowledge, neither the Company
nor any of its subsidiaries infringes, misappropriates or otherwise violates, or has infringed, misappropriated or otherwise violated,
any Intellectual Property Rights; (vi) all employees or contractors engaged in the development of Intellectual Property Rights on behalf
of the Company or any subsidiary of the Company have executed an invention assignment agreement whereby such employees or contractors
presently assign all of their right, title and interest in and to such Intellectual Property Rights to the Company or the applicable
subsidiary, and to the Company&rsquo;s knowledge no such agreement has been breached or violated; and (vii) the Company and its subsidiaries
use, and have used, commercially reasonable efforts to appropriately maintain all information intended to be maintained as a trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) (i)
The Company and its subsidiaries use and have used, to the Company&rsquo;s knowledge, any and all software and other materials distributed
under a &ldquo;free,&rdquo; &ldquo;open source,&rdquo; or similar licensing model (including but not limited to the MIT License, Apache
License, GNU General Public License, GNU Lesser General Public License and GNU Affero General Public License) (&ldquo;<B>Open Source
Software</B>&rdquo;) in compliance with all license terms applicable to such Open Source Software; and (ii) to the Company&rsquo;s knowledge,
neither the Company nor any of its subsidiaries uses or distributes or has used or distributed any Open Source Software in any manner
that requires or has required (A) the Company or any of its subsidiaries to permit reverse engineering of any software code or other
technology owned by the Company or any of its subsidiaries or (B) any software code or other technology owned by the Company or any of
its subsidiaries to be (1) disclosed or distributed in source code form, (2) licensed for the purpose of making derivative works or (3)
redistributed at no charge, where such requirements would have a material adverse effect on the Company and its subsidiaries, taken as
a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w) (i)
The Company and each of its subsidiaries have complied and are presently in material compliance with all internal and external privacy
policies, contractual obligations, industry standards, applicable laws, statutes, judgments, orders, rules and regulations of any court
or arbitrator or other governmental or regulatory authority and any other legal obligations, in each case, relating to the collection,
use, transfer, import, export, storage, protection, disposal and disclosure by the Company or any of its subsidiaries of personal, personally
identifiable, household, sensitive, confidential or regulated data (&ldquo;<B>Data Security Obligations</B>&rdquo;, and such data, &ldquo;<B>Data</B>&rdquo;);
(ii) the Company has not received any notification of or complaint regarding and is unaware of any other facts that, individually or
in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation; and (iii) there is no action, suit or proceeding
by or before any court or governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance
with any Data Security Obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x) The
Company and each of its subsidiaries have taken all technical and organizational measures necessary to protect the information technology
systems and Data used in connection with the operation of the Company&rsquo;s and its subsidiaries&rsquo; businesses. Without limiting
the foregoing, the Company and its subsidiaries have used reasonable efforts to establish and maintain, and have established, maintained,
implemented and complied with, reasonable information technology, information security, cyber security and data protection controls,
policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster
recovery and security plans that are designed to protect against and prevent breach, destruction, loss, unauthorized distribution, use,
access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any information technology system
or Data used in connection with the operation of the Company&rsquo;s and its subsidiaries&rsquo; businesses (&ldquo;<B>Breach</B>&rdquo;).
To the knowledge of the Company, there has been no such Breach except as would not reasonably be expected, singly or in the aggregate,
to have a Material Adverse Effect, and the Company and its subsidiaries have not been notified of and have no knowledge of any event
or condition that would reasonably be expected to result in, any such Breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y) The
Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date
of this Agreement or have requested extensions thereof (except where the failure to file would not, singly or in the aggregate, have
a material adverse effect on the Company and its subsidiaries, taken as a whole) and have paid all taxes required to be paid thereon
(except for cases in which the failure to file or pay would not, singly or in the aggregate, have a material adverse effect on the Company
and its subsidiaries, taken as a whole, or, except as currently being contested in good faith and for which reserves required by generally
accepted accounting principles (&ldquo;<B>U.S. GAAP</B>&rdquo;) have been created in the financial statements of the Company), and no
tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate, has had (nor
does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to
be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect
on the Company and its subsidiaries, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z) The
financial statements included or incorporated by reference in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, together with the related schedules and notes thereto, comply as to form in all material respects with the applicable accounting
requirements of the Securities Act and present fairly the consolidated financial position of the Company and its subsidiaries as of the
dates shown and its results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity
with U.S. GAAP applied on a consistent basis throughout the periods covered thereby except for any normal year-end adjustments in the
Company&rsquo;s quarterly financial statements. The other financial information included in each of the Registration Statement, the Time
of Sale Prospectus and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and
presents fairly in all material respects the information shown thereby. The statistical, industry-related and market-related data included
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the
Company reasonably and in good faith believes are reliable and accurate and such data is consistent with the sources from which they
are derived, in each case in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa) Each
of Friedman LLP and BF Borgers CPA PC, who have certified certain financial statements of the Company and its subsidiaries and delivered
its report with respect to the audited consolidated financial statements and schedules filed with the Commission as part of the Registration
Statement and included in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered
public accounting firm with respect to the Company within the meaning of the Securities Act and the applicable rules and regulations
thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb) The
Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
is accurate. Since the end of the Company&rsquo;s most recent audited fiscal year, there has been (i) no material weakness in the Company&rsquo;s
internal control over financial reporting (whether or not remediated) and (ii) no change in the Company&rsquo;s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc) The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and
guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd) The
Company (i) has not alone engaged in any Testing-the-Waters Communication with any person other than Testing-the-Waters Communications
with the consent of B. Riley Securities with entities that are reasonably believed to be qualified institutional buyers within the meaning
of Rule 144A under the Securities Act or institutions that are reasonably believed to be accredited investors within the meaning of Rule
501 under the Securities Act and (ii) has not authorized anyone other than B. Riley Securities to engage in Testing-the-Waters Communications.
The Company reconfirms that B. Riley Securities has been authorized to act on its behalf in undertaking Testing-the-Waters Communications.
The Company has not distributed any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under
the Securities Act. &ldquo;<B>Testing-the-Waters Communication</B>&rdquo; means any communication with potential investors undertaken
in reliance on Section 5(d) or Rule 163B of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee) As
of the time of each sale of the Shares in connection with the offering when the Prospectus is not yet available to prospective purchasers,
none of (A) the Time of Sale Prospectus, (B) any free writing prospectus, when considered together with the Time of Sale Prospectus,
and (C) any individual Testing-the-Waters Communication, when considered together with the Time of Sale Prospectus, included, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <I>Agreements
to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the
representations and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not
jointly, to purchase from the Company the respective numbers of Firm Shares set forth in Schedule I hereto opposite its name at $23.9375
a share (the &ldquo;<B>Purchase Price</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the basis of the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees
to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not jointly,
up to 210,000 Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional
Shares shall be reduced by an amount per share equal to any dividends declared by the Company and payable on the Firm Shares but not
payable on such Additional Shares. B. Riley Securities may exercise this right on behalf of the Underwriters in whole or from time to
time in part by giving written notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the
number of Additional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase
date must be at least one business day after the written notice is given and may not be earlier than the closing date for the Firm Shares
or later than ten business days after the date of such notice. Additional Shares may be purchased as provided in Section 4 hereof solely
for the purpose of covering sales of shares in excess of the number of the Firm Shares. On each day, if any, that Additional Shares are
to be purchased (an &ldquo;<B>Option Closing Date</B>&rdquo;), each Underwriter agrees, severally and not jointly, to purchase the number
of Additional Shares (subject to such adjustments to eliminate fractional shares as B. Riley Securities may determine) that bears the
same proportion to the total number of Additional Shares to be purchased on such Option Closing Date as the number of Firm Shares set
forth in Schedule I hereto opposite the name of such Underwriter bears to the total number of Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <I>Terms
of Public Offering</I>. The Company is advised by B. Riley Securities that the Underwriters propose to make a public offering of their
respective portions of the Shares as soon after the Registration Statement and this Agreement have become effective as in B. Riley Securities&rsquo;
judgment is advisable. The Company is further advised by B. Riley Securities that the Shares are to be offered to the public initially
at $25.00 a share (the &ldquo;<B>Public Offering Price</B>&rdquo;) and to certain dealers selected by B. Riley Securities at a price that
represents a concession not in excess of $0.6375 a share under the Public Offering Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <I>Payment
and Delivery. </I>Payment for the Firm Shares shall be made to the Company in Federal or other funds immediately available in New York
City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time,
on October 4, 2021, or at such other time on the same or such other date, not later than October 14, 2021, as shall be designated in
writing by B. Riley Securities. The time and date of such payment are hereinafter referred to as the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against delivery
of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified
in the corresponding notice described in Section 2 or at such other time on the same or on such other date, in any event not later than
November 12, 2021, as shall be designated in writing by B. Riley Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Firm Shares and Additional Shares shall be registered in such names and in such denominations as B. Riley Securities shall request not
later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares
and Additional Shares shall be delivered to B. Riley Securities on the Closing Date or an Option Closing Date, as the case may be, for
the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer of the Shares to
the Underwriters duly paid, against payment of the Purchase Price therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <I>Conditions
to the Underwriters&rsquo; Obligations</I>. The several obligations of the Underwriters are subject to the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) no
order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to
Section 8A under the Securities Act shall be pending before or threatened by the Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any of the securities of the
Company or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is defined
in Section 3(a)(62) of the Exchange Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Preferred Stock shall have been approved for listing on the Nasdaq Global Market; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) there
shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in
the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus
that, in B. Riley Securities&rsquo; judgment, is material and adverse and that makes it, in B. Riley Securities&rsquo; judgment, impracticable
to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Underwriters shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer of the
Company, to the effect set forth in Sections 5(a)(i) and 5(a)(ii) above and to the effect that the representations and warranties of
the Company contained in this Agreement are true and correct as of the Closing Date and that the Company has complied with all of the
agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Dorsey &amp; Whitney LLP, outside counsel
for the Company, dated the Closing Date, each in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Underwriters shall have received on the Closing Date an opinion and negative assurance letter of Duane Morris LLP, counsel for the Underwriters,
dated the Closing Date, with respect to the due authorization and valid issuance of the Preferred Stock, the Registration Statement, the
Prospectus and other related matters as B. Riley Securities may reasonably request, and such counsel shall have received such papers
and information as they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Underwriters shall have received, on each of the date hereof and the Closing Date, a letter dated the date hereof or the Closing Date,
as the case may be, in form and substance satisfactory to the Underwriters, from each of Friedman LLP and BF Borgers CPA PC, independent
public accountants, containing statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo;
to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the
Time of Sale Prospectus and the Prospectus; <I>provided</I> that the letter delivered on the Closing Date shall use a &ldquo;cut-off
date&rdquo; not earlier than the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The
Underwriters shall have received on the Closing Date such other documents as B. Riley Securities may reasonably request with respect
to the good standing of the Company, the due authorization and issuance of the Firm Shares and other matters related to the issuance
of the Firm Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The
several obligations of the Underwriters to purchase Additional Shares hereunder are subject to the delivery to B. Riley Securities on
the applicable Option Closing Date of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) a
certificate, dated the Option Closing Date and signed by an executive officer of the Company, confirming that the certificate delivered
on the Closing Date pursuant to Section 5(b) hereof remains true and correct as of such Option Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) an
opinion and negative assurance letter of Dorsey &amp; Whitney LLP, outside counsel for the Company, dated the Option Closing Date, relating
to the Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section
5(c) hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) an
opinion and negative assurance letter of Duane Morris LLP, counsel for the Underwriters, dated the Option Closing Date, relating to the
Additional Shares to be purchased on such Option Closing Date and otherwise to the same effect as the opinion required by Section 5(d)
hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) a
letter dated the Option Closing Date, in form and substance satisfactory to the Underwriters, from each of Friedman LLP and BF Borgers
CPA PC, independent public accountants, substantially in the same form and substance as the letter furnished to the Underwriters pursuant
to Section 5(e) hereof; <I>provided</I> that the letter delivered on the Option Closing Date shall use a &ldquo;cut-off date&rdquo; not
earlier than two business days prior to such Option Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v) such
other documents as B. Riley Securities may reasonably request with respect to the good standing of the Company, the due authorization
and issuance of the Additional Shares to be sold on such Option Closing Date and other matters related to the issuance of such Additional
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Prior to the Closing Date, the Board of Directors of the Company shall adopt the COD and establishing the rights, preferences and entitlements
thereof, which shall conform in all material respects to the description thereof in the Registration Statement, the Time of Sale Prospectus
and the Prospectus. The Company shall file such COD with the Secretary of State of the State of Delaware, accompanied by all fees required
to be paid therewith, and cause the COD to become effective on or prior to the Closing Date.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To furnish or make available through EDGAR to B. Riley Securities, without charge, 10 signed copies of the Registration
Statement (including exhibits thereto and documents incorporated by reference) and for delivery to each other Underwriter a
conformed copy of the Registration Statement (without exhibits thereto but including documents incorporated by reference) and to
furnish to B. Riley Securities in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next
succeeding the date of this Agreement and during the period mentioned in Section 6(f) or 6(f) below, as many copies of the Time of
Sale Prospectus, the Prospectus, any documents incorporated by reference therein and any supplements and amendments thereto or to
the Registration Statement as B. Riley Securities may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Before
amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus, to furnish to B. Riley Securities
a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which B. Riley Securities
reasonably objects, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) To
furnish to B. Riley Securities a copy of each proposed free writing prospectus to be prepared by or on behalf of, used by, or referred
to by the Company and not to use or refer to any proposed free writing prospectus to which B. Riley Securities reasonably objects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Not
to take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d)
under the Securities Act a free writing prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) If
the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time when the Prospectus is not yet available to prospective
purchasers and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or if any event shall occur or
condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement
then on file, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus
to comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and
to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to
a prospective purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) If,
during such period after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters the Prospectus
(or in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is required by law to be delivered in connection with
sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement
the Prospectus in order to make the statements therein, in the light of the circumstances when the Prospectus (or in lieu thereof the
notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion of counsel
for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable law, forthwith to prepare, file
with the Commission and furnish, at its own expense, to the Underwriters and to the dealers (whose names and addresses B. Riley Securities
will furnish to the Company) to which Shares may have been sold by B. Riley Securities on behalf of the Underwriters and to any other
dealers upon request, either amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented
will not, in the light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of the Securities
Act) is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) To
use its reasonable best efforts to list, effect and maintain, subject to notice of issuance, the Shares on the Nasdaq Global Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) To
endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as B. Riley Securities
shall reasonably request to the extent that exemptions from such qualification are not available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) To
make generally available to the Company&rsquo;s security holders and to B. Riley Securities as soon as practicable an earnings statement
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement
which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) Whether
or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid all
expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of
the Company&rsquo;s counsel and the Company&rsquo;s accountants in connection with the registration and delivery of the Shares under
the Securities Act and all other fees or expenses in connection with the preparation and filing of the Registration Statement, any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred
to by the Company and amendments and supplements to any of the foregoing, including all printing costs associated therewith, and the
mailing and delivering of copies thereof to the Underwriters and dealers, in the quantities hereinabove specified, (ii) all costs and
expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon,
(iii) the cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the offer and sale of the Shares
under state securities laws and all expenses in connection with the qualification of the Shares for offer and sale under state securities
laws as provided in Section 6(i) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters
in connection with such qualification and in connection with the Blue Sky or Legal Investment memorandum, (iv) all filing fees and the
reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and qualification of the offering
of the Shares by the Financial Industry Regulatory Authority, (v) all costs and expenses incident to listing the Shares on the Nasdaq
Global Market, (vi) the cost of printing certificates representing the Shares, (vii) the costs and charges of any transfer agent, registrar
or depositary, (viii) the costs and expenses of the Company relating to investor presentations on any &ldquo;road show&rdquo; undertaken
in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation
or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses
of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging
expenses of the representatives and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection
with the road show, (ix) the reasonable fees and disbursements of counsel to the Underwriters in connection with the transactions contemplated
in this Agreement in an aggregate amount not to exceed $125,000 and (x) all other costs and expenses incident to the performance of the
obligations of the Company hereunder for which provision is not otherwise made in this Section. It is understood, however, that except
as provided in this Section, Section 8 entitled &ldquo;Indemnity and Contribution&rdquo; and the last paragraph of Section 10 below,
the Underwriters will pay all of their costs and expenses, including taxes payable on resale of any of the Preferred Stock by them and any
advertising expenses connected with any offers they may make.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) If
at any time following the distribution of any Testing-the-Waters Communication that is a written communication within the meaning of
Rule 405 under the Securities Act there occurred or occurs an event or development as a result of which such Testing-the-Waters Communication
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will
promptly notify B. Riley Securities and will promptly amend or supplement, at its own expense, such Testing-the-Waters Communication
to eliminate or correct such untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m) The
Company will deliver to each Underwriter (or its agent), on the date of execution of this Agreement, a properly completed and executed
Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company
undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification
of the foregoing Certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also covenants with each Underwriter that, without the prior written consent of B. Riley Securities on behalf of the Underwriters,
it will not, and will not publicly disclose an intention to, during the period ending 30 days after the date of the Prospectus (the &ldquo;<B>Restricted
Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of Preferred Stock or any securities convertible into or exercisable or exchangeable for Preferred Stock, or (2) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Preferred Stock, whether
any such transaction described in clause 1 or 2 above is to be settled by delivery of Preferred Stock or such other securities, in cash
or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Preferred Stock or any
securities convertible into or exercisable or exchangeable for Preferred Stock. The restrictions contained in the foregoing sentence shall
not apply to (A) the Shares to be sold hereunder, (B) the issuance by the Company of shares of Preferred Stock upon the exercise of an option
or warrant or the conversion of a security outstanding on the date hereof as described in each of the Time of Sale Prospectus and Prospectus,
or (C) facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule
10b5-1 under the Exchange Act, for the transfer of shares of Preferred Stock, <I>provided</I> that (i) such plan does not provide for the
transfer of Preferred Stock during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act,
if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall
include a statement to the effect that no transfer of Preferred Stock may be made under such plan during the Restricted Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <I>Covenants
of the Underwriters</I>. Each Underwriter, severally and not jointly, covenants with the Company not to take any action that would result
in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such
Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <I>Indemnity
and Contribution.</I> (a) The Company agrees to indemnify and hold harmless each Underwriter, each person, if any, who controls any Underwriter
within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act and each affiliate of any Underwriter
within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or
claim) that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement or any amendment thereof, any preliminary prospectus, the Time of Sale Prospectus or any amendment or supplement thereto, any
issuer free writing prospectus as defined in Rule 433(h) under the Securities Act, any Company information that the Company has filed,
or is required to file, pursuant to Rule 433(d) under the Securities Act, any &ldquo;road show&rdquo; as defined in Rule 433(h) under
the Securities Act (a &ldquo;road show&rdquo;), the Prospectus or any amendment or supplement thereto, or any Testing-the-Waters Communication,
or arise out of, or are based upon, any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities arise out of,
or are based upon, any such untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity
with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through B. Riley Securities
expressly for use therein, it being understood and agreed that the only such information furnished by the Underwriters through B. Riley
Securities consists of the information described as such in paragraph (b) below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who sign the Registration
Statement and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section
20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such Underwriter, but only with reference to
information relating to such Underwriter furnished to the Company in writing by such Underwriter through B. Riley Securities expressly
for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus, road
show, or the Prospectus or any amendment or supplement thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 8(a) or 8(b), such person (the &ldquo;<B>indemnified party</B>&rdquo;) shall promptly notify the person
against whom such indemnity may be sought (the &ldquo;<B>indemnifying party</B>&rdquo;) in writing and the indemnifying party, upon request
of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and
any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have
mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include
both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due
to actual or potential differing interests between them. It is understood that the indemnifying party shall not, in respect of the legal
expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the
fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified parties and that all such
fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by B. Riley Securities, in the case
of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The
indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from
and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated
by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any
proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying
party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such
request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party,
effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party
and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of
such indemnified party from all liability on claims that are the subject matter of such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) To
the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect
of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of indemnifying
such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if the allocation provided by clause 8(d)(i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with
the offering of the Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Shares
(before deducting expenses) received by the Company and the total underwriting discounts and commissions received by the Underwriters,
in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the Shares. The
relative fault of the Company on the one hand and the Underwriters on the other hand shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Underwriters&rsquo; respective obligations to contribute pursuant
to this Section 8 are several in proportion to the respective number of Shares they have purchased hereunder, and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were determined
by <I>pro rata</I> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the
limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available
to any indemnified party at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The
indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements of the Company
contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement,
(ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any affiliate of any Underwriter
or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment
for any of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <I>Termination</I>.
The Underwriters may terminate this Agreement by notice given by B. Riley Securities to the Company, if after the execution and delivery
of this Agreement and prior to or on the Closing Date or any Option Closing Date, as the case may be, (i) trading generally shall have
been suspended or materially limited on, or by, as the case may be, any of the New York Stock Exchange, the NYSE American, the Nasdaq
Global Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of
any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption
in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any moratorium on commercial banking
activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation
of hostilities, or any change in financial markets or any calamity or crisis that, in B. Riley Securities&rsquo; judgment, is material
and adverse and which, singly or together with any other event specified in this clause (v), makes it, in B. Riley Securities&rsquo;
judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms and in the manner contemplated
in the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <I>Effectiveness;
Defaulting Underwriters</I>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
on the Closing Date or an Option Closing Date, as the case may be, any one or more of the Underwriters shall fail or refuse to purchase
Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase is not more than one-tenth of the aggregate number of the Shares to be purchased
on such date, the other Underwriters shall be obligated severally in the proportions that the number of Firm Shares set forth opposite
their respective names in Schedule I bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting
Underwriters, or in such other proportions as B. Riley Securities may specify, to purchase the Shares which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase on such date; <I>provided</I> that in no event shall the number of Shares that
any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant to this Section 10 by an amount in excess of
one-ninth of such number of Shares without the written consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters
shall fail or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which such default occurs is more
than one-tenth of the aggregate number of Firm Shares to be purchased on such date, and arrangements satisfactory to B. Riley Securities
and the Company for the purchase of such Firm Shares are not made within 36 hours after such default, this Agreement shall terminate
without liability on the part of any non-defaulting Underwriter or the Company. In any such case either B. Riley Securities or the Company
shall have the right to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if
any, in the Registration Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be
effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to purchase Additional Shares and the aggregate
number of Additional Shares with respect to which such default occurs is more than one-tenth of the aggregate number of Additional Shares
to be purchased on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i) terminate their obligation
hereunder to purchase the Additional Shares to be sold on such Option Closing Date or (ii) purchase not less than the number of Additional
Shares that such non-defaulting Underwriters would have been obligated to purchase in the absence of such default. Any action taken under
this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company
to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform
its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement
with respect to themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably
incurred by such Underwriters in connection with this Agreement or the offering contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <I>Entire
Agreement</I>. (a) This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent
not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and
the Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct
of the offering, and the purchase and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Company acknowledges that in connection with the offering of the Shares: (i) the Underwriters have acted at arms length, are not agents
of, and owe no fiduciary duties to, the Company or any other person, (ii) the Underwriters owe the Company only those duties and obligations
set forth in this Agreement, any contemporaneous written agreements and prior written agreements (to the extent not superseded by this
Agreement), if any, and (iii) the Underwriters may have interests that differ from those of the Company. The Company waives to the full
extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in
connection with the offering of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <I>Recognition
of the U.S. Special Resolution Regimes</I>. (a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under
this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section a &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and
shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k). &ldquo;<B>Covered Entity</B>&rdquo; means any of the following: (i)
a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered
bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b). &ldquo;<B>Default Right</B>&rdquo; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.
&ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <I>Counterparts</I>.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <I>Applicable
Law</I>. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <I>Headings</I>.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <I>Notices.
</I>All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to B. Riley Securities at 299 Park Avenue, 21<SUP>st</SUP> Floor, New York, New York 10171, Attention: General Counsel; and if
to the Company shall be delivered, mailed or sent to 800 Third Avenue, Suite 2800, New York, New York 10022, Attention: Justin Schreiber.
An electronic communication (&ldquo;Electronic Notice&rdquo;) shall be deemed written notice for purposes of this Section 16 if sent
to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the
time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party receiving Electronic Notice
may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;Nonelectronic Notice&rdquo;) which
shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
    INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Marc Benathen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Marc Benathen</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">CFO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
    as of the date hereof</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.
    RILEY SECURITIES, INC.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
    severally on behalf of themselves and the several Underwriters named in Schedule I hereto.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. Riley Securities,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Patrice McNicoll</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Patrice McNicoll</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Co-Head of Investment Banking</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Firm Shares To Be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">B. Riley Securities, Inc.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">927,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Ladenburg Thalmann &amp; Co. Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Colliers Securities LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">EF Hutton, division of Benchmark Investments, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Aegis Capital Corp.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">The Benchmark Company, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Boenning &amp; Scattergood, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chapin Davis Investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">B.C. Ziegler &amp; Company</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">73,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 2.5pt">Total:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,400,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
of Sale Prospectus</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
of Sale: 5:30 pm New York City time, on September 29, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
Free Writing Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 433</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-256911</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,400,000
Shares of 8.875% Series A Cumulative Perpetual Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(Liquidation
Amount of $25.00 Per Share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Final
Term Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
    Inc</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.875%
    Series A Cumulative Perpetual Preferred Stock (the &ldquo;Series A Preferred Stock&rdquo;)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,400,000
    Shares of Series A Preferred Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    to Purchase Additional Shares:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 210,000 Shares Series A Preferred Stock</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    4, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Nasdaq &ldquo;LFMDP&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Size:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$35,000,000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to $5,250,000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
    Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perpetual
    (unless redeemed by us on or after October 15, 2022 or in connection with a change of control or delisting event).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rating:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Series A Preferred Stock will not be rated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Rate (Cumulative):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will pay cumulative cash dividends on the Series A Preferred Stock, when and as declared by our Board of Directors, at the rate of
    8.875% of the $25.00 liquidation preference per year, equivalent to $2.21875.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Payment Dates:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    will be payable quarterly in arrears, on or about the 15th day of January, April, July and October, beginning on or about January
    15, 2022; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable
    on that dividend payment date may be paid on the next succeeding business day, and no interest, additional dividends or other sums
    will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance, which is expected
    to be October 4, 2021. The first dividend, which is scheduled to be paid on or about January 15, 2022 in the amount of $0.622483
    per share, will be for more than a full quarter and will cover the period from, and including, the first date we issue and sell the
    Series A Preferred Stock through, but not including, January 15, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    to the Public:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
    Count:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30/360</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation
    Preference:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    liquidation preference of each share of Series A Preferred Stock is $25.00. Upon liquidation, holders of Series A Preferred Stock
    will be entitled to receive the liquidation preference with respect to their shares of Series A Preferred Stock plus an amount equal
    to accumulated but unpaid dividends with respect to such shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
    Redemption:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    and after October 15, 2022 and prior to October 15, 2023, the shares of Series A Preferred Stock will be redeemable at our option,
    in whole or in part, at a redemption price equal to $25.75 per Preferred Share, plus any accrued and unpaid dividends up to, but
    not including, the date of redemption. On and after October 15, 2023 and prior to October 15, 2024, the shares of Series A Preferred
    Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.50 per Preferred Share, plus any
    accrued and unpaid dividends up to, but not including, the date of redemption. On and after October 15, 2024 and prior to and prior
    to October 15, 2025, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption
    price equal to $25.25 per Preferred Share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.
    On and after October 15, 2025, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a
    redemption price equal to $25.00 per Preferred Share, plus any accrued and unpaid dividends up to, but not including, the date of
    redemption. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined herein), we may, subject
    to certain conditions, at our option, redeem the Series A Preferred Stock, in whole or in part within 90 days after the first date
    on which such Delisting Event occurred or within 120 days after the first date on which such Change of Control occurred, as applicable,
    by paying $25.00 per share, plus any accumulated and unpaid dividends up to, but not including, the redemption date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
    Optional Redemption Upon a Change of Control or Delisting Event:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
    optional redemption by the Company upon a change of control or delisting event, in whole or in part, for $25.00 per share, plus accrued
    but unpaid dividends, to, but not including, the redemption date (the &ldquo;Redemption Right&rdquo;). The circumstances that will
    constitute a &ldquo;change of control&rdquo; and a &ldquo;delisting event&rdquo; will be set forth in the documents governing the
    Series A Preferred Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
    Conversion Right Upon a Change of Control or Delisting Event:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the occurrence of a change of control or delisting event, in the event the Company does not exercise the Redemption Right, holders
    of the Series A Preferred Stock will have the right to convert some or all of the Series A Preferred Stock held by such holder into
    a number of common shares at a predetermined ratio.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DRD/QDI
    Eligible:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
    Denomination / Multiples:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25.00/$25.00</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP/ISIN:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53216B
    203 / US53216B2034</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    Book-Runners:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities, Inc., Ladenburg Thalmann &amp; Co. Inc., Colliers Securities LLC and EF Hutton, division of Benchmark Investments,
    LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Managers:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aegis
    Capital Corp., The Benchmark Company, LLC, Boenning &amp; Scattergood, Inc., Chapin Davis Investments and B.C. Ziegler &amp; Company</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict
    of Interest:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities, Inc. has a &ldquo;conflict of interest&rdquo; in this offering within the meaning of Rule 5121 of the Financial
    Industry Regulatory Authority (&ldquo;FINRA&rdquo;). Accordingly, this offering will be made in compliance with the applicable provisions
    of FINRA Rule 5121(a)(2), which requires that a &ldquo;qualified independent underwriter&rdquo; as defined in FINRA Rule 5121(f)(5),
    participate in the preparation of the registration statement and prospectus and exercise its usual standards for due diligence in
    respect thereto. EF Hutton, division of Benchmark Investments, LLC has agreed to act as the qualified independent underwriter for
    this offering and has agreed in so acting to undertake the legal responsibilities and liabilities of an underwriter under the Securities
    Act, specifically including those inherent in Section 11 thereof. EF Hutton, division of Benchmark Investments, LLC will not receive
    a fee for acting as the qualified independent underwriter for this offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
communication is intended for the sole use of the person to whom it is provided by the issuer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuer has filed a registration statement (including a base prospectus dated June 22, 2021) and a preliminary prospectus supplement dated
September 28, 2021 with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) for the offering to which this communication relates.
Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC
for more complete information about the issuer and this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
may get these documents for free by visiting EDGAR on the SEC Web site at <I>www.sec.gov. </I>Alternatively, the issuer, any underwriter
or any dealer participating in the offering will arrange to send you the prospectus and related preliminary prospectus supplement if
you request them from B. Riley Securities, Inc. at 1300 17th Street, Suite 1300, Arlington, VA 22209, or by calling (703) 312-9580, or
by emailing <U>prospectuses@brileyfin.com</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANY
DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS
OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIABLOOMBERG OR ANOTHER E-MAIL SYSTEM.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.3
<SEQUENCE>4
<FILENAME>ex1-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATE
OF DESIGNATION<BR>
OF<BR>
8.875% SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK<BR>
OF<BR>
LIFEMD, INC.<BR>
<BR>
Pursuant to the General Corporation Law of the State of Delaware</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), hereby certifies, that pursuant to the authority expressly vested
in the Board of Directors of the Corporation (the &ldquo;<U>Board</U>&rdquo;) by the Certificate of Incorporation of the Corporation
(as amended, restated or otherwise modified from time to time, the &ldquo;<U>Certificate of Incorporation</U>&rdquo;), the Board has
duly adopted the following resolutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RESOLVED,
that, pursuant to authority expressly set forth in the Certificate of Incorporation, a series of preferred stock, par value $0.0001 per
share (the &ldquo;<U>Preferred Stock</U>&rdquo;) to be known as the &ldquo;8.875% Series A Cumulative Perpetual Preferred Stock&rdquo;
be, and it hereby is, created, and that the designation and number of shares of such series, and the voting and other powers, preferences
and relative, participating, optional or other rights, and the qualifications, limitations and restrictions thereof are as set forth
in the Certificate of Incorporation and this Certificate of Designation (as amended, restated or otherwise modified from time to time,
this &ldquo;<U>Certificate of Designation</U>&rdquo;) as set forth on Exhibit A hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Certificate of Designation is executed on behalf of the Corporation by its Chief Financial Officer this 4th day
of October, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Marc Benathen</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
    Benathen</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A<BR>
TO<BR>
CERTIFICATE OF DESIGNATION<BR>
OF<BR>
8.875% SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK<BR>
OF<BR>
LIFEMD, INC.</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1. <U>Designation and Number</U></B></FONT>. The designation of the series of preferred stock shall be 8.875% Series A Cumulative Perpetual
Preferred Stock, par value $0.0001 per share (hereinafter referred to as the &ldquo;<U>Series A Preferred Stock</U>&rdquo;). Each share
of Series A Preferred Stock shall be identical in all respects to every other share of Series A Preferred Stock. The number of authorized
shares of Series A Preferred Stock shall be 1,610,000. Such number may from time to time be increased (but not in excess of the total
number of authorized shares of preferred stock) or decreased (but not below the number of shares of Series A Preferred Stock then outstanding)
by further resolution duly adopted by the Board of Directors of the Corporation or any duly authorized committee of the Board of Directors
of the Corporation and by the filing of a certificate pursuant to the provisions of the Delaware General Corporation Law stating that
such increase or reduction, as the case may be, has been so authorized. The Corporation shall have the authority to issue fractional
shares of Series A Preferred Stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2. <U>Rank</U></B></FONT><B>.</B> The Series A Preferred Stock will, as to dividend rights and rights upon liquidation, dissolution or
winding-up of the Corporation, rank (1) senior to all classes or series of the Corporation&rsquo;s common stock and to all other equity
securities issued by the Corporation other than any equity securities issued with terms specifically providing that those equity securities
rank on a parity with the Series B Preferred Stock, (2) on parity with the Corporation&rsquo;s Series B Preferred Stock, (3) junior to
all equity securities issued by the Corporation with terms specifically providing that those equity securities rank senior to the Series
A Preferred Stock with respect to the payment of dividends and the distribution of assets upon liquidation, dissolution or winding up
of the Corporation; and (4) effectively junior to all the Corporation&rsquo;s existing and future indebtedness (including indebtedness
convertible into the Corporation&rsquo;s common stock or preferred stock) and to the indebtedness and other liabilities of (as well as
any preferred equity interests held by others in) the Corporation&rsquo;s existing or future subsidiaries.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3. <U>Dividends.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the preferential rights of the holders of any class or series of capital stock of the Corporation ranking senior to the Series
A Preferred Stock as to dividend rights, the holders of shares of the Series A Preferred Stock shall be entitled to receive, when, as
and if authorized by the Board of Directors and declared by the Corporation, out of funds legally available for the payment of dividends,
cumulative cash dividends at the rate of 8.875% per annum of the $25.00 liquidation preference per share of the Series A Preferred Stock.
Such dividends shall accrue and be cumulative from and including the first date on which any shares of Series A Preferred Stock are issued
(the &ldquo;<U>Original Issue Date</U>&rdquo;), or, if later, the most recent Dividend Payment Date (as defined below) to which dividends
have been paid in full (or declared and the corresponding Dividend Record Date (as defined below) for determining stockholders entitled
to payment thereof has passed), and shall be payable quarterly in arrears on each Dividend Payment Date, commencing on or about January
15, 2022; <U>provided</U>, <U>however</U>, that if any Dividend Payment Date is not a Business Day (as defined below), then the dividend
which would otherwise have been payable on such Dividend Payment Date may be paid, at the Corporation&rsquo;s option, on either the immediately
preceding Business Day or the next succeeding Business Day, except that, if such Business Day is in the next succeeding calendar year,
such payment shall be made on the immediately preceding Business Day, in each case with the same force and effect as if paid on such
Dividend Payment Date, and no interest or additional dividends or other sums shall accrue on the amount so payable from such Dividend
Payment Date to such next succeeding Business Day; <U>provided</U>, <U>further</U>, that no dividends shall accrue on any share of Series
A Preferred Stock for any Dividend Period (as defined below) having a Dividend Record Date (as defined below) before the date such share
of Series A Preferred Stock was issued. The amount of any dividend payable on the Series A Preferred Stock for any period greater or
less than a full Dividend Period shall be prorated and computed on the basis of a 360-day year consisting of twelve 30-day months. Dividends
will be payable to holders of record as they appear in the stockholder records of the Corporation at the close of business on the applicable
Dividend Record Date. Notwithstanding any provision to the contrary contained herein, each holder of an outstanding share of Series A
Preferred Stock shall be entitled to receive a dividend with respect to any Dividend Record Date equal to the dividend paid with respect
to each other share of Series A Preferred Stock that is outstanding on such date. &ldquo;<U>Dividend Record Date</U>&rdquo; shall mean
the date designated by the Board of Directors for the payment of dividends that is not more than 30 or fewer than 10 days prior to the
applicable Dividend Payment Date. &ldquo;<U>Dividend Payment Date</U>&rdquo; shall mean the 15th calendar day of each January, April,
July and October commencing on January 15, 2022. &ldquo;<U>Dividend Period</U>&rdquo; shall mean the respective periods commencing on
the 15th day of January, April, July and October of each year and ending on and including the day preceding the first day of the next
succeeding Dividend Period (other than the initial Dividend Period, which shall commence on the Original Issue Date and end on but exclude
January 15, 2022, and other than the Dividend Period during which any shares of Series A Preferred Stock shall be redeemed pursuant to
Section 5 or Section 6 hereof, which shall end on and include the day preceding the redemption date with respect to the shares of Series
A Preferred Stock being redeemed).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<U>Business Day</U>&rdquo; shall mean any day, other than a Saturday or Sunday, that is neither a federal holiday nor a day
on which banking institutions in New York City are authorized or required by law, regulation or executive order to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding anything contained herein to the contrary, dividends on the Series A Preferred Stock shall accrue whether or not the
Corporation has earnings, whether or not there are funds legally available for the payment of such dividends, and whether or not such
dividends are authorized or declared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
Except as provided in Section 3(d) or 3(f) below, no dividends shall be declared and paid or declared and set apart for payment, and
no other distribution of cash or other property may be declared and made, directly or indirectly, on or with respect to any shares of
Common Stock or shares of any other class or series of capital stock of the Corporation ranking, as to dividends, on parity with or junior
to the Series A Preferred Stock for any period, nor shall any shares of Common Stock or any other shares of any other class or series
of capital stock of the Corporation ranking, as to payment of dividends and the distribution of assets upon the Corporation&rsquo;s liquidation,
dissolution or winding up, on parity with or junior to the Series A Preferred Stock be redeemed, purchased or otherwise acquired for
any consideration, nor shall any funds be paid or made available for a sinking fund for the redemption of such shares, and no other distribution
of cash or other property may be made, directly or indirectly, on or with respect thereto by the Corporation, unless full cumulative
dividends on the Series A Preferred Stock for all past Dividend Periods shall have been or contemporaneously are (i) declared and paid
or (ii) declared and a sum sufficient for the payment thereof is set apart for such payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as provided in Section 3(f) below, when dividends are not paid in full (or declared and a sum sufficient for such full payment
is not so set apart) on the Series A Preferred Stock and the shares of any other class or series of capital stock ranking, as to dividends,
on parity with the Series A Preferred Stock, all dividends declared upon the Series A Preferred Stock and each such other class or series
of capital stock ranking, as to dividends, on parity with the Series A Preferred Stock (which, for the avoidance of doubt, shall not
include the redemption or repurchase of shares of any such class or series) shall be declared <I>pro rata</I> so that the amount of dividends
declared per share of Series A Preferred Stock and such other class or series of capital stock shall in all cases bear to each other
the same ratio that accrued dividends per share on the Series A Preferred Stock and such other class or series of capital stock (which
shall not include any accrual in respect of unpaid dividends on such other class or series of capital stock for prior Dividend Periods
if such other class or series of capital stock does not have a cumulative dividend) bear to each other. No interest, or sum of money
in lieu of interest, shall be payable in respect of any dividend payment or payments on the Series A Preferred Stock which may be in
arrears.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Holders of shares of Series A Preferred Stock shall not be entitled to any dividend, whether payable in cash, property or shares of capital
stock, in excess of full cumulative dividends on the Series A Preferred Stock as provided herein. Any dividend payment made on the Series
A Preferred Stock shall first be credited against the earliest accrued but unpaid dividends due with respect to such shares which remain
payable. Accrued but unpaid dividends on the Series A Preferred Stock will accrue as of the Dividend Payment Date on which they first
become payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Notwithstanding the provisions of this Section 3 or Sections 5 or 6 and regardless of whether dividends are paid in full (or declared
and a sum sufficient for such full payment is not so set apart) on the Series A Preferred Stock or the shares of any other class or series
of capital stock ranking, as to dividends, on parity with the Series A Preferred Stock for any or all Dividend Periods, the Corporation
shall not be prohibited or limited from (i) paying dividends on any shares of stock of the Corporation in shares of Common Stock or in
shares of any other class or series of capital stock ranking junior to the Series A Preferred Stock as to payment of dividends and the
distribution of assets upon the Corporation&rsquo;s liquidation, dissolution and winding up, (ii) converting or exchanging any shares
of stock of the Corporation for shares of any other class or series of capital stock of the Corporation ranking junior to the Series
A Preferred Stock as to payment of dividends and the distribution of assets upon the Corporation&rsquo;s liquidation, dissolution and
winding up, or (iii) purchasing or acquiring shares of Series A Preferred Stock pursuant to a purchase or exchange offer made on the
same terms to holders of all outstanding shares of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4. <U>Liquidation Preference.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, before any distribution or payment shall
be made to holders of shares of Common Stock or any other class or series of capital stock of the Corporation ranking, as to rights upon
any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, junior to the Series A Preferred Stock, the holders
of shares of Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation legally available for distribution
to its stockholders, after payment of or provision for the debts and other liabilities of the Corporation and any class or series of
capital stock of the Corporation ranking, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, senior to the Series A Preferred Stock, a liquidation preference of $25.00 per share, plus an amount equal to any accrued
and unpaid dividends (whether or not authorized or declared) up to but excluding the date of payment. In the event that, upon such voluntary
or involuntary liquidation, dissolution or winding up, the available assets of the Corporation are insufficient to pay the full amount
of the liquidating distributions on all outstanding shares of Series A Preferred Stock and the corresponding amounts payable on all shares
of other classes or series of capital stock of the Corporation ranking, as to rights upon the Corporation&rsquo;s liquidation, dissolution
or winding up, on parity with the Series A Preferred Stock in the distribution of assets, then the holders of the Series A Preferred
Stock and each such other class or series of capital stock ranking, as to rights upon any voluntary or involuntary liquidation, dissolution
or winding up, on parity with the Series A Preferred Stock shall share ratably in any such distribution of assets in proportion to the
full liquidating distributions to which they would otherwise be respectively entitled. Written notice of any such voluntary or involuntary
liquidation, dissolution or winding up of the Corporation, stating the payment date or dates when, and the place or places where, the
amounts distributable in such circumstances shall be payable, shall be given not fewer than 30 or more than 60 days prior to the payment
date stated therein, to each record holder of shares of Series A Preferred Stock at the respective addresses of such holders as the same
shall appear on the stock transfer records of the Corporation. After payment of the full amount of the liquidating distributions to which
they are entitled, the holders of Series A Preferred Stock will have no right or claim to any of the remaining assets of the Corporation.
The consolidation, merger or conversion of the Corporation with or into any other corporation, trust or entity, or the voluntary sale,
lease, transfer or conveyance of all or substantially all of the property or business of the Corporation, shall not be deemed to constitute
a liquidation, dissolution or winding up of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In determining whether a distribution (other than upon voluntary or involuntary liquidation), by dividend, redemption or other acquisition
of shares of capital stock of the Corporation or otherwise, is permitted under the Delaware General Corporation Law, amounts that would
be needed, if the Corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution
of holders of shares of Series A Preferred Stock shall not be added to the Corporation&rsquo;s total liabilities.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5. <U>Redemption.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to Section 6(a) below, the Corporation, at its option, upon notice in accordance with Section 5(d), may redeem the Series A Preferred
Stock, in whole or in part, at any time or from time to time, for cash, as follows: (i) on and after October 15, 2022 but prior to October
15, 2023, at a redemption price of $25.75 per share, (ii) on and after October 15, 2023 but prior to October 15, 2024, at a redemption
price of $25.50 per share, (iii) on and after October 15, 2024 but prior to October 15, 2025, at a redemption price of $25.25 per share,
(iv) after October 15, 2025 at a redemption price of $25.00 per share, in each case, plus any accrued and unpaid dividends (whether or
not authorized or declared) thereon up to but not including the date fixed for redemption, without interest, to the extent the Corporation
has funds legally available therefor (the &ldquo;<U>Optional Redemption Right</U>&rdquo;) .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On or after October 15, 2025, the Corporation, at its option, upon notice in accordance with Section 5(d), may redeem the Series A Preferred
Stock, in whole or in part, at any time or from time to time, for cash at a redemption price of $25.00 per share, plus, subject to Section
5(e), all accrued and unpaid dividends (whether or not authorized or declared) thereon up to but not including the date fixed for redemption,
without interest, to the extent the Corporation has funds legally available therefor (together with the Optional Redemption Right described
in Section 5(a) above, the &ldquo;<U>Redemption Right</U>&rdquo;). If fewer than all of the outstanding shares of Series A Preferred
Stock are to be redeemed pursuant to this Section 5(b), the shares of Series A Preferred Stock to be redeemed shall be redeemed pro rata
(as nearly as may be practicable without creating fractional shares) or by lot as determined by the Corporation. Holders of Series A
Preferred Stock to be redeemed shall surrender such Series A Preferred Stock at the place, or in accordance with the book-entry procedures,
designated in such notice and shall be entitled to the redemption price of $25.00 per share and any accrued and unpaid dividends payable
upon such redemption following such surrender. If (i) notice of redemption of any shares of Series A Preferred Stock has been given (in
the case of a redemption of the Series A Preferred Stock), (ii) the funds necessary for such redemption have been set aside by the Corporation
for the benefit of the holders of any shares of Series A Preferred Stock so called for redemption, and (iii) irrevocable instructions
have been given to pay the redemption price and all accrued and unpaid dividends, then from and after the redemption date, dividends
shall cease to accrue on such shares of Series A Preferred Stock, such shares of Series A Preferred Stock shall no longer be deemed outstanding,
and all rights of the holders of such shares shall terminate, except the right to receive the redemption price plus any accrued and unpaid
dividends payable upon such redemption, without interest. So long as full cumulative dividends on the Series A Preferred Stock and any
class or series of parity Preferred Stock for all past Dividend Periods shall have been or contemporaneously are (i) declared and paid,
or (ii) declared and a sum sufficient for the payment thereof is set apart for payment, nothing herein shall prevent or restrict the
Corporation&rsquo;s right or ability to purchase, from time to time, either at a public or a private sale, all or any part of the Series
A Preferred Stock or its common stock at such price or prices as the Corporation may determine, subject to the provisions of applicable
law, including the repurchase of shares of Series A Preferred Stock or its common stock in open-market transactions duly authorized by
the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as provided in Section 3(f) above, unless full cumulative dividends on the Series A Preferred Stock for all past Dividend Periods
shall have been or contemporaneously are (i) declared and paid in cash, or (ii) declared and a sum sufficient for the payment thereof
in cash is set apart for payment, no shares of Series A Preferred Stock shall be redeemed pursuant to the Redemption Right or Special
Optional Redemption Right (defined below) unless all outstanding shares of Series A Preferred Stock are simultaneously redeemed, and
the Corporation shall not purchase or otherwise acquire directly or indirectly any shares of Series A Preferred Stock or any class or
series of capital stock of the Corporation ranking, as to payment of dividends and the distribution of assets upon liquidation, dissolution
or winding up of the Corporation, on parity with or junior to the Series A Preferred Stock (except by conversion into or exchange for
shares of capital stock of the Corporation ranking, as to payment of dividends and the distribution of assets upon liquidation, dissolution
or winding up of the Corporation, junior to the Series A Preferred Stock); provided, however, that the foregoing shall not prevent the
purchase of Series A Preferred Stock, or any other class or series of capital stock of the Corporation ranking, as to payment of dividends
and the distribution of assets upon liquidation, dissolution or winding up of the Corporation, on parity with or junior to the Series
A Preferred Stock, by the Corporation pursuant to the provisions of Article IV of the Certificate of Incorporation or Sections 5 and
9 of this Certificate of Designation or any comparable provision of the Certificate of Incorporation relating to any class or series
of capital stock hereinafter classified and designated, or the purchase or acquisition of Series A Preferred Stock pursuant to a purchase
or exchange offer made on the same terms to holders of all outstanding shares of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notice of redemption pursuant to the Redemption Right will be mailed by the Corporation, postage prepaid, not fewer than 30 or more than
60 days prior to the redemption date, addressed to the respective holders of record of the Series A Preferred Stock to be redeemed at
their respective addresses as they appear on the stock transfer records of the Corporation. No failure to give or defect in such notice
shall affect the validity of the proceedings for the redemption of any Series A Preferred Stock except as to the holder to whom such
notice was defective or not given. In addition to any information required by law or by the applicable rules of any exchange upon which
the Series A Preferred Stock may be listed or admitted to trading, each such notice shall state: (i) the redemption date; (ii) the redemption
price; (iii) the number of shares of Series A Preferred Stock to be redeemed; (iv) the place or places where the certificates, if any,
representing shares of Series A Preferred Stock are to be surrendered for payment of the redemption price; (v) procedures for surrendering
noncertificated shares of Series A Preferred Stock for payment of the redemption price; (vi) that dividends on the shares of Series A
Preferred Stock to be redeemed will cease to accrue on such redemption date; and (vii) that payment of the redemption price and any accumulated
and unpaid dividends will be made upon presentation and surrender of such Series A Preferred Stock. If fewer than all of the shares of
Series A Preferred Stock held by any holder are to be redeemed, the notice mailed to such holder shall also specify the number of shares
of Series A Preferred Stock held by such holder to be redeemed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If a redemption date falls after a Dividend Record Date and on or prior to the corresponding Dividend Payment Date, each holder of Series
A Preferred Stock at the close of business of such Dividend Record Date shall be entitled to the dividend payable on such shares on the
corresponding Dividend Payment Date notwithstanding the redemption of such shares on or prior to such Dividend Payment Date, and each
holder of Series A Preferred Stock that surrenders its shares on such redemption date will be entitled to the dividends accruing after
the end of the Dividend Period to which such Dividend Payment Date relates up to but excluding the redemption date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
All shares of the Series A Preferred Stock redeemed or repurchased pursuant to this Section 5, or otherwise acquired in any other manner
by the Corporation, shall be restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series
or class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6. <U>Special Optional Redemption by the Corporation.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the occurrence of a Delisting Event or Change of Control (each as defined below), the Corporation will have the option upon written
notice mailed by the Corporation, postage pre-paid, no fewer than 30 nor more than 60 days prior to the redemption date and addressed
to the holders of record of shares of the Series A Preferred Stock to be redeemed at their respective addresses as they appear on the
stock transfer records of the Corporation, to redeem the Series A Preferred Stock, in whole or in part, within 90 days after the first
date on which such Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable,
for cash at $25.00 per share plus, subject to Section 6(d), accrued and unpaid dividends, if any, to, but not including, the redemption
date (&ldquo;<U>Special Optional Redemption Right</U>&rdquo;). No failure to give such notice or any defect thereto or in the mailing
thereof shall affect the validity of the proceedings for the redemption of any shares of Series A Preferred Stock except as to the holder
to whom notice was defective or not given. If, on or prior to the Delisting Event Conversion Date or Change of Control Conversion Date
(each as defined below), as applicable, the Corporation has provided or provides notice of redemption with respect to the Series A Preferred
Stock (whether pursuant to the Redemption Right or the Special Optional Redemption Right), the holders of shares of Series A Preferred
Stock will not have the conversion right described below in Section 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;<U>Change of Control</U>&rdquo; is when, after the original issuance of the Series A Preferred Stock, each of the following have
occurred and are continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the acquisition by any person, including any syndicate or group deemed to be a &ldquo;person&rdquo; under Section 13(d)(3) of the Securities
Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), of beneficial ownership, directly or indirectly, through a
purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of stock of the Corporation
entitling that person to exercise more than 50% of the total voting power of all stock of the Corporation entitled to vote generally
in the election of the Corporation&rsquo;s directors (except that such person will be deemed to have beneficial ownership of all securities
that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of
a subsequent condition); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
following the closing of any transaction referred to in (i) above, neither the Corporation nor the acquiring or surviving entity (or,
if in connection with such transaction holders of Common Stock receive Alternative Form Consideration consisting of common equity securities
of another entity, such other entity) has a class of common securities (or American depositary receipts representing such securities)
listed on the Nasdaq Stock Market (&ldquo;<U>NASDAQ</U>&rdquo;), the New York Stock Exchange (the &ldquo;<U>NYSE</U>&rdquo;), or the
NYSE American, LLC (the &ldquo;<U>NYSE AMER</U>&rdquo;), or listed or quoted on an exchange or quotation system that is a successor to
NASDAQ, the NYSE or the NYSE AMER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;<U>Delisting Event</U>&rdquo; occurs when, after the original issuance of Series A Preferred Stock, both (i) the shares of Series
A Preferred Stock (or the depositary shares) are no longer listed on NASDAQ, the NYSE or the NYSE AMER, or listed or quoted on an exchange
or quotation system that is a successor to NASDAQ, the NYSE or the NYSE AMER, or (ii) the Corporation is not subject to the reporting
requirements of the Exchange Act, but any Series A Preferred Stock is still outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In addition to any information required by law or by the applicable rules of any exchange upon which the Series A Preferred Stock may
be listed or admitted to trading, such notice shall state: (i) the redemption date; (ii) the redemption price; (iii) the number of shares
of Series A Preferred Stock to be redeemed; (iv) the place or places where the certificates, if any, representing shares of Series A
Preferred Stock are to be surrendered for payment of the redemption price; (v) procedures for surrendering noncertificated shares of
Series A Preferred Stock for payment of the redemption price; (vi) that dividends on the shares of Series A Preferred Stock to be redeemed
will cease to accrue on the redemption date; (vii) that payment of the redemption price and any accumulated and unpaid dividends will
be made upon presentation and surrender of such Series A Preferred Stock; (viii) that the shares of Series A Preferred Stock are being
redeemed pursuant to the Special Optional Redemption Right in connection with the occurrence of a Delisting Event or Change of Control,
as applicable, and a brief description of the transaction or transactions constituting such Delisting Event or Change of Control, as
applicable; and (ix) that holders of the shares of Series A Preferred Stock to which the notice relates will not be able to tender such
shares of Series A Preferred Stock for conversion in connection with the Delisting Event or Change of Control, as applicable, and each
share of Series A Preferred Stock tendered for conversion that is selected, prior to the Delisting Event Conversion Date or Change of
Control Conversion Date, as applicable, for redemption will be redeemed on the related redemption date instead of converted on the Delisting
Event Conversion Date or Change of Control Conversion Date, as applicable. If fewer than all of the shares of Series A Preferred Stock
held by any holder are to be redeemed, the notice mailed to such holder shall also specify the number of shares of Series A Preferred
Stock held by such holder to be redeemed. Holders of Series A Preferred Stock to be redeemed shall surrender such Series A Preferred
Stock at the place, or in accordance with the book-entry procedures, designated in such notice and shall be entitled to the redemption
price of $25.00 per share and any accrued and unpaid dividends payable upon such redemption following such surrender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
fewer than all of the outstanding shares of Series A Preferred Stock are to be redeemed pursuant to the Special Optional Redemption Right,
the shares of Series A Preferred Stock to be redeemed shall be redeemed pro rata (as nearly as may be practicable without creating fractional
shares) or by lot as determined by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If (i) the Corporation has given a notice of redemption pursuant to the Special Optional Redemption Right, (ii) the funds necessary for
such redemption have been set aside by the Corporation in trust for the benefit of the holders of the shares of Series A Preferred Stock
so called for redemption, and (iii) irrevocable instructions have been given to pay the redemption price and all accrued and unpaid dividends,
then from and after the redemption date, dividends shall cease to accrue on such shares of Series A Preferred Stock, such shares of Series
A Preferred Stock shall no longer be deemed outstanding, and all rights of the holders of such shares shall terminate, except the right
to receive the redemption price plus any accrued and unpaid dividends payable upon such redemption, without interest. So long as full
cumulative dividends on the Series A Preferred Stock for all past Dividend Periods shall have been or contemporaneously are (i) declared
and paid, or (ii) declared and a sum sufficient for the payment thereof is set apart for payment, nothing herein shall prevent or restrict
the Corporation&rsquo;s right or ability to purchase, from time to time, either at a public or a private sale, all or any part of the
Series A Preferred Stock at such price or prices as the Corporation may determine, subject to the provisions of applicable law, including
the repurchase of shares of Series A Preferred Stock in open-market transactions duly authorized by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If a redemption date falls after a Dividend Record Date and on or prior to the corresponding Dividend Payment Date, each holder of Series
A Preferred Stock at the close of business of such Dividend Record Date shall be entitled to the dividend payable on such shares on the
corresponding Dividend Payment Date notwithstanding the redemption of such shares on or prior to such Dividend Payment Date, and each
holder of Series A Preferred Stock that surrenders its shares on such redemption date will be entitled to the dividends accruing after
the end of the Dividend Period to which such Dividend Payment Date relates up to but excluding the redemption date. Except as provided
herein, the Corporation shall make no payment or allowance for unpaid dividends, whether or not in arrears, on Series A Preferred Stock
for which a notice of redemption has been given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
All shares of the Series A Preferred Stock redeemed or repurchased pursuant to this Section 6, or otherwise acquired in any other manner
by the Corporation, shall be retired and shall be restored to the status of authorized but unissued shares of Preferred Stock, without
designation as to series or class.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7. <U>Voting Rights.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Holders of the Series A Preferred Stock shall not have any voting rights, except as set forth in this Section 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Whenever dividends on any shares of Series A Preferred Stock shall be in arrears for six or more consecutive or non-consecutive quarterly
periods (a &ldquo;<U>Preferred Dividend Default</U>&rdquo;), the holders of Series A Preferred Stock and the holders of all other classes
or series of preferred stock of the Corporation ranking on parity with the Series A Preferred Stock with respect to payment of dividends
and the distribution of assets upon the Corporation&rsquo;s liquidation, dissolution or winding up and upon which like voting rights
have been conferred, and are exercisable (&ldquo;<U>Parity Preferred</U>&rdquo;) and with which the holders of Series A Preferred Stock
are entitled to vote together as a single class voting together as a single class, shall be entitled to vote for the election of a total
of two additional directors to serve on the Board of Directors of the Corporation (the &ldquo;<U>Preferred Directors</U>&rdquo;) until
all dividends accumulated and unpaid on such Series A Preferred for all past Dividend Periods shall have been fully paid. At such time
as the holders of Series A Preferred Stock become entitled to vote in the election of Preferred Directors, the number of directors serving
on the Board of Directors will be increased automatically by two directors (unless the number of directors has previously been so increased
pursuant to the terms of any class or series of Parity Preferred). For the purposes of determining whether a Preferred Dividend Default
has occurred or is continuing, a dividend in respect of Series A Preferred Stock shall be considered timely made if made within two Business
Days after the applicable Dividend Payment Date if at the time of such late payment date there shall not be any prior quarterly Dividend
Periods in respect of which full dividends were not timely made at the applicable Dividend Payment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
A Preferred Director will be elected by a plurality of the votes cast in the election of Preferred Directors and shall serve until the
next annual meeting of stockholders and until his or her successor is duly elected and qualifies, subject to Section 7(e) or such Preferred
Director&rsquo;s earlier death, disqualification, resignation or removal. The election of Preferred Directors will take place at (i)
either (A) a special meeting called in accordance with Section 7(d) below if the request is received more than 90 days before the date
fixed for the Corporation&rsquo;s next annual or special meeting of stockholders or (B) the next annual or special meeting of stockholders
if the request is received within 90 days of the date fixed for the Corporation&rsquo;s next annual or special meeting of stockholders,
and (ii) at each subsequent annual meeting of stockholders, or special meeting at which Preferred Directors are to be elected, until
the right of holders of Series A Preferred Stock to elect Preferred Directors shall have terminated as specified in Section 7(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
At any time when holders of Series A Preferred Stock are entitled to vote in the election of Preferred Directors, the Secretary of the
Corporation shall, unless the request is received more than 90 days before the date fixed for the Corporation&rsquo;s next annual or
special meeting of stockholders, call or cause to be called, upon written request of holders of record of at least 10% of the outstanding
shares of Series A Preferred Stock and Parity Preferred with which the holders of Series A Preferred Stock are entitled to vote together
as a single class in the election of Preferred Directors, call a special meeting of stockholders for the purpose of electing Preferred
Directors by mailing or causing to be mailed to the stockholders entitled to vote a notice of such special meeting to be held not fewer
than ten or more than 45 days after the date such notice is given. The record date for determining holders of the Series A Preferred
Stock entitled to notice of and to vote at such special meeting will be the close of business on the third Business Day preceding the
day on which such notice is mailed. The holder or holders of one-third of the outstanding shares of Series A Preferred Stock and Parity
Preferred with which the holders of Series A Preferred Stock are entitled to vote together as a single class in the election of Preferred
Directors, present in person or by proxy, will constitute a quorum for the election of the Preferred Directors except as otherwise required
by law. Notice of all meetings of stockholders at which holders of Series A Preferred Stock are entitled to vote in the election of Preferred
Directors will be given to such holders at their addresses as they appear in the Corporation&rsquo;s stock transfer records. At any such
meeting or adjournment thereof, in the absence of a quorum, subject to the provisions of any applicable law, the affirmative vote of
a majority of the holders of the Series A Preferred Stock and Parity Preferred with which the holders of Series A Preferred Stock are
entitled to vote together as a single class in the election of Preferred Directors present in person or by proxy, voting together as
a single class, shall be sufficient to adjourn the meeting for the election of the Preferred Directors, without notice other than an
announcement at the meeting, until a quorum is present. If a Preferred Dividend Default shall terminate after the notice of a special
meeting for the purpose of electing Preferred Directors has been given but before such special meeting has been held, the Corporation
shall, as soon as practicable after such termination, mail or cause to be mailed notice of such termination to holders of the Series
A Preferred Stock that would have been entitled to vote at such special meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If and when all accumulated dividends on such Series A Preferred Stock for all past Dividend Periods shall have been fully paid, the
right of the holders of Series A Preferred Stock to elect such additional two directors shall immediately cease (subject to revesting
in the event of each and every Preferred Dividend Default), and, unless there are outstanding shares of Parity Preferred upon which like
voting remain exercisable, the term of office of each Preferred Director so elected shall terminate and the number of directors constituting
the Board of Directors shall be reduced accordingly. If the rights of holders of Series A Preferred Stock to elect Preferred Directors
have terminated in accordance with this Section 7(e) after any record date for the determination of stockholders entitled to vote in
the election of such Preferred Directors but before the closing of the polls in such election, holders of Series A Preferred Stock outstanding
as of such record date shall not be entitled to vote in such election of Preferred Directors. Any Preferred Director may be removed at
any time with or without cause by the vote of, and shall not be removed otherwise than by the vote of, the holders of record of a majority
of the outstanding shares of Series A Preferred Stock and the Parity Preferred then entitled to vote together as a single class in the
election of Preferred Directors (voting together as a single class). So long as a Preferred Dividend Default shall continue, any vacancy
in the office of a Preferred Director may be filled by written consent of the Preferred Director remaining in office, or if none remains
in office, by a plurality of the votes cast in the election of Preferred Directors. Each of the Preferred Directors shall be entitled
to one vote on any matter before the Corporation&rsquo;s board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
So long as any shares of Series A Preferred Stock remain outstanding, the affirmative vote or consent of the holders of two-thirds of
the outstanding shares of Series A Preferred Stock and each other class or series of Parity Preferred with which the holders of Series
A Preferred Stock are entitled to vote together as a single class on such matter (voting together as a single class), given in person
or by proxy, either in writing or at a meeting, will be required to: (i) authorize, create or issue, or increase the number of authorized
or issued number of shares of, any class or series of capital stock ranking senior to the Series A Preferred Stock with respect to payment
of dividends or the distribution of assets upon liquidation, dissolution or winding up of the Corporation (collectively, &ldquo;<U>Senior
Capital Stock</U>&rdquo;) or reclassify any authorized shares of capital stock of the Corporation into Senior Capital Stock, or create,
authorize or issue any obligation or security convertible into or evidencing the right to purchase any Senior Capital Stock; or (ii)
amend, alter or repeal the provisions of the Certificate of Incorporation , including the terms of the Series A Preferred Stock, whether
by merger, consolidation, transfer or conveyance of all or substantially all of its assets or otherwise (an &ldquo;<U>Event</U>&rdquo;),
so as to materially and adversely affect any right, preference, privilege or voting power of the Series A Preferred Stock; <U>provided
however</U>, with respect to the occurrence of any Event, so long as the Series A Preferred Stock remains outstanding with the terms
thereof materially unchanged, taking into account that, upon the occurrence of such Event, the Corporation may not be the surviving entity
and the surviving entity may not be a corporation, the occurrence of such Event shall not be deemed to materially and adversely affect
such rights, preferences, privileges or voting power of Series A Preferred Stock, and in such case such holders shall not have any voting
rights with respect to the occurrence of any Event. In addition, if the holders of the Series A Preferred Stock receive the greater of
the full trading price of the Series A Preferred Stock on the date of an Event or the $25.00 liquidation preference per share of the
Series A Preferred Stock plus all accrued and unpaid dividends thereon pursuant to the occurrence of any Event, then such holders shall
not have any voting rights with respect to such Event. If any Event would materially and adversely affect the rights, preferences, privileges
or voting powers of the Series A Preferred Stock disproportionately relative to other classes or series of Parity Preferred with which
the holders of Series A Preferred Stock are entitled to vote together as a single class on such Event, the affirmative vote of the holders
of at least two-thirds of the outstanding shares of the Series A Preferred Stock, voting as a separate class, will also be required.
Notwithstanding the foregoing, holders of shares of Series A Preferred Stock shall not be entitled to vote with respect to (A) any increase
in the total number of authorized shares of Common Stock or Preferred Stock of the Corporation, (B) any increase in the number of authorized
shares of Series A Preferred Stock or the creation or issuance of any other class or series of capital stock or (C) any increase in the
number of authorized shares of any other class or series of capital stock; <U>provided that</U>, in each case referred to in clause (A),
(B) or (C) above, such capital stock ranks on parity with or junior to the Series A Preferred Stock with respect to the payment of dividends
and the distribution of assets upon liquidation, dissolution or winding up of the Corporation. Except as set forth herein, holders of
the Series A Preferred Stock shall not have any voting rights with respect to, and the consent of the holders of the Series A Preferred
Stock shall not be required for, the taking of any corporate action, including an Event, regardless of the effect that such corporate
action or Event may have upon the powers, preferences, voting power or other rights or privileges of the Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The foregoing voting provisions of this Section 7 shall not apply if, at or prior to the time when the act with respect to which such
vote would otherwise be required shall be effected, all outstanding shares of Series A Preferred Stock shall have been redeemed or called
for redemption upon proper notice pursuant to this Certificate of Designation, and sufficient funds, in cash, shall have been deposited
in trust to effect such redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
In any matter in which the Series A Preferred Stock may vote together as a single class with holders of all other classes or series of
parity preferred stock (as expressly provided herein), each share of Series A Preferred Stock shall be entitled to one vote per $25.00
of liquidation preference.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8. <U>Conversion</U></B></FONT><B>.</B> The shares of Series A Preferred Stock are not convertible into or exchangeable for any other
property or securities of the Corporation, except as provided in this Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the occurrence of a Delisting Event or Change of Control, as applicable, each holder of outstanding shares of Series A Preferred
Stock shall have the right, unless, on or prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable,
the Corporation has provided or provides notice of its election to redeem the Series A Preferred Stock pursuant to the Redemption Right
or Special Optional Redemption Right, to convert some or all of the Series A Preferred Stock held by such holder (the &ldquo;<U>Delisting
Event Conversion Right</U>&rdquo; or &ldquo;<U>Change of Control Conversion Right</U>,&rdquo; as applicable) on the Delisting Event Conversion
Date or Change of Control Conversion Date, as applicable, into a number of shares of Common Stock per share of Series A Preferred Stock
to be converted (the &ldquo;<U>Common Stock Conversion Consideration</U>&rdquo;) equal to the lesser of (A) the quotient obtained by
dividing (i) the sum of (x) the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount
of any accrued and unpaid dividends to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date,
as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, is after a Dividend Record
Date and prior to the corresponding Dividend Payment Date, in which case no additional amount for such accrued and unpaid dividends will
be included in such sum) by (ii) the Common Stock Price (as defined herein) and (B) 7.29927 (the &ldquo;<U>Share Cap</U>&rdquo;),
subject to the immediately succeeding paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Share Cap is subject to pro rata adjustments for any stock splits (including those effected pursuant to a distribution of the Common
Stock), subdivisions or combinations (in each case, a &ldquo;<U>Share Split</U>&rdquo;) with respect to the Common Stock as follows:
the adjusted Share Cap as the result of a Share Split shall be the number of shares of Common Stock that is equivalent to the product
obtained by multiplying (i) the Share Cap in effect immediately prior to such Share Split by (ii) a fraction, the numerator of which
is the number of shares of Common Stock outstanding after giving effect to such Share Split and the denominator of which is the number
of shares of Common Stock outstanding immediately prior to such Share Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a Delisting Event or Change of Control, as applicable, pursuant to which shares of Common Stock shall be converted into cash,
securities or other property or assets (including any combination thereof) (the &ldquo;<U>Alternative Form Consideration</U>&rdquo;),
a holder of shares of Series A Preferred Stock shall receive upon conversion of such shares of Series A Preferred Stock the kind and
amount of Alternative Form Consideration which such holder would have owned or been entitled to receive upon the Delisting Event or Change
of Control, as applicable, had such holder held a number of shares of Common Stock equal to the Common Stock Conversion Consideration
immediately prior to the effective time of the Delisting Event or Change of Control, as applicable (the &ldquo;<U>Alternative Conversion
Consideration</U>&rdquo;; and the Common Stock Conversion Consideration or the Alternative Conversion Consideration, as may be applicable
to a Delisting Event or Change of Control, as applicable, shall be referred to herein as the &ldquo;<U>Conversion Consideration</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that holders of Common Stock have the opportunity to elect the form of consideration to be received in the Delisting Event
or Change of Control, as applicable, the Conversion Consideration will be deemed to be the kind and amount of consideration actually
received by holders of a majority of the shares of Common Stock that were voted in such an election (if electing between two types of
consideration) or holders of a plurality of the shares of Common Stock that were voted in such an election (if electing between more
than two types of consideration), as the case may be, and will be subject to any limitations to which all holders of Common Stock are
subject, including, without limitation, pro rata reductions applicable to any portion of the consideration payable in the Delisting Event
or Change of Control, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;<U>Delisting Event Conversion Date</U>&rdquo; or &ldquo;<U>Change of Control Conversion Date</U>&rdquo;, as applicable, shall
be a Business Day set forth in the notice of Delisting Event or Change of Control, as applicable, provided in accordance with Section
8(c) below that is no less than 20 days nor more than 35 days after the date on which the Corporation provides such notice pursuant to
Section 8(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;<U>Common Stock Price</U>&rdquo; shall be (i) if the consideration to be received in the Change of Control by the holders of Common
Stock is solely cash, the amount of cash consideration per share of Common Stock or (ii) if the consideration to be received in the Change
of Control by holders of Common Stock is other than solely cash (x) the average of the closing sale prices per share of Common Stock
(or, if no closing sale price is reported, the average of the closing bid and ask prices or, if more than one in either case, the average
of the average closing bid and the average closing ask prices) for the ten consecutive trading days immediately preceding, but not including,
the effective date of the Change of Control as reported on the principal U.S. securities exchange on which the Common Stock is then traded,
or (y) the average of the last quoted bid prices for the Common Stock in the over-the-counter market as reported by OTC Markets Group,
Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the effective date of the
Change of Control, if the Common Stock is not then listed for trading on a U.S. securities exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;<U>Common Stock Price</U>&rdquo; for any Delisting Event will be the average of the closing price per share of the Corporation&rsquo;s
common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No fractional shares of Common Stock shall be issued upon the conversion of Series A Preferred Stock. In lieu of fractional shares of
Common Stock otherwise issuable in respect of the aggregate number of shares of Series A Preferred Stock of any holder that are converted,
that holder shall be entitled to receive the cash value of such fractional shares based on the Common Stock Price. If more than one share
of Series A Preferred Stock is surrendered for conversion at one time by or for the same holder, the number of full shares of Common
Stock issuable upon conversion thereof shall be computed on the basis of the aggregate number of shares of Series A Preferred Stock so
surrendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Within 15 days following the occurrence of a Delisting Event or Change of Control, as applicable, a notice of occurrence of the Delisting
Event or Change of Control, as applicable, describing the resulting Delisting Event Conversion Right or Change of Control Conversion
Right, as applicable, shall be delivered to the holders of record of the Series A Preferred Stock at their addresses as they appear on
the Corporation&rsquo;s stock transfer records and notice shall be provided to the Corporation&rsquo;s transfer agent. No failure to
give such notice or any defect thereto or in the mailing thereof shall affect the validity of the proceedings for the conversion of any
share of Series A Preferred Stock except as to the holder to whom notice was defective or not given. Each notice shall state: (i) the
events constituting the Delisting Event or Change of Control, as applicable; (ii) the date of the Delisting Event or Change of Control,
as applicable; (iii) the last date on which the holders of Series A Preferred Stock may exercise their Delisting Event Conversion Right
or Change of Control Conversion Right, as applicable; (iv) the method and period for calculating the Common Stock Price; (v) the Delisting
Event Conversion Right or Change of Control Conversion Date, as applicable; (vi) that if, on or prior to the Delisting Event Conversion
Right or Change of Control Conversion Date, as applicable, the Corporation has provided or provides notice of its election to redeem
all or any portion of the Series A Preferred Stock, the holder will not be able to convert shares of Series A Preferred Stock designated
for redemption and such shares of Series A Preferred Stock shall be redeemed on the related redemption date, even if they have already
been tendered for conversion pursuant to the Delisting Event Conversion Right or Change of Control Conversion Right; (vii) if applicable,
the type and amount of Alternative Conversion Consideration entitled to be received per share of Series A Preferred Stock; (viii) the
name and address of the paying agent and the conversion agent; and (ix) the procedures that the holders of Series A Preferred Stock must
follow to exercise the Delisting Event Conversion Right or Change of Control Conversion Right, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
The Corporation shall issue a press release for publication on the Dow Jones &amp; Corporation, Inc., Business Wire, PR Newswire or Bloomberg
Business News (or, if such organizations are not in existence at the time of issuance of such press release, such other news or press
organization as is reasonably calculated to broadly disseminate the relevant information to the public), or post notice on the Corporation&rsquo;s
website, in any event prior to the opening of business on the first Business Day following any date on which the Corporation provides
notice pursuant to Section 8(c) above to the holders of Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
In order to exercise the Delisting Event Conversion Right or Change of Control Conversion Right, as applicable, a holder of shares of
Series A Preferred Stock shall be required to deliver, on or before the close of business on the Delisting Event Conversion Right or
Change of Control Conversion Date, as applicable, the certificates (if any) representing the shares of Series A Preferred Stock to be
converted, duly endorsed for transfer, together with a written conversion notice completed, to the Corporation&rsquo;s transfer agent.
Such notice shall state: (i) the relevant Delisting Event Conversion Date or Change of Control Conversion Date, as applicable; (ii) the
number of shares of Series A Preferred Stock to be converted; and (iii) that the shares of Series A Preferred Stock are to be converted
pursuant to the applicable provisions of this Certificate of Designation. Notwithstanding the foregoing, if the shares of Series A Preferred
Stock are held in global form, such notice shall comply with applicable procedures of The Depository Trust Corporation (&ldquo;<U>DTC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Holders of Series A Preferred Stock may withdraw any notice of exercise of a Delisting Event Conversion Right or Change of Control Conversion
Right (in whole or in part), as applicable, by a written notice of withdrawal delivered to the Corporation&rsquo;s transfer agent prior
to the close of business on the Business Day prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.
The notice of withdrawal must state: (i) the number of withdrawn shares of Series A Preferred Stock; (ii) if certificated shares of Series
A Preferred Stock have been issued, the certificate numbers of the shares of withdrawn Series A Preferred Stock; and (iii) the number
of shares of Series A Preferred Stock, if any, which remain subject to the conversion notice. Notwithstanding the foregoing, if the shares
of Series A Preferred Stock are held in global form, the notice of withdrawal shall comply with applicable procedures of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Shares of Series A Preferred Stock as to which the Delisting Event Conversion Right or Change of Control Conversion Right, as applicable,
has been properly exercised and for which the conversion notice has not been properly withdrawn shall be converted into the applicable
Conversion Consideration in accordance with the Delisting Event Conversion Right or Change of Control Conversion Right, as applicable,
on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, unless, on or prior to the Delisting Event
Conversion Date or Change of Control Conversion Date, as applicable, the Corporation has provided or provides notice of its election
to redeem such shares of Series A Preferred Stock, whether pursuant to its Redemption Right or Special Optional Redemption Right. If
the Corporation elects to redeem shares of Series A Preferred Stock that would otherwise be converted into the applicable Conversion
Consideration on a Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, such shares of Series A Preferred
Stock shall not be so converted and the holders of such shares shall be entitled to receive on the applicable redemption date $25.00
per share, plus any accrued and unpaid dividends thereon to, but not including, the redemption date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)
The Corporation shall deliver the applicable Conversion Consideration no later than the third Business Day following the Delisting Event
Conversion Date or Change of Control Conversion Date, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The shares of Series A Preferred Stock shall not be convertible into or exchangeable for any other property or securities of the Corporation
or any other entity, except as otherwise provided herein.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9. <U>No Conversion Rights</U></B></FONT><B>.</B> The shares of Series A Preferred Stock shall not be convertible into or exchangeable
for any other property or securities of the Corporation or any other entity, except as otherwise provided herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10. <U>Debt Incurrence</U>. <FONT STYLE="font-weight: normal">So long as at least 30% of the number of shares of Series A Preferred Stock
sold at the closing are outstanding, the Corporation shall not, and shall not permit any of its Subsidiaries to, directly or indirectly,
without the affirmative written consent of the holders of at least 50%, in the aggregate, of the then outstanding shares of the Series
A Preferred Stock, incur any Indebtedness other than Permitted Indebtedness (&ldquo;<U>Debt Incurrence</U>&rdquo;). During any Dividend
Period in which Indebtedness exceeds Permitted Indebtedness at any time during such Dividend Period, then Dividends during such Dividend
Period shall accrue at the Debt Incurrence Rate rather than at the rate of 8.875% per annum of the $25.00 liquidation preference per
share of the Series A Preferred Stock. </FONT><BR>
<FONT STYLE="font-weight: normal"><BR>
&ldquo;<U>Indebtedness</U>&rdquo; means (a) any liabilities for borrowed money or amounts owed (excluding any trade accounts payables
and any leases characterized as operating leases under generally accepted account principles in effect on the date hereof incurred in
the ordinary course of business) and (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&ldquo;<U>Permitted
Indebtedness</U>&rdquo; means (a) the Indebtedness existing on the Original Issue Date and (b) any Indebtedness for borrowed money in
an amount not to exceed $25,000,000 at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Debt
Incurrence Rate</U>&rdquo; means cumulative cash dividends at the rate of 10.875% per annum of the $25.00 liquidation preference per
share of the Series A Preferred Stock.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
11. <U>Record Holders</U></B></FONT><B>.</B> The Corporation and its transfer agent may deem and treat the record holder of any Series
A Preferred Stock as the true and lawful owner thereof for all purposes, and neither the Corporation nor its transfer agent shall be
affected by any notice to the contrary.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
12. <U>No Maturity or Sinking Fund</U></B></FONT><B>.</B> The Series A Preferred Stock has no maturity date, and no sinking fund has
been established for the retirement or redemption of Series A Preferred Stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13. <U>Exclusion of Other Rights</U></B></FONT><B>.</B> The Series A Preferred Stock shall not have any preferences or other rights,
voting powers, restrictions, limitations as to dividends or other distributions, qualifications or terms or conditions of redemption
other than expressly set forth in the Certificate of Incorporation and this Certificate of Designation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
14. <U>Headings of Subdivisions</U></B></FONT><B>.</B> The headings of the various subdivisions hereof are for convenience of reference
only and shall not affect the interpretation of any of the provisions hereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
15. <U>Severability of Provisions</U></B></FONT><B>.</B> If any preferences or other rights, voting powers, restrictions, limitations
as to dividends or other distributions, qualifications or terms or conditions of redemption of the Series A Preferred Stock set forth
in this Certificate of Designation are invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy,
all other preferences or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications
or terms or conditions of redemption of Series A Preferred Stock set forth in this Certificate of Designation which can be given effect
without the invalid, unlawful or unenforceable provision thereof shall, nevertheless, remain in full force and effect and no preferences
or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications or terms or conditions
of redemption of the Series A Preferred Stock herein set forth shall be deemed dependent upon any other provision thereof unless so expressed
therein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16. <U>No Preemptive Rights</U></B></FONT><B>.</B> No holder of Series A Preferred Stock shall be entitled to any preemptive rights to
subscribe for or acquire any unissued shares of capital stock of the Corporation (whether now or hereafter authorized) or securities
of the Corporation convertible into or carrying a right to subscribe to or acquire shares of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
5.1</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
4, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">800
    Third Avenue, Suite 2800</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as legal counsel to LifeMD, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) of a Prospectus Supplement (the &ldquo;<B>Prospectus
Supplement</B>&rdquo;) dated September 28, 2021 to the Prospectus included in the Registration Statement on Form S-3 (File No. 333-256911)
(the &ldquo;<B>Registration Statement</B>&rdquo;), filed by the Company with the Commission under the Securities Act of 1933, as amended
(the &ldquo;<B>Securities Act</B>&rdquo;) related to the offer and sale by the Company of 3,833,334 shares (including 500,000 shares
pursuant to the Underwriter&rsquo;s over-allotment option) (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s common stock, par
value $0.01 per share (&ldquo;<B>Common Stock</B>&rdquo;), pursuant to an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;)
dated September 28, 2021 by and between the Company and the several underwriters named therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.8pt 0pt 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes
of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted
to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies.
We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to
our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public
officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.8pt 0pt 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that the Shares, when issued and delivered against payment of the consideration therefor specified
in the Underwriting Agreement, will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.8pt 0pt 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.8pt 0pt 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions expressed above are limited to the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the
requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to reference the firm&rsquo;s name under the
caption &ldquo;Legal Matters&rdquo; in the prospectus which forms part of the Registration Statement, and we hereby consent thereto.
In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AJM/AE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M .8# 2(  A$! Q$!_\0
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MYU'3&59V_P!;"_"2C^AJS%JL)(2Z1[2;^Y,, _1NAJ_2,H92K $'J"*  ,&
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M5U=5S86;3-,UK"97&&<H,D4 4+\Y\)2DG)-H.?\ @(J:ZMOMF@- /O- "O\
MO  C]15XPQ-#Y)C4Q8V[".,>F*< %4*   , #M0!RJ732;=?8'9$Z1$?[&W#
M?^/']*VM(B-MH\;2 ^8X,SXZY;YJN?9H/(,'DQ^2<YCVC:?PJ4  8 P!0!QU
MU,)-!25!90122AXX4R9 =W7.>OKQ70:W;M/IKO$/WT!$T?U7G^6:G&FV*M(P
MM( 9/OGRQ\U5=>U"33M/#Q*I>1Q$"?X<@\TQ$>CN+^[N]4P=LF(HL_W5'/ZD
M_E4-RH_M.^EMYK9Y"BK/!=#' '&UO0C\*UK"U2RL8;=.5C4#/J>YHN+&TNF5
MKBVBE9>A= 2*0$6D212Z3;/!$8HBGRH3G:/K2ZK<)::1>7$L1ECCA9FC!P6&
M.E6P H 4  #  [4, RD$ @C!![TTTFFQ23<6D>?32,/^$<&[3(E-U$T4%H"7
MC4^K9Y'//J:WO$T4<VI:!'*BNC7O*L,@_*:U8=%TNW&(=.MD^<2?+$!\PZ'\
M*MRV\$SQ/+$CO$VZ-F7)0^H]*ZI8B/,FEM?\;G!#!S4)1DUKR_A;_(P((DB\
M?W"QJJ!].5F"C&X[\9-9UTMVWC>\"SV43FU3R/MD98,G\6WD=\YKL/L\/VDW
M/E)YY389-OS;<YQGTS4-[IMEJ"*MY:0SA3E?,0-CZ5,:Z3NUTL7/"2<;)_:<
MO^ 9F@6XTKP_(OVF*ZC1Y9 ;8?*!DDJO/8Y%<C>7 ?PU9RQC2[:&2XCD@MX<
MM,OSYSNSU]>*]'@@BMH5A@B2*-1A410 /PJHFB:4AE*Z;:@RD%\1#YB#G^?-
M53Q$8R<I*]W<BM@YSIQA!I)*W7R^?Y&7XQV_8K$3_P#'H;^+[1GILR>OMG%0
MN;,^/M/^S& O]CE\SRL>VW./QKIIH8IX6BFC22-AAD<9!'N*K6NE:?9%3:V5
HO"4SM*1@$9Z\^^!40K)0Y7Y_B:5,-*57F5K7B_/3MZERBBBN<[3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>7
<FILENAME>ex5-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit
5.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><IMG SRC="ex5-2_001.jpg" ALT="" STYLE="height: 33.5pt; width: 172.75pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">October
4, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">LifeMD,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">800
    Third Avenue, Suite 2800</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">New
    York, New York 10022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have acted as legal counsel to LifeMD, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the preparation
and filing with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) of a Prospectus Supplement (the &ldquo;<B>Prospectus
Supplement</B>&rdquo;) dated September 28, 2021 to the Prospectus included in the Registration Statement on Form S-3 (File No. 333-256911)
(the &ldquo;<B>Registration Statement</B>&rdquo;), filed by the Company with the Commission under the Securities Act of 1933, as amended
(the &ldquo;<B>Securities Act</B>&rdquo;) related to the offer and sale by the Company of 1,400,000 shares (the &ldquo;<B>Shares</B>&rdquo;)
of the Company&rsquo;s 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share (&ldquo;<B>Preferred Stock</B>&rdquo;),
pursuant to an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) dated September 29, 2021 by and between the Company
and the several underwriters named therein. Pursuant to the Certificate of Designation establishing the powers, designations, preferences
and rights of the Preferred Stock (the &ldquo;<B>Certificate of Designation</B>&rdquo;), the Shares will be convertible, upon the occurrence
of certain conditions, into shares of common stock, par value $0.01 per share, of the Company (the &ldquo;<B>Conversion Shares</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes
of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted
to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies.
We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to
our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public
officials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Based
on the foregoing, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
    Shares, when issued and delivered against payment of the consideration therefor specified in the Underwriting Agreement, will be
    validly issued, fully paid and non-assessable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
    Conversion Shares, when issued upon conversion of the Shares in accordance with the Certificate of Designation, will be validly issued,
    fully paid and non-assessable</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
opinions expressed above are limited to the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the
requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to reference the firm&rsquo;s name under the
caption &ldquo;Legal Matters&rdquo; in the prospectus which forms part of the Registration Statement, and we hereby consent thereto.
In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AJM/AE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-2_001.jpg
<TEXT>
begin 644 ex5-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ", M # 2(  A$! Q$!_\0
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MN4$_[(H0%_QI_P %4OBUK>KS2^'[71?#>F[CY5L+4W,JCMO=S@GZ*/I7._\
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M3."<%SG8B@<X&3NXQ5#'_P##U#XW?WO#O_@M;_XY1_P]0^-W][P[_P""UO\
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M=17X.?M!?L\>*?V</'$WA[Q+ LB.OF6.I6RM]GO(O[Z$CJ/XDZJ?;!/Z0?\
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M7'F_@X_Q5JI["1['1116904444 %%%% !1110 4444 %%%% !7EO[0.CK?\
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M'?\ V$KG_P!%+7RW_P $U_\ D[KPG_U[WO\ Z2R5]2?\%@?^1%^'?_82N?\
MT4M?+?\ P37_ .3NO"?_ %[WO_I+)5(?0_:RBBBI$%%%% %>:);A&CD57C9=
MK(_(8&OQB_X*&? 72O@=\;A+X?A6VT+Q#:_VE!9JNU+67>5EC0?W<C<!V#8[
M5^TM?C=_P4H^->D_%KXY0:=H=PE[I?AFU:PDN86#)+<&0M*4(Z@?*N?56[52
M!&)_P3I^(M[X#_:>\-V,#_Z%XA632KR'=PP8;HV^HD1/PW>M?M97XC_\$]?
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MM_ ?PV^'=_X"\::K#X<N8;V34+.^O"?L]PD@0&,L =CJ5SSP0WJ*^0_VN_\
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M?A7Y?^HS;_\ Q=>>>,OV[/@=X*MIII_'MCJ<R=+;1P]Y(Q] 4!7\V K\S_\
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M;:G=?8%L+S2Y[A8'7824D0OA2"'8$$@C:N,YX^2/^'<'Q]_Z$^'_ ,&EK_\
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M*- /,-1\>^-_B9)):^'M.N-.T\_QPMM/_ IC@#Z"M;PG^SO%&ZW/B"Z^U/\
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MXQ\=?$E=+US6FOK-K.67RV@C7YE*X/RJ#WKZVQA ,?+Z5\+?L;9'QBC(&?\
MB7S_ ,TK[H9%D8'J3TKZ;B>C2H8_DHQ45RK1*W?L?!<!XJOB\H=3$5'.7.U>
M3;=M-+NY-1117R)^CA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=3Z)K)\5_P#(J:S_ -><W_H#5K5D^*_^14UG_KSF_P#0&J2CP#]G3_D=Y?\
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MNVG[8OC*\BBM+?2K6>^<!!(BEB[>NP+7ZGC,-BLQP>'_ +-DO9J.J3M9^?\
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M"T7P4TGS%,;--<8#@@_ZYNQKV4\,17#FS_X4*]OYI?F>OP\O^$?"7_Y]P_\
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MZ7IZ6NJ:-;ZC?1KM:X>3R6)]2@3%1:5\3?BS\9?$]C)HD#06%M.K>1&D:0*
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MZ=U%Z-+]W:Z6S:5VNFW0]=&$^4#)-?$?[9VF-;?%"VO#]V[L5Y]U8C^M?;Y
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MBBI *?3**"@HHHI#"BBB@ HHHH H7&D6EQ)YLMM&[^K(&-6T41KM3I3R.:0
M9-5SMHGE2=TAU%%%24-(60;3TJM::?;V3L\,$<;GJR*!_*K#D[@.U//2KNT9
MV3=[$U0T45(PHHHI%E6\L8+R,+/!'-M^[YBAOYU+;P+;H4C50HZ!:D'2@]*N
1[V(TWMJ+1114%A1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>9
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 48px; width: 166px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Launch of Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, September 28, 2021 &ndash; </B><U>LifeMD, Inc.</U> (the &ldquo;Company&rdquo;) (NASDAQ: LFMD), a leading direct-to-patient telehealth
company, today announced that it has commenced an underwritten registered public offering of shares of its common stock, par value $0.01
per share. In connection with this offering, the Company expects to grant the underwriters a 30-day option to purchase additional shares
of common stock at the public offering price, less underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from this offering to repay a portion of its indebtedness and the remaining net proceeds for
working capital and general corporate purposes including, but not limited to, new patient customer acquisition expenses and capital expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc. is acting as the sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-256911) and preliminary prospectus
supplement filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The preliminary prospectus supplement relating
to the offering will be available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when available, may also be obtained from B. Riley Securities, Inc. You should direct any requests to
B. Riley Securities, Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone
at (703) 312-9580 or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there
be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  P *8# 2(  A$! Q$!_\0
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M=.41VZR, -YZL >]=)_;6FC_ )?[;_OZ*>JZ!H^IA27WB30AYU_'%J5HO+O
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F"BLV$LQ$LW8]E^E:AWAP  5[FE*2V1O0I24G4J;LDHHHK,[#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>11
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-2_001.jpg" ALT=""></FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Launch of Public Offering of 1,400,000 Shares of Preferred Stock</B></FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NEW
YORK, September 28, 2021 &mdash; </B><U>LifeMD, Inc.</U> (&ldquo;the Company&rdquo;) (NASDAQ: LFMD), a rapidly growing direct-to-patient
telehealth company</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">today announced it has commenced an
underwritten registered public offering of 1,400,000 shares of its Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per
share (the &ldquo;Series A Preferred Stock&rdquo;), total liquidation preference of $35,000,000. In connection with this offering, the
Company expects to grant the underwriters a 30-day option to purchase 210,000 additional shares of Series A Preferred Stock at the public
offering price, less underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to use the net proceeds of this offering to fund the segregated dividend account and to repay a portion of certain indebtedness,
and the remaining net proceeds for general corporate purposes including, but not limited to, funding future acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc., Ladenburg Thalmann &amp; Co. Inc., Colliers Securities LLC and EF Hutton, division of Benchmark Investments,
LLC are acting as book-running managers for the offering. Aegis Capital Corp., The Benchmark Company, LLC, Boenning &amp; Scattergood,
Inc., Chapin Davis Investments and B.C. Ziegler &amp; Company will be acting as co-managers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-256911) and preliminary prospectus
supplement filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The preliminary prospectus supplement relating
to the offering will be available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when available, may also be obtained from B. Riley Securities, Inc. You should direct any requests to
B. Riley Securities, Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone
at (703) 312-9580 or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there
be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects &mdash; both business
and financial. While we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements
are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements
are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release
may be identified by the use of forward-looking words such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;should,&rdquo; &ldquo;planned,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimated,&rdquo; and
&ldquo;potential,&rdquo; among others. Important factors that could cause actual results to differ materially from the forward-looking
statements we make in this news release include market conditions and those set forth in reports or documents that we file from time
to time with the SEC, including the Risk Factors contained in the Company&rsquo;s Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q, which are available at the SEC&rsquo;s website at www.sec.gov. You are urged to consider these factors carefully in evaluating
the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which
are qualified in their entirety by this cautionary statement. Unless otherwise required by law, the Company expressly disclaims any obligation
to update publicly any forward-looking statements, whether as result of new information, future events or otherwise, except as required
by law. All forward-looking statements attributable to LifeMD, Inc. or a person acting on its behalf are expressly qualified in their
entirety by this cautionary language.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex99-2_001.jpg
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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M3S,77IIR5_AU9I9HS7%?\)=??\\;;\F_QIT?B^[# R6T#+W"D@_UJO92.?\
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="E.Y)YJ9R37+'8Z<-0FINM5^)_@34445D=Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>13
<FILENAME>ex99-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-3_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Pricing of Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, September 28, 2021 &ndash; </B><U>LifeMD, Inc.</U> (the &ldquo;Company&rdquo;) (NASDAQ: LFMD), a leading direct-to-patient telehealth
company, today announced the pricing of its previously announced underwritten registered public offering of 3,333,334 shares of its common
stock, par value $0.01 per share, for gross proceeds of approximately $20 million at a public offering price of $6.00 per share of common
stock, prior to deducting underwriting discounts and commissions and estimated offering expenses. In connection with this offering, the
Company has granted the underwriters a 30-day option to purchase 500,000 additional shares of common stock at the public offering price,
less underwriting discounts and commissions. The offering is expected to close on October 4, 2021, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from this offering to repay a portion of its indebtedness and the remaining net proceeds for
working capital and general corporate purposes including, but not limited to, new patient customer acquisition expenses and capital expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc. is acting as the sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-256911) and preliminary prospectus
supplement filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The preliminary prospectus supplement relating
to the offering will be available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when available, may also be obtained from B. Riley Securities, Inc. You should direct any requests to
B. Riley Securities, Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone
at (703) 312-9580 or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there
be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex99-3_001.jpg
<TEXT>
begin 644 ex99-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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M3S,77IIR5_AU9I9HS7%?\)=??\\;;\F_QIT?B^[# R6T#+W"D@_UJO92.?\
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="E.Y)YJ9R37+'8Z<-0FINM5^)_@34445D=Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>15
<FILENAME>ex99-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-4_001.jpg" ALT="https:||www.lexissecuritiesmosaic.com|gateway|secdata|21|0001493152-21-013322|ex99-1_001.jpg" STYLE="height: 48px; width: 166px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NEW
YORK, September 29, 2021 &mdash; </B><U>LifeMD, Inc.</U> (&ldquo;the Company&rdquo;) (NASDAQ: LFMD), a rapidly growing direct-to-patient
telehealth company</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">today announced the pricing of its
previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred
Stock, par value $0.0001 per share (the &ldquo;Series A Preferred Stock&rdquo;), with a total liquidation preference of $35,000,000.
In connection with this offering, the Company has granted the underwriters a 30-day option to purchase an additional 210,000 shares of
Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close
on October 4, 2021, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds of this offering to fund the segregated dividend account and to repay a portion of certain indebtedness,
and the remaining net proceeds for working capital and general corporate purposes including, but not limited to, new patient customer
acquisition expenses and capital expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc., Ladenburg Thalmann &amp; Co. Inc., Colliers Securities LLC and EF Hutton, division of Benchmark Investments,
LLC are acting as book-running managers for the offering. Aegis Capital Corp., The Benchmark Company, LLC, Boenning &amp; Scattergood,
Inc., Chapin Davis Investments and B.C. Ziegler &amp; Company will be acting as co-managers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-256911) and preliminary prospectus
supplement filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). The preliminary prospectus supplement relating
to the offering will be available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when available, may also be obtained from B. Riley Securities, Inc. You should direct any requests to
B. Riley Securities, Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone
at (703) 312-9580 or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there
be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex99-4_001.jpg
<TEXT>
begin 644 ex99-4_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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MQ\-V%TOF6I\^9HCRK,JC&1WKJ$LK6, );0J%Z8C Q56BDKD7DV[=">BBBH-
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&161WG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>17
<FILENAME>ex99-5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>Exhibit 99.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="ex99-5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters&rsquo; Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, October 4, 2021 &ndash; </B><U>LifeMD, Inc.</U> (the &ldquo;Company&rdquo;) (NASDAQ: LFMD), a leading direct-to-patient telehealth
company, today announced the closing of its previously announced underwritten registered public offering of 3,833,334 shares of its common
stock, par value $0.01 per share, which includes 500,000 shares of common stock issued upon the exercise in full of the underwriter&rsquo;s
option to purchase additional shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds after deducting the underwriting discounts and commissions and estimated offering expenses
payable by the Company, but before repayment of debt, of approximately $21.4 million to repay a portion of its indebtedness and the
remaining net proceeds for working capital and general corporate purposes including, but not limited to, new patient customer acquisition
expenses and capital expenditures. The Company anticipates using approximately $5 million of net proceeds to repay existing indebtedness. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc. acted as the sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock was offered under the Company&rsquo;s shelf registration statement on Form S-3, which was declared effective by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) on June 22, 2021. The offering was made only by means of a final prospectus supplement and
the accompanying prospectus available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the final prospectus supplement
and the accompanying prospectus may also be obtained from B. Riley Securities, Inc. You should direct any requests to B. Riley Securities,
Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone at (703) 312-9580
or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>18
<FILENAME>ex99-6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 99.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="ex99-6_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LifeMD
Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>NEW
YORK, October 4, 2021 &mdash; </B><U>LifeMD, Inc.</U> (&ldquo;the Company&rdquo;) (NASDAQ: LFMD), a rapidly growing direct-to-patient
telehealth company</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">today announced the closing of its
previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred
Stock, par value $0.0001 per share (the &ldquo;Series A Preferred Stock&rdquo;), with a total liquidation preference of $35,000,000.
In connection with this offering, the Company has granted the underwriters a 30-day option to purchase an additional 210,000 shares of
Series A Preferred Stock at the public offering price, less underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds after deducting the underwriting discounts and commissions, the structuring fee and
estimated offering expenses payable by the Company, but before repayment of debt, of approximately $32.9 million to fund the
segregated dividend account and to repay a portion of certain indebtedness, and the remaining net proceeds for working capital and
general corporate purposes including, but not limited to, new patient customer acquisition expenses and capital expenditures. The
Company anticipates using approximately $10 million of net proceeds to repay existing indebtedness. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc., Ladenburg Thalmann &amp; Co. Inc., Colliers Securities LLC and EF Hutton, division of Benchmark Investments,
LLC acted as book-running managers for the offering. Aegis Capital Corp., The Benchmark Company, LLC, Boenning &amp; Scattergood, Inc.,
Chapin Davis Investments and B.C. Ziegler &amp; Company acted as co-managers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock was offered under the Company&rsquo;s shelf registration statement on Form S-3, which was declared effective
by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on June 22, 2021. The offering was made only by means of a final prospectus
supplement and the accompanying prospectus available on the SEC&rsquo;s website located at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus may also be obtained from B. Riley Securities, Inc. You should direct any requests to B. Riley
Securities, Inc., Attention: Prospectus Department, 1300 17th Street North, Suite 1300, Arlington, Virginia 22209, by telephone at (703)
312-9580 or by email at prospectuses@brileyfin.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there
be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc. is a rapidly growing direct-to-patient, telehealth company, offering cash-pay virtual medical care across all 50 states. LifeMD&rsquo;s
telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate,
prescription medications and over-the-counter products delivered directly to the patient&rsquo;s home. To learn more, visit <U>www.LifeMD.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Note Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section
21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; predict,&rdquo; &ldquo;continue,&rdquo; and &ldquo;potential,&rdquo;
or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking
statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance
and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving
regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the
effects of any of the foregoing on our future results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,
beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,
and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements
relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult
to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may
differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited
to, &ldquo;Risk Factors&rdquo; identified in our filings with the Securities and Exchange Commission, including, but not limited to,
our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,
performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative
of our actual results, performance, or financial condition in subsequent periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement made in the news release is based on information currently available to us as of the date on which this release
is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future
events, or otherwise, except as may be required under applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
Contact</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashley
Robinson</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci
Advisors, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>arr@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex99-5_001.jpg
<TEXT>
begin 644 ex99-5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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M3S,77IIR5_AU9I9HS7%?\)=??\\;;\F_QIT?B^[# R6T#+W"D@_UJO92.?\
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="E.Y)YJ9R37+'8Z<-0FINM5^)_@34445D=Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex99-6_001.jpg
<TEXT>
begin 644 ex99-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P *8# 2(  A$! Q$!_\0
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M3S,77IIR5_AU9I9HS7%?\)=??\\;;\F_QIT?B^[# R6T#+W"D@_UJO92.?\
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="E.Y)YJ9R37+'8Z<-0FINM5^)_@34445D=Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>lfmd-20210928.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaqHGbP9z5Z8qekhvWB5bckqzyEpTAYmSi880UfmoZQN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LFMD="http://lifemd.com/20210928" elementFormDefault="qualified" targetNamespace="http://lifemd.com/20210928">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lifemd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20210928_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20210928_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20210928_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="LFMD_CommonStockParValue0.01PerShareMember" name="CommonStockParValue0.01PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" name="SeriesPreferredStockStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>lfmd-20210928_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20210928.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" xlink:label="loc_LFMDSeriesPreferredStockStockParValue0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesPreferredStockStockParValue0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>lfmd-20210928_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="LFMD_CommonStockParValue0.01PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_CommonStockParValue0.01PerShareMember" xlink:to="LFMD_CommonStockParValue0.01PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_CommonStockParValue0.01PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.01 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" xlink:label="LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" xlink:to="LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Series A Preferred Stock Stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>lfmd-20210928_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20210928.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20210928.xsd#LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember" xlink:label="loc_LFMDSeriesPreferredStockStockParValue0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesPreferredStockStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LFMD="http://lifemd.com/20210928"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lfmd-20210928.xsd" xlink:type="simple"/>
    <context id="From2021-09-28to2021-09-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesPreferredStockStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-09-28to2021-09-28">0000948320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-09-28to2021-09-28">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-09-28to2021-09-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2021-09-28to2021-09-28">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-09-28to2021-09-28">2021-09-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-09-28to2021-09-28">LIFEMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-09-28to2021-09-28">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-09-28to2021-09-28">001-39785</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-09-28to2021-09-28">76-0238453</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-09-28to2021-09-28">800 Third Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-09-28to2021-09-28">Suite 2800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-09-28to2021-09-28">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-09-28to2021-09-28">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-09-28to2021-09-28">10022</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-09-28to2021-09-28">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-09-28to2021-09-28">351-5907</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-09-28to2021-09-28">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-09-28to2021-09-28">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-09-28to2021-09-28">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-09-28to2021-09-28">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember">Common     Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember">LFMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-282021-09-28_custom_CommonStockParValue0.01PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember">Series     A Preferred Stock Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember">LFMDP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-09-282021-09-28_custom_SeriesPreferredStockStockParValue0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-09-28to2021-09-28">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139814498610120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 28,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIFEMD,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000948320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0238453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800
Third Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">351-5907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember', window );">Common Stock, par value $0.01 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember', window );">Series A Preferred Stock Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Series
    A Preferred Stock Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMDP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M',$8  <,2=/^/7CW/DK&]U1R^8^P^0E02P,$%     @ -(9$4Y>*NQS
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M7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ -(9$4R0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  TAD13R@AM5>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  T
MAD13F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( #2&1%/J1PT2HP0  .H3   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  T
MAD13X/0ZB:H"   P#   #0              @ 'G#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( #2&1%.7BKL<P    !,"   +              "  ;P/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( #2&1%.JQ"(6,P$  "("   /
M          "  :40  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  TAD13
M)!Z;HJT   #X 0  &@              @ $%$@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  TAD1399!YDAD!  #/ P  $P
M        @ 'J$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(   T%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lifemd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex1-1.htm</File>
    <File>ex1-2.htm</File>
    <File>ex1-3.htm</File>
    <File>ex5-1.htm</File>
    <File>ex5-2.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>ex99-3.htm</File>
    <File>ex99-4.htm</File>
    <File>ex99-5.htm</File>
    <File>ex99-6.htm</File>
    <File>lfmd-20210928.xsd</File>
    <File>lfmd-20210928_def.xml</File>
    <File>lfmd-20210928_lab.xml</File>
    <File>lfmd-20210928_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>32
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "lfmd-20210928_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lfmd-20210928_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lfmd-20210928_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lfmd-20210928.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "LFMD",
   "nsuri": "http://lifemd.com/20210928",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-09-28to2021-09-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://lifemd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-09-28to2021-09-28",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "LFMD_CommonStockParValue0.01PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.01 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.01PerShareMember",
     "nsuri": "http://lifemd.com/20210928",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "LFMD_SeriesPreferredStockStockParValue0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "SeriesPreferredStockStockParValue0.0001PerShareMember",
     "nsuri": "http://lifemd.com/20210928",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>33
<FILENAME>0001493152-21-024517-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-024517-xbrl.zip
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MMB^7I%34,7P)*!>?%J*6RT4WJF<6L'(01[#+<+>3FMZJ8>> _\+EF<"?Y)[
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M=9DN]29)"JO9)6&R%1L^,L\)'X@8BI3(S+D5MNB%V&229DVIM&NP<)8)7Z/
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MT!)KQG]*$0*5B."WEPRI4H+=!5L'Q@ AH.Q9VFU;RNA/H=">2JY6?*F86<H
M@YZ\+$@<G<?8&S"&M4A(2)+R?/+TTWW*!+.PL0YF9<O2R8JT\:8LN98,E4XF
M] 3-#W(F<*F7[R"R24@4O1NOV,%4$LDF9D+:$D??%(APRLF-QJEXIY8M3X"\
M+LMU_0'LM8"U&J="*P]F.R="3+F6^/R?S73.-YK3V.'74S5!@[N@\%8T+^#
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M#9NYU=#&Q@,NPHEA=0;;U6-/@1X%XMU'%EMF*YVJ2NHP3=?N[;*HTH"QV).
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MDB.'.S,\H)/?BNY K)[.Z<1+CN-C+H0LL.J][*8PX(!W9PS45/&MJ5 5QN0
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MJ?3>IJA[F?84>LN6@FFT;PI)72$-%XEB8MO-71<-F+U@F399S9AYGK[H1]N
M I$^7([5RS5=#L9\\?240@;]C+&7"M=<A;9;-PK!(3O!#EXO.5MM;71G0;7)
MN+C'%+W!A_IH[T/=K0_UX=Z'>A=\J-\LO?I<*F'[U.^T$OY+PA\50[A1D[1F
M"'-6&YJ56U%.".)D"G]FNT5,;M;]%HV=R9"J'-8BA 'DR:8N-E*?P+#@BGT1
M*[ 65B)2 G.WC0-1"T$UOJW"MS;!JW5PF@U&7]9KL-U0D-$+9KUK' ZV6N2Z
M(T3G"YR9=AF2T_CF^=5$)@@H2L)*IFT6K(/VU'9D7<[!9YZ&#ZQ0<#WU2JJI
MK7V4)=<QUY#S4@LMQ>-^G8$<6:Q+QTB\U(SR&G=[J7*$EPB%<:GCMVXV1-#Z
M7$YBBEI42FXPQQWB+=#TT>@[M*JP2H5#: $(!K\HA]ZDKZK6GE+Q.0-U;-,3
MTUS>-9S!A7!%FSO8,S4FW&E#\#0I9W&]+BJD\_ Z8KV0*"OR.:-4$(73^3(_
MZW,U[.SK_11XC[6WN[D43.@_GV$176/+Y\658IN+S-(2,<R=M.1P\Q*G/<G-
MF%]+% X'(P*N@4NH&I8@NAT38Y&YX/S:SW/\ V)GA=M7'^"5=+.F@!;%K+<7
MM8M;C V*,@T"UK;#F+?%?XD(YHO[5:1N4!7IV7[L\/SY^^^A6B<N%PS*_34"
MU!;9?[8$?>?Y5#Y/9@X'NQ2:MGZ V]&,KB\1T-%BGR?3*5!/I8(A 9P+$)_C
M^7+\! ?6;^0T4[/V-H7:>[K>K&_+)_,F]#PD%& D,OW/D_E;B_EM!;OLRTTE
M^^:[\#FL:#C8?!?6:@1[,7Q/Q?"<'=?H$T9^83RY@E:C9LB%Z)8@5&!L\H*I
M36-*5DKL%B()<2*BI23!Q*Z 7H,SN*>-6[:4T273!E[UY(HCQMC055J/NMUC
M2!T3K*S,[3/F8I^6T;.L@=<^DA9DJWO^A">J:3I9UU)#(QJ&D03P2[ 5+&(3
MS%%0BR4/1VG(]!F>.M8LD; LN36K<7CLR>^6+06+VY#\2,N<JUQW&G4]5(ZJ
M(47QE28Y4#- N7!4A6! 3K<SQ-""@66DNC@!K;0: 'I]!.LKT98*(AGH9K?U
MM<I KUG .B[100?;1V7_1E5C8V:65@C7"]18UIUJ.P'JI&]L:! ,^@5WZN66
MP)2/S_>2,M4K76&J$U..CWN59%.(7S:9J'REFC=9TH;GU)KF/BH2'3_>1T5V
M&Q5YM(^*[*,B?;+@SX/HCTO%AAXH$I3)<"FMG1+1'+JXN!W,4'BD:A8+>H(,
M>>\)^($;1B=DRQ F$<69)TE3F1[H24HXH)BG278UI>:E4TDYDOQ <N5+!CC9
MX4[9O]:.W&_'-H7RIVC$.-[1C)IL3]-JW)25D\]G/MR"3#4B4'N\#,I.Z^].
M655?TZS2]=5V6X88[8\6P[,("!5R2Y$!CFO!K70V+?A=]G/8S\[2S''S]7F0
M.85%VH277EK5VDRV<-+E9V0?W"P1Q_%&<-6:YXYP6@<@'YL7Y)JR*;:XJ4O0
M$6KNQ%-154553%)=R%<JW,Y8'S^J4+R++<A2\FLMN2NRN!=Z/$3B6S&>C/]@
M0@<?M;0N)?!?DP,71USZ3<Z JI;8C#G[5KF$:="VALZ"-8;.GKA=X4S'3+\]
M'"\RCX<# Y5/L\,OF?W$9A)E,6TF>E1CL\!?7JLYJ&[G^97BYO310BT*^.JT
M6?31<\LR\A:E4V!(Q71-)3*/]/W9=&-\N\;?M5[;K/U);%!X7;$>S'6.?E+S
M7-="NILN=Y.NME$AK0/!_-[G8!L\\M24HKW.D &7AQSG--R61X9$>L5$&EB)
MDR*ZS5)"-P=VBE'W>WDL=B6A<8.'J(,<I@)%3E4XRBL#S74.RP&VN$+^B&H[
M%N6><0$49LV/KEI7,0J*+MT+HL]=,QQX_AH<M^\6.?@@E<7]]@>G]YT!!'>,
M,OLKW;C%LH8Y,7HMEE@-F*IE4:4U<'P>K#.:(RD])NR6T:=$&W3O773R(G?[
MKY1% O?GLKC65;ITC:@G09!@\6,,[.](KW#0RKE1ML !)1G/)+:+<+A\2%[R
MEH")IG2#4KV+U%^^+/)T$IF%;!P7F: >Q+P556"ER%V8E\D23%"L]=;70P])
M%"L@[AAV(DU#Y7,XQ?[;8+[A'X0S)2SVX/8E2=8ZTAA)Y4ITGJR8SJ64QC]_
M%X+^2N8LN#?!-A0FV]Q9AY&KANSIZ;2<E&"S$P'7W;">$[)QCF"4?CJX.=L,
M\YK^WJ<A!5EZ,/OZ+V5])G/XQ9SJ'!>H)>JT8?4)2V6B?X")%Q]AL0U,<?3I
MP-'Q-O"7@&I,?#8 B65@^@W>%8H*=G@8]X;.6[(YG=1)6Z]+A-=A=$Z:/0T#
M][P Y03V'N&X8NTMG*AE34"2KO!S!XF-*'P2(2.K,35?6 ,P7[7(J><VK/PY
M['&9CJG5GFF_)/22)=1.MDSHYGC.F2.I&0JTI*60"AHBMOE &MIK5S+[B@_%
MP[3ZX6B77IL@%BH+3?:P'5/R#%#9JSE/H3'3-($&FTD@G<%>T5]WC]U"=W,I
MHX^<5IC4+%;3A=O.D[R,*%>%<#6=7"C2"![ WQ_\D1 U(LTTN594Z/ZDU),'
MJ+56R(3<OSL5,PN5Y"S[A@-. S]ZU%\;0[JZ;5N$:BS^NR+7[)44^[B=BX(Y
M#L2Z-RT".:' K"*/H;1P^0U^#3@@(I,9-S#MC6T+A!@H-+T%KM\9 G]!N9DU
M]VOQW["I CJA0GH!?5%&!:5[D.$B@9#*- *E(^\F/+C,%AD-6<Z+99UQ][U9
M.#1/G5N(+>F' ]D.X1R$+8\$Y0U;\]Q@7(/"T>O=(Z'])]_T/>8\&QS2/^P=
MTKMU2#_>.Z3W#ND^>9H)KJO+/+7ORI3=NXE[E,V#*AL:L@>Q-JUU<,_V9^Y$
M^F)NQ@>J<[;BW!I54RN_J;R%VOQS8W'C&.]!@2])$WRF<@6_1L'S]CH7,X>=
M(B]1D5U%SV''B@7YT^IB3CYV5NYLV3JI\+"K;H&_&*<M%[.XM&KJB\<E!*A0
M,]].+. *BHFBK#L#HASO;%T/.$R/R8/.S9D1)&U':N1MU#V6%G=S*=Z=2K*J
MV BNPAT=M=_$^@FL0II7HK;=.,L0S+&T=C+TC=Z#:A1G(@,]@N8\R0IJ"\E-
MB5DU+F(!C="&+R8,2"7^CT>,XQ8*\OLY@/BS&)H_/_OEO4(E?4(W_AV-^//W
MSWX1.Q.8RNCX@.VQ.%I26S%0N%26<1L"3' @C91^@__-]ALC'''>L'E()P;&
M%HXZ_##I:CSD'%OY.8_%4<FZ:JG[_/DC9[ ;L=<WU//AP[YR9_%9+'V8LQ7W
M%=4_<;BF$F<Z[)YGT4I_4\>O#G,FY0*-8CBI@@-2JIRD%1O*^"/W.F57#/S"
M;\8"OQB='$2D8_ 0](GK9&G6 486KG6N4WY1%Y=527B''B-]GCJ9\IJH?6#L
MFN<*I@MJ[81)F+4/8L<%,?++=!EN&'.M Z7&>^5X@4!&51.P\\0_E5%D\QBG
M<"(='%.#@Z5J\G.,5UY0IKW'#KA^Y2#BX.A)=4E.27N^N'^G!Q;*P0LS6H4^
ME-[<@C[UO*F6#$(S)+FT0S)@]*=2[J)QK7D%6U;@(/<AQ9$R=2B3G;)B*4M\
M=';0BG)I #+C^H);_8P?,K!BK9 B)M*%%V]:#\KRQ ,D]Y/.1M],"<7PWE3:
M"6"SJ1!_V8"N=1IFH-SV*,MM_-)7K83LU(F]TG1&SP_00DXS<G\+\X2=AH-(
MJTMK@-?2XWV9);G/Q!/>#,[^BBVL>2E,I.@D7;4KU(>#XZ/QHP?'CGO"[88>
MF[B5Y59])Q"'H4,QPL\5+SA]TWI>:TLR/K!6YP/>P3J2Q<J$Z)W4SZ!GEH(A
M7FID8E!5\[QH@(ZT[2S1KY[5@@RD"Q9[I2P%M>.Y*C+,(Z!F->1\;5%F:?30
MX#&:+1"_0,_$Y.(8IXS#* *M9O,BZMTV[@_$4Y5 J#V%-5NZUQ-OV5)^Z,'H
M<[4W!NI[V5(84?.YTKFD HKR)S!J4B=:RJ9+RA(%V8B=(8&5SX+*8))T0#(^
M$PJ#H3<[8!@!\ N\#4'<H=9%KAUQA(!OF@,F$VNS>KN_OS&W;"E/Z,:88!5#
MHKK1JD,23P2(Z$9!T0M1<9R<7IWQM;DD'24I%QD"ZK6M,NDQBYT!T0S0 @34
M7;8;BJRB2^2\P@'23K! %W"92-FCGASFPCYS<J2?<049.TQP6LD,!8L87%M.
M8W/(@BH-*'HVQX8F; CI)!ZP#RE$!PIWNB"8_T4R%T\Z3&6,^@X.9'$@8YY)
M.QD !\W(?6.RG)RT*N,C69=Z,E4S"PC'V0\4?Y6$)Y;$<J\1ZP"G?, <!"0]
MZI!-3499P6V(Q@FFOJ&JR=,+N>=A#Q3&_K>)IJP%/W Q*<7 LP!PM<Y1:N4#
M1ENF W9'[-1O(GIBS!8%JN,8F>YAT*01S_0Z#%._[$>$XWGKF^?B003[UQ.C
M9JTYK3H")NX#7MKP^;Z$EPW+":: CI*^X0[:F9=;;[T\MRF$Q/NR%;WJT)%+
MI^9W)H)7:Y#-%K6VI"<]/#5/XP7RRH+71/@ZP3E.3(#MKHI90C#"=#?[> E,
MWV4EWMIE-[J+WQA06W][G>=T\@5>.[)2R?BT:7I(S21X3.: 2^&N==]BR=WN
M#?:*F(LWEJ7X2@]#]P;KR8!K8E$S\$K492B_VP1::XVO8W)&A+&7BLY6+F.1
M9_)5=R5VMJ)#M? &_#D!/_,<$U5:U28-QAW66M>:#MAG),DDB#1)*21[Q>N6
M+05/!HT07R%GO6JM,;)!Y_*2WS"RI-T;%?]H\MI0ZT(LZK6RU"A':W4V/UU@
M-^K:<-"CKWGMB,2%4;6<:ZE)OB+URS-9B@Y'8-N%KJUT%C 0R@7:;6%VU.$K
M7X$?188=,<0$U6.O;ZW[F3H.O[A>=XDI1Q%K;C%)L8/VNZ6LOL><:$,JQI-]
M*L9N4S%^V*=B[%,QUF OGX,4F>@8)? Q#>H_\BN$YEC G5.R0>9:OD5^('74
M8V2[\-NZX2+"JR*[TF^S9&05ESO26# EZU81%W.%G+X.=C]]0H78)?SO^" V
MP%<X="O:JZ4_@HIC='#E!GMEPNUT/8DU5]3T1AP1(,(76F74XM*?9L^'*>&C
M^V5'S.GTC^X;L0?$8QRTG37%D49VH'[S.L?=\66$>LUUAL$_F.S^GD>H",T@
M!E4]$Z>M 6T;:!CMOC0W>/.:JJB6BG<_X1WOS]F7Z@&]*%WW!K+5'_00:-@:
M9/;W(JX[:W%:G^,$.-!.>T#;J/,NY<NL^'@S]4HUO%F:FR!FCCQI5M.=3).3
M1JKK5@-[VJ:3T$+@[C1UP[JP6%I\V+ F2:IH3Q4#AKKJ!_&J>-!4F3K*]M&U
M&$**R53)U+YWH%-_AP,0Q)<W7PZ#)[@5+#AI&DM/3<Q"TFOU0M@A3]R'"ER6
M)?DGIXUB2,L);@P5)Q:T%_##--4!<$PZP6@THD[4UXJ1I!;=P@=KN0:6Q.>@
MX:H<#D<YQ^AQ],MIPF09<#>V6#*5Q_(UL+\UZ%JT*2X@#.%2H5LC<\*B'2+&
M"2U KD?4+['(,7F!RJ((=6.!QVZRSS1I9 7B<,@!'-#@A*01(G&=],Q.4'DJ
M- ]S=TJ5+H@33,5H69'[1?ME#Z,/^!V:G'G',)UIRY((MAR2'4.Q1W=8S].;
M>X_XX50F/\;CC1C=:,#QP2%G0ZZCJ]9!<FH.9I@8/[!/*!S3E4H3=&,A3VME
M=3%? U-5YZH(>*(NV1+;))U)00$R-=ATS$#\LYG.Z<LZE+7,$,\*+E7<>^L#
ML9 P%T!CE",L;C  '7>NEV[%;9%0T!G.YFY):29YB-C]N#:3@A'.,6&SW:GQ
M2')[*$'A(?*9\DE#:R:1(J3<M]BB[(H5MUXM:9>>:0Z(&4Y3N5AI.37+J$P2
MK'%P;3P4JD2I[67:1&I4Z7 36L.M-7D;SG!IQ>E@=&O1PVOXT*F7Y5>JB4I!
M2QZO?!ZSHDI%7HRPVP1/MD*@"9WK:E(Z.J]VKID<JV$_X4-#ACB9@(E(KEI3
M9&TZ.MG66FYV8FOM2):]D]DR*3.L%(*LT4!S039A UCU)=P@&-.3)T$EO4=B
M59S-V)!O30-3)OQ7:1QIM.;V8Z(^VS+%]N$Z:JXH21WR87VCXEHC ]V:D+:H
MF!4+1POS&8XO&I92Y!(8T!$["3<(1!]WK+3)-U8!O1?&X'VR:Z>,?^9D<'EW
M15+]3<GJC--(0U8FJX$><IK#[2TYT0A5@X[C5 J"Y1:9@NXM@T\N.*F)J]0(
M<DI.Y@#/<-.Q+-/7^*=8A.#QRYX+X>:I,$N<Z!0' Q@G9<T$Y(,:M53)]E[=
M=FVA&X23\'C_1J#$<$Q(*GK@,@<LFW14?1*TLXS3V)0XH(G/8 $'07."_+CJ
MIN9P,B8<$&B]EXF1IZVXDZ1L<L8 /68<YCU8VMJV2D4F9:@P^R0',Y$,XB=
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M&9P^;'5,;"GCU>FU>K9MSVVVY#11F-$XG/# PG;:;+C.2M$_0GMN<8,XK9\
MA739)'=>\IU3%Z[^G% ';9DAYBTB/A#-<TW9+V\+XQ.DM9V*ADGI3!91C)&0
M)/'8I$BCD.<.,QX1H,U+^9=;DN2>Y]RRI1R?D)!_KR;%/$^]'GZ_'WXXC#Y@
MG ,LT_<*=.5&-SO$,:T:<"Z1W2NE&W"U/7RV;S&V$$$#Z277Q7"<N'(+/1('
M)$/:&\+OUD^&N9!I0T/$V_&W!&Q@K7OHF]GB.>R"]1Q%SLMDT8[=('<_@JZ9
MF@$><T+CN<:'7[](KCGR&)!=@52R!)<1<V42HS%:9P6P!Y.TY^? (1N7,MW0
MW_>7^)8M!16'\UR@2S[C%M)Y/_O7<X*!/G,3RSN7:,.%U7=E\X65G)+H/5>0
MA!Q(/&%!SM0=U2S$5V=NJ+U868BX%-Y[,%708>94GU=:B)=$_-NM"4W,134#
MW/2B>CZJ_0V\SS?P%3:>D-K.;EU?XF"]=JZ9 _5*D??:J21+*D0HM'5UZ 35
M8YD"$/UR2BTFICHN.1:%<UDJP3EI 9#%T?$)4?+SP^B?%4SU:73\Y.'QZ./!
MH3-?GU6XD\5)5JZ_>59D67$-\R;# YF ##.1,;@8UNEPPI%-7%3JMCN))7]V
MX^R?'[XZ?&]F?_+HY/#)"3##IVQSM+\/_"#)/WZUSS_\X?"4/LY1L< $HE<?
MSN7SL#N[_O[IDY/#$\*&M*?G,;4 I0T'85(S\Y+)W(2DO%FY1W,<XQZ=X/[@
M7(\I*<S:*X?#@9WX>@[;)4-MG6B+5^?7OU"4' 3BL6HX_5^WIN* ^KS))(2!
MR,Y--N?\[-H&2PT4X 66:$;GYYK<7Q33Z8-7,.C'Z _<G0\U<'O8:G2$<F>J
MYS!NLX QWI5%+;Q@B\]']=_!U7\WEW)\*IT0J3X% W65*9;R=!<-^,V7"AT6
MUX5)=)PXK\>&=B4+P<!!H_&1SA$]-;9V-1L7 M98:1P"!K)M.-N LV:)RN2?
MI'V8%%P: E6HLF%427<U>N*2F0MSOTH3A.BIT@6UN5*(#E86>3J!1].L#?%L
M_PR"2,]*(I?XC%D(W?"97-.7'\Y_?<.-2F;1R='148P*#UVDE_9[%[:OLNEJ
MPKZF-MB9.IP?PJ9=7Q]BW@K.XQ"F<&"[([-%9GHI,?B"-J:<X\'0H]V* %:!
M4][32%>9*R#):;9RWB/T7\5_8!EMS3\=EM3:P_[*W[*E'#^D*W]F2&PX>)U<
MKTU^]S1]*8_&ZQ84FG0;2*YB HYK$WS0!H N$=O3QBU;RO$CHHU_<0NYRJF;
MO91?Z;.LU*0G%<-A(<"455D++@.U!L]3G<UD(=S(5>XC,EB6E.CLD;;#:D\[
MMVPIQX^)=MY0S70%9(/4<T80JDYCQ<HI5G"T<*\CB!4F1!K2"(3AK\F4F&D#
M,ISW;P153"*="@?*B#M[!+.!,7!T\N./T;ND_!B= 94VH!B<'/_\X?=WOU1@
M9^#_1J^RHBACP[OLOV#]QS^ ]G]62Y^)GZ)?N=J:-)%*94]EV@)^%\A)ZDPY
M<F;\Y.@(.7,Y-7/[T&"!P,D35"R"$SHZ.?$F]'^0!J@ZH53I&!3QX> L=W4?
M[Y"BD5@NCK+"Y]IJ'V/OJ0X_2<D\7OA>_\'Q8\;<-VB JJ.%)=-I27#7IEIV
MK)%;$0NS@_NKVS6097H8=>;=F:_!U.1<9)@(>KITMAH6@C/$47<D>9.P0+ !
M@PF'.PCM@9ERQB8/;O_4&9X[ +FX[4%4'9F$9-?2O!"H)%EB92^U&<V+W-E4
M4CWUJ;[Q_M0Z6-+:':>+)D*=L,V-4V4A&BT(#GYT?'3 >/7.5HBPT,2AEX74
M$9K$/>;I&S+!3O:98+O-!#O^FV6"?7VEQ)*22SIMTKKQ*CS*ZJ7 [V@#'3K;
M_@,!BOQ.'X>EPFW'^XK[#&1II_7\+6[SF__^[N3&>^K2Y"V@IO\AQ!M<%UB,
MH,ZML%@J]JB+%GV;YARX ;=NCC\_^^7U^:N7O[V(>7+G;YX?HB/Y+YGUEG3X
MS.RD-R_+@F_)K39LZ!$)G+_DAG_V%'<ZPV>KG]9.;Y..P4/>: $/=[L"L#F_
MK[[GB?^6E)/HF<H3T#H)]<M=VVTBN%M*9#L]%YX0:69?.JO6N>X/<[MI48CO
MBS?_^:NWK2T7O7FOMGX[M?7;ZH=?O>[DC# XT7.'"TZ,VYDZR3&XSN[UG&]1
M37,W)HZ)/H<\V??GKU_^._KP\OGO[\\OSE]^B+^BXGE'#Z3M8*(=W.'58. 7
MG*C%M6D#XTK%J,G-T/U5/(\Y]SSV46NZ&%6W1Z7H"L>OJ@9\$8_5<_VRO7-&
MN4T:SS<R1FXPO4N@\ ?5,D'O:EY<E\GR:]D?H>[*8I'GD\,=VWY?VSR]342V
MFSL4I(5[?CWOIH/@:SD%WB4U]0?Y;?(F1<6\[1>X%=M\VZ_B[E8J#H&=['_W
M:/?G^5>O5#L9=G*@SXL'F'R$2NPYM9V@C*)GC$9^-TYW=\Z1O\*L"_KGOT+L
MG2.[NYS\_PL\_H/.R!T.*)I:%]'K=*9^>Q&3\H5Y-@M"CL-V!,;TP?P%#_[A
M_[MK:X>EZX,[;Q_<ADR#TWVFP6XS#4[^9ID&MXHKC1'2[W.7P%7,10D4W2R7
MV$$$"=!='6%@[G)MVM$R')S?SI7=S.[I<[7OF 5L-ZF6;M7F#\R\>I2F!]<*
M-X2W/<2]M^&!CF^-K_[:;RR3*688F@%IJ![#M,<3M9-9OPE"[EX4T3/L_BT8
MG^WU!"<O].Y.:J.)'#XEF#?,<UX633Y%$BE*H-CY>'1R]# ^.7T2GSQZ=! X
M22&<)T@W74D0<M2(C\9?G QS\E_KW02;+5]-R,'IN!OS.8,^_J_@C3Z-3T_Q
M_Q_VK&KS9+[HE/Y 9XMS-*UEKMW0;?<HL.K-#^YXG5M0H[XC^&7F8-U+?\*7
M_@+;F/ZTZ9*=K.$0Z\B'WHNF13/.U!=28O]0F\@ON)BM2=$857=!@?F<!."'
M3W6'LY_P2Y(J;W3UX[VNWM+5SQ]\5KN@O;+^#0 B[["6?DO5]%M\7E_-Z8%_
M)C2O%I[DG5S,7UCXM[MIMQ3\'"@WR;[[!>T&C8'_4^1H /=A<??IH-Y*AU%]
M5(^.CN*CHZ/[L;C[=%#O2BH%K NPP,=9.ODI^L?CPZ,CA /#>L!2W8]EWJ<C
M<Q.K3)?6%VE%X!MP?D>'IX__%N>WP=!Y%#1THM=)5?]]K1T9^O3TO[9Q9;3L
MH=.': Y]'7MH\Q1[+::[:]/LX'*&CLNU$>E.M>A9OBT?_?[9VQ?_QBCR]_^Z
M^.WU+_\_4$L#!!0    ( #2&1%,JR9WQQ6P  *C< @ )    97@Q+3(N:'1M
M[;UI<]M6MC;ZG57\#WB[NKND*IC18#E.G..ZFIRHKZ=K*9V;^PTD-R7$(,!@
MD,SSZ^^:]H2!I&S*EF2>>M^.)0$;>UA[S>M9O_QV\>;URW[OE]].#T_@OP'^
MWR\79Q>O3U_^\@/_%_[Z@_SYEZ-W)W\&YQ=_OC[]GW],LK3\.=C=F97!13Q5
M1?!6W00?LFF4AOR+,#A7>3SY![P(K[[7[Y7J4_DD2N++].<@CR^ORA?!JD.]
M"*91?AG#B_#H/U[^\NK=VPMW.D\FT31.YC\O&X6>+>+_5?S1?[S\=SHL9B]^
M^0$'A(6_KTUY]?FU+&[QE%?;P5^.7IY^NHJ'<=GO[0[V?OGAZ.4:)LLS>U)F
M,YJ=^<4P*\ML*K]S5S12::GR=6X\+$SO_=(E#;-D?%LB"7;N>@6[X=.=G7!G
M9Z??.[^*<E4\R%6L= 'NY]1?G[TZ?7,2]GMG;X\'#W(%#WCSGP^>_WCP+_HS
MO'<8'%?3*HG*^%H%[U4^4V45)<'[7$U4GJLQ7)$R&WU\D"M]P(?T^]N3TP]_
M?#B[.'O[:[]W^.N'T],WIV\O'N1:UB:I%\SZKZHHX\E\G=,^5[-238<J[_?V
M?@J#O9V]W0>WAM:MAXG_GR=/@E>Q2L8_!^^C2_4"!OB[4ND(7PR>/!&U\I>3
ML__J:=3TC&>H9PRS?*QR\[NC)!I]#'8'!["T(DOB,:SDXO#H]6EP?/KZ]?O#
MDQ,@YO_YQ\X_Z.?S]X?'^F?YAHPWRI(DFA4P%_VO%\%-/"ZO<%4[_VI322X^
MZ#&N55[&HRC1FPJ:DK_+B9K0&R?Z#6=HNV$7)ZA,?\#_P17 ?V$O6K9EF*OH
MXY.AFF0YS&9&>^GJ:,]H>N_]713%4G_KO3^Z<S8_X.'P>3Q8:EOSM$E#?]#7
M?.TK>*#\]6C0[WV($S6')T95'I<Q/GV6CI9IA/=O*5_Q!.27<3I6..C.X"!.
MU[F4PP).1<W *(+Q62O,)D%YI8)" 6\%U?!W^'1^ ^>E\F6&TT,YJ5M)J88H
M^@S+O6FW>T)L]5%;Q!TZ;QSQUDI#JW] 5KLSV%LSH8U^R,PQH+2U,_X\U\T=
M<:C@%O^WA)L9G>(>'K2O^:SM+/9^^@D4S/QC<'BMTDJ!>-TMRN!5DF6YW8_;
M;?**__<=;3(^_6>6?PP#_2]D3KL_[M[U%HMNO!;.S_]+7&85N??$,*1UB9X'
M.P%K1CP,$?PZ&@-O[/>B=!S\"DM)U%2E/S\23>*;ZGS>+L<3]>:$)5 81,&)
M2J*;*%=@4^>S+ ?-+DN#+=#K^KU_)^._J^S%+T<OC[/I+$KGZ-C_=TZ_W Z#
M69[-L@)64&9!7!25"O#D"I4D^)LNS3!(HZD:!W$:G(^NU+A*%&_867"E<@4O
MXK<#^VE?J[3?[_>,MSXHR%F/^FA<%L'M_)@!N3%A-5$>7$<)K.*?.P,8=#>8
MJ9Q'IG4E\=]5/.;MF='+Z!:!;_9[_]P[@#><YVM+>!7GTT '%.P*!L$%/"9;
M&T1)D7WVEF9E,,UR.++R*DH#_'_C<8Q3A2?W=K_))O5[WBX%RS;IT,ZXN55!
M/*'Q91. Z('@X9]1&1P-.M2K8,L.WF92^L0<%4'>:MVX&QWBU.$LKB+X^UC!
MKZ9QJFA:ZI/*1W$!F@S0QU#!8Y/6$?"(%)OZ^-JLRD=740'G6HVN@L8>!)=Y
ME);*+-P[=;Q":H3/^RRGZ_KO$7=*\NG2)XE1[/5[>".S"=.I0\1\%/"[YGSQ
M8/&M.(TF,$ERU.$<KU4R#PPUP6I@O_WSYP$&SJG09YEJ^SW8RZ]\KQL4&])E
M+YT["^L8PJ-5690P5)Q>!KSJR_@:?U"3":S=W-PH@6F/8)O5= ;SABGB3@WG
MC4U;N$_U $S'CFGB@ZE.866MF['KKRUPEW:K.?%'3$3HZ.5 )G2OI. C$NB?
MNY0+%.OZB('O!!-@BF.PY<LK.E++'>ENG'X"YI1>,A6!/-*J0>WH^2\>OXZ
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MA[F4K?&X9B=L4?M"3LJ-$@2*K8&67"A2!I_ D3[Y RFI((JH4IVP:W)'I>&
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MF**7A%(.-J&4]892GFY"*0\AE/+-\IW/I":^2_V."^&_)/Q1,80;-8I+[FC
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MFZC()BK2)0L^;@=_7"DV]$"1H$R&*^GS%HGFT$3(;J 'PR-%-9W2$V3(>T_
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M5JQW424PMSQ+XU%@%K)T7&2">A#S5E" E2)WX3*/9F""(N2#OAYZ2*)8:>>
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M84*D(8U &/Z:3(F)-B#;\_Z-H I)I%/A0!YP9X_6;& ,'.W]]%/P/LH_!H=
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M'K'Q=WZYO_/IY_H['Z9'LGY7?CAZ=_(G6H(__';QYO7+_Q]02P,$%     @
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MI!Y$W+#V4&7]UAX4[R Z2A ?PZ')-.]ZR*PIP\-!'HY8)'Y6I?42]K7&2:3
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M34Q>YPG<5=<E!1//ZAHNY[Q*I@P"#Z'7@]MT)?\!#/2O)2">D(#XG!1?/'$
M/R+!3_32>74OLSQG\BNC67:!/',F#@+&_OFOJR406I[]MLIFXKJ9 6FI:UU6
MX]%E1E?_T6H9N+YQ5,$$H[W'^R",B@QH'^4 4.TT3^H:R;&RI)3W\-^J&D5
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MJ"I7TB] N!V#U)#1N0%(3&"/*B% XK3B7I19@8#.CP]BLQ\0W>QE^PROV>$
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MS :AF2'V,(%KT/]&9/\L0?]3\2=02P,$%     @ -(9$4V+?BZ%)"   9RT
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MJI7<Z^M6NYV]_F*=,H^LU;X]9GVE!T)7 "?DL0&\[+^2*P_-WLV7"Y@*;67
MPRP96A67TF+3[+7_$N#M74%'#L5EN^QA7D1!=7$;O3;]NGDJ]MB>"=[4:AY5
M;RSU@+6F(DH$#B?2"M; NU^?27#.H_JD]&]EQX;^(U]L-#:;8]^%[<D.YING
MB[?#!U*88H%' _9!1#84$Q$=[0[^/[%WOG/\-3%6#N>>Y?_?A\IH(.A\K7HH
MH^TI]K,H%L9\*A@/K!@P;E@H1CP$51(9$2*N69I874XM,\[:(N0SK@5H=*PT
MMU)%;,^.!7L1#CXGZAC]X9F:Q#R:4X/X0KN'+\M,1C@212)P)V;2CAF=BK6(
MN6?C'60H0QF-E@1=$21:6C@0H[?/;X,QCT:"0<A$&K-9?/I.'@%30\"_ULK$
MP) 8),8X=IYHUQDLB8J%)=4*LP$G@W5%;,4$30ORJV]:R&3$+"='1D&8#$ -
M"]!;-V(DC4TMU[5@Y##@Q7NE)ZQ;.6![[V4HV$=511]Z4&D<OGI;K[\L%M9@
M;F:T:G58$Y+[<R<YO9>E;7,V3.!Q>MW@K<"2V>IO#P[*Y!T< J#)'22K1U8,
MI>$O9*K4+FHXA!BZ2,.AXAHPDE7^KE8KUVHU9L9P,[-^-UWW-"^B6,"Q')<7
MVM!SP]Y4W[P^_-:% @%C9\DD 1@)?[\6.A8V@:M?:P%$FB[3J@!% M[(ICQ,
M!/NF5@6..HN!V(%A>WD?63FW8O5B(4ZT23AN%6KSB/U(QIV1A>#9K9$6&]UN
M,]7#;O<V=3L8DHS:%W8F1)0WAX\J>F $ZC943C(Y0AL6X4[=VUK(J,JN<\ =
M$ZKT0]1Z2W>'Z#=(<][CA+&\'THS)K@NE-4,',MLL"3"J]@92D1!5@'<<&U8
M>FEK=KP3R_?*7_5SY[C>868R#&$(RC:N3^F'Z(*26'FKJ "NZN XOPE P7UJ
M&L@4L8R@?.I]1((@P6&SR3URSE%FJVYX-RL1'!=K=WVXNJ5]QM]41YY_@12W
MX!?!2TT2C-E !0G%IB])CD"+J12SC.!S@N@@;R*G0,&DY#D3GA*N9B0B$+2H
MAL(8KI'YD!3C6*M82W+UH?*Y&'DD5H8B!WQ4HIF*9>3X&F&)"HF\+T(UJZ)
M P-%-H7C0Z3E!1)N3))&/^,)?D?HZJ5U>9@CB)9JFJ0_D=92ZD=LH*A!'X5
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MO<4>W\'^%Q_9IR]*^V].TQ>L_P!02P,$%     @ -(9$4YKEN+%\#   (3H
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M1O>=R+U-?^+I_^:3_C3T_U!+ P04    "  TAD13OD.L4M@+   8,0  "@
M &5X.3DM,BYH=&WM6VMO&S<6_2Y _X%K=(,$&,F2W+3U(\;*LMT&51S7<EID
MORPX,Y2&]8B<D!PKVE^_YY(<27;LI-LF7:>; (FL&3X.[_/<R_C@A\L7X\-V
MZ^"'D^$Q/AG].;A\?CD^.3S8#I]XNQU?'QR]/'[-)I>OQR?/MJ9:N3W6[U6.
M7<JYL.Q,+-B%GG.5A <)FP@CIUN8B*GGM^8-/C1OG\VYF4FUQWK[S(FWKL-+
M.</73"@GS-;AP>G+L\O_'LTCE=IJ_V";9N.0YQ\;GI&SPMV!KC/E<UDN]SZT
MK!]KY;]%. Y6.CH\>5O(5+IV:W>W.SC8/CK\=/#OE>[OQO^I!?X'[>'@^8OO
MV>1B]&Q+O-W=[0S^U>OUN[]6LRTV'%\^V]JZ+>N_B+P_*)D_$3$L?"RGXL5Q
MNS542M<JP_0QQV?!])2=UVDI,_9R.L5\-:-'_>3K7B_I]7IL4G"#T33," PP
M(F<3I[.K.]SD#ZON<U+3K[5U<KK\>)#W6<JSJYF!?O).IDMM]MBBD$YX!9Z=
M_-)NO7YY\2--KYR8I\*PP7<)&_0&??9HGG-;[#.OE%=1VPE[KK+NP?:K0_;X
M49F_J?6^*P0;Z7G%U?*1\4^>L,=GP\GQ\*<]-CY]<?PD89P97LF\7#)@69!!
MY-*(S'6<[E3<29AGN^5$*0K!2U>P+*P7)<T^G@:=SOF2\6BQ.9..%=S2?G/A
M'W#5;D%8PBR,=$XH9L1,6C@/WE7!J/6=1FU71BV=]?OCVY"-ZGE=XH37@IT+
M4PE7\_*VV2>LXH9=\[(6[*M>%ZOU625,N^779(])PE'8JW5O+=%(/F%..^Q0
MRC>US+&O5JSR0^EXA.ZKG:>$E_YVH4P<72EH@@8N)$3O"FE71\1RA6BWHGJ9
M>%MAJ,4>T"-7CMZRE;2$L5#T3J]#(M:57Q(CJ]IDD+%@@WZ0%,]S22\!<RVT
M^P[&>-@ER+[=6@F_,C(3"2N%M6L(P;)L!NT")E>YUZRT%MO9[F?DN)]AK-DZ
MO+S'5FHHGW2HA(/:="9$[G5^P]1HX!2*]".MF,'ON(,5Y/):Y@+/>>;5ZK6*
ML494Y,FLTL9;&M;+A'%<*B9A#BGF*MA&TF[QN*@1<[REK6X F6K#9D() WO,
MM,%ZV)>LMM(6QY<J*^O<^T):.Z:T@W/-)4%S.O&0:<EI[6KX*L_@=]:;]Q=[
M^]20C[KMUH4LQ1(CLIK<GT93@DI 16 T:6UF[++@)593[!&?5_M(5=TX9*3+
M4E+06L]FX_'(&]C)*?NA=DX#!!F@C19VA"A:X(!76.):6(>DX<C$_#2O?A^"
MD%%2K:\ZIE;>WK ]G]%.9&MDBHW1=]F0T@L;(3M2V![!_H ,CK2Q5?2HA, E
M[$B+L&@XSB3C2%-FIG4.'/%@!993[)@#^"90?[*C[JC+_BG%K$2R;T027'8A
MRY*EFZ?(=*?!_L6:/WGTE'8COT%UJ0C&D_MP9&N?<36TR 1&99Y4V$*4TTA2
M3,CWUB& D<(9OIQJ,V>3S@XH&0Q_9V>G,WCZS6Z__\0; Z@!!3/%S9("HJ60
M70.%K:NJ#&M,X6!Y0PT$>]6==#<=QCO+6R1X-?,T,";;FZ3E9-3PDZZW[;NW
M91N[8@ G(P0KU#<\9FVDUUR6/"T%G9)&^%TL[6+90J0(PH*5.O-)!"2B<*[:
MV]Y>+!9=*[+N3%]W@;>2(J:BWX!JG4HH%WF?"4RD&9N 7(,RKJ E4!YR5&DU
M(=8I92>@F1H]AQ^RNV,7>ZUKJ%7791Y9,B/G-.)-#4>FA-INW3LY84-BK60'
M>Z!2JT,<(UL:'P42UM\!">M_"X5.G!%(A6=(H04,LR:1T5NL8DH<S<>_GR5Y
M@.1L,!CT=I$%EXR8>E5HA70/R3[^MK?SA.WT!YW=I]_U&$(<AE"N+4GN:^D(
M^X_4$.JI5%W([TM$^5,B"LP:%!FV+8B$@W'#?XC%@/AC1U=#YUP%_Z+H8@7>
MQS1E-3@W$E-#L#;'I?4R4K55+ CQRH\0>8)-3-P.XPQLA;P6EFQY*1J?NV\V
M:%<82[&,X&A: T(RTN8RE"L8@EHV*^"AONF B<D-R E-]+LMO#>E5*R4?#&M
M2Q*+U"80R8W8B4=O4*')J<S" U]:W(:*-6R0QS)L_AZ8_^]6_I&;3L-4UPC$
MH1OQL=NJ#UN2GUSYL<43:"01D-_0MDG8NVV;9)VM,VZ+#A5JU]+XUL=<P"^H
MT@IT&<D!VR!$/.T%)[)=%F TN3STA?PT)$]6@1=,B=,(11G6KA9&2J8X1_QH
MB@&YIP:A P &K CK:G.D/>X"NZ%4C(@AE*4&C]%4;!I/:YID7N$I@@6P)2&8
M9D:&YD98SM=Z?B=]+4P' :#C"U7$ <S,:RJ"<S"+:Q_7@@ AT<AKHAA7S*70
M<P&2I!G"M<$6VH!%4 'BV,&K0V(O03R40*D-]U!=]4[S![Z_=3KL5(HR!SU!
M78$"AGB-RF@BZW3BA=;!\?.?&Q@!7B?5*,?F>^P;W]6$@B'KYME1R;,KUN\^
MQ6$I >0XR>7P:'S"1B?C\?GP^/CYV??/MGI;_OOD?#AJOL<]XGH9*D)>66!I
M?MH'W\Q=0:?J_?VNB'1YT:P!_3JRKL9!G:YN>FPIIG[&<3/CW0[]C>W60KP\
MIJN]"_J'3H5/R.<.4:6PZZM.*F#_0%AY^4;Q 8V7'0"<WY0L%+^IL/.;JV_H
M:YL4%G1T3U_^01G;PXZU2&4C7OLVJ%FV6V<:_.%"S+CQW214;0O\R,9:7]'W
M25/2V4][D_A9,(H_B3<KL5C3YM %%+Z#0YKIE%$SJV+;^AI9AEIT+KB*-P23
MV%P??#ML2.]&^3Q$=4?7"+L[.SZ%K$;W3^+H=FMC^*K27L_[.J%&#0>$G$BW
M:6P(C^>:('A&2LAFX*RUH0RJ<'A/>4%]8PW?E&EV=>^#X%J Y5M);=10^J)P
MXRJ3O.RR7PI)O%J 5)=27%.#%\7>QOI2Q3HTK!_:P3%9&C$M\2W0?.+H]6R&
MVA;?4U]40.#WRQE0##5SN=4J%-E D=&5#@IE:ZD+NT0%[?'@C>\7\*SP(+$7
M)I;0==SF7; 8LHFUV_CBO4BDHNI&44ZW=?HKU>M454A[A87IELDWI5?-$H(X
MK^+:+ZB"B%;Q'LL"A8FM V]?8&:;QMEN49<!Q0WUR>$+<B5'WWG'\K>77B#=
MV5"YP'9BER8J,HFMFN9Q$,;MIQP;9;(B4A3?M%OQ56A=W)Y @L8!;C\F[=Q^
MAM/<?N3U\\YDF(R<4W]G]0("7N&HM-<I7Z^_X1"0_?,Y71U03VW*,Z=!^KS)
M9+Y4S#B)#L^)6H+SU66XRLBEKW]I5U#"$CKW#/(._;5;FZ$!(8%?B3O5U\06
M"G!7PM?EX7XLV(LK-)7M>#&E-@TM800A]Z::ZZP.6S3V3OVZ" I1+O3/\,.Z
M@S<Y&27K6PW_Z +&RDZC%&X9V\;E;J2H0Z5(*A<>Q:K'V.]U?O2 ?ZJY@70@
MFHL&IVJWFC$_);%H]_Q_U<.+MWQW]?#H6)M-.VJ/T>3:S/P=C&]DR%BE4^1H
MSH%!J/2! ^<0=+O:=!3?[VR-CAKU>*<U%&)\NL:>%&GH8A.LTU]_UA2.2LG]
M#:L*?G7_!E$ (7C$9L-*V!+1!T9KA%L&'Y:VV9C:DJM5NNR5\E>?WIH7T@K?
M()0F^'[)%\FF[BBD41L(PJ#KT9++N?7="YTBB_I(YRVEKO)P^467K>72#WG_
M281/+]Q&)Z%H ^/&::A(BUV8>#>&X**"U:Y )P"6B<J%!0+^=BL<H,N&B-SO
M411WSLBT=MZ  '[S?RC0+IPNT9$DFOL,:ADYZC,5O)QZE:ZE\JX>VJWW*0+1
M;%:##G^PN_/7:3]\;/8;+),NC!%O,O=;B.W_"NZ-QLA#!?F"FZS=.A**PWXQ
M?'3Z\J%"/7AU>$+W QO*_W GXXLGW>-)X897(V)=^%LS8@Z?@5,-;5$*^/^%
M3J5"F'ZH.,GY)YELMX;YM;1@%OXB_J&BA6MQ8_Z!9"8L*K4(^2_8+1SLLY>A
MC-IC8V[=E^;A[VD>?L;MO6WZS8;PJP[T&Q'_ 5!+ P04    "  TAD13I_!(
M,MX,  #"-0  "@   &5X.3DM,RYH=&WM6VMO&S<6_2Y _X$UND$#C&39;M+Z
M$:/RJPWJV*[MM,BG!6>&DAA3PPG)D>S]]7LNR1F-'.?1K=.U=Q,@ML0A+R_O
M\]S+\<XOEZ^.=[N=G5\.AP?XS>C?SN7+R^/#W9W5\!M/5^/CG;W3@S?LXO+-
M\>&+E9$NW!9;&Y2.7<JIL.Q$S-FYGO(B"0,)NQ!&CE:P$$O/_NRZ;3;E9BR+
M+493!RN[3XK4EML[JV>W"#IQ[7I<R3&F&CF>N&WV'^^QL[=[>#V1J71L<[._
ML;.ZM_O^AE_T!)DHG#!__@@]ITN_43.0:N?TU(_A8"]?_<PNSO=?K(CKS<W>
MQC\'@[7^VW*\PH;'ER]65N[SF/=&:IN]+QF0/SH]N6Q3[HWX5*J;K4_1]G.M
M_)<(K"ST000?#]>PT6,Y$J\.NIUA4>BJR+#\S,A,%F.F1^RL2I7,V.EH! )A
M:%]/I[I@%TYG5\&F']>1_PY%O:VLDZ.;>];4R>$?W<Z;T_-?:5;IQ#05AJW_
MF+#UP?H:>U+DW$ZVF=?)ZZC6A+TLLO[.ZNM=]IV;"/9$Y>\JO0T=EKRX>6+\
MMZ?LNY/AQ<'PMRUV?/3JX&G".%."YZ3P7!J1.02$7LF=A#)P3B4F@BLWZ7:R
M0"=A3N?\AO%H0CFCO<J%&4EG\57,I*ZL:L^KBER8N9'.B8(9,986VL9X&>Q.
MM^QN(]G8H/_?,SOA!K*+=#-OC]V.)8-,6,D-FW%5"?;MH#]88R5DY!<DD*EA
M8Z,M\:(S(7)/@Y?X=BVG' >[8=^N#Q@4I"1,G#L(XC8G="I!Z[Y]WA\,%N1I
MZ#8K1F)'IUDN\BISM+HY;Y"MS2 'G($7N5\LK<7&X;N "1%3^6)O<5V*P@K;
MAU8QORB@&F)T+MT$(I>VF9J0!KJ=J&<VX18GYX6+JFG8$ :;L8U!C]2G2T\-
M#)>5R;!&L&>#03+ ,7F>2WK(54OZX;C,GY:$Y95^E[B2;D<)B/WS3M]GEQ.Q
MH(!3T;DSS[MFF=+@"]N>9DZ3 WP?[#]AMDK?8IJ?!/^#5YD;/YVH0%KA!+;_
MZ%S_D4:LR[8%2MA> 8>#<BKHCTRE$&[AB".CI\LF3%.-*"FLL%(;;YK1Y27L
M*(4]%&149#U$SH@IEP4M7":L3;<SU^;*6P$OI8,-TYJQ*(3!YTP;D(>CD=67
M,"ZBGZDJ]VZ45HX5VC$EIS)88 +Z<U9'PV!I,$.>O:ND]2;6^&FP[+BG'X0-
M5O">>[?!AV]N]\GA7K_;.9=*W&!&5E$\H=F4Z2A:\!!J$?+(+*Q6@J5:7_5,
M57CSP Y\#(U1.G"M2/,U,/PYMC^O8+N$3W<[[6B>BJ"%W'N<K7CA8S:'WV 6
ME#>#UB9"C2(@@&]*GV;@HU/R.7PYTF;*+GH;0"ZZSP ,>NO/GF^NK3WU+@>H
M0?Y:4 ) (+"4/2IP8:NR5('&".:3UXE3L-?]BW[+F#R5PVODP&(L/.(-N6D)
M1%T<[M< *J2LN[=EK5TQ@9-Q=CLX<-OVP(E2D SC,RX53Y5/<33#[V)I%\OF
M(D6$$4SIS ,#Y-R)<^76ZNI\/N];D?7'>M8'OZ4,&=I]#E?=3AU">18!7<C<
M]=R$S2> 9PUK"92'J*RL)HYUZA!WP8T/X7M]]@'/?*,KJ%57*H^@DE%>,.)=
M!:1#B:';^>#BA T)(9(=;*$\:0YQ@/Q@'!TB86L;P"EK/T"A%\X(I( 3)(T)
M[+ BD=%34#$*1W,:5OJ[)).7G*VOKP\V$>AO/+(M)[I VH)DO_MAL/&4;:RM
M]S:?_3A@"!:80CE&D=P7TA'VI]00UR-9]"&__UH8^3Q_?+1@@L((;!D9'P8M
M")P"B<)I*#L#W6%'5T'1O A.12'%"CR/41YY .6(XS6.:,]+JYLP9Q$ 0I#R
M,T2.E*]-W [S# R$7!7F:[D2M:-]:#7@1)A+ 8S8T40#0C+2YC(@>$R93V0V
M@5OBAU^8++&<T$*_V]R[4$H@7O'YJ%(DEEAH+ 5,#+VKH)&1S,* A]^W606-
M4 81A[3Y1]A\T+ %!7)MV_??E+AG1H>IKA!W0XW^T/E]I!$C-D"ZG087,@,H
MGJ/('QL]O[.YD;2Z&ZQI;C1).N-VTJ.*9":-@VNQJ8!G4 U!#0">^=X"!8EG
M@^!&J&4#&W4*1^(7E'5S:HT@-P,.C C*B((2JVT((Q-3I"-8-,*$W"."4"<7
M,U'XTJ/>'-F.NP!J* ,C9E#Q02A(SV3N*_PBKW,X-3L0+L!;$L)I9F0H^P,Y
MU_0?]$R8'D) SU?IB 1826T,RW( BIF/;$& D&B$,U&,#6"9H#0"-M+43C+8
M0E,;9D9E$MMYO4N@)8B'\B8UJ;ZZP9?H&^[SRO=NS$VW<Z(1W,_%F!O?W@..
MGN,C.T:!1-\O:I!MOWQK]W^N(/J+X*80\P6V"2T(X?L7I*&>BAIJRB#KJQ<9
MJH2IX$7LDU[$IN#Z#\,:F;0*FR%P-T;7-C<V$BJ1.4CE(M^NEW4[ZVN'=ZQK
MBJ$%@>^7"=1%A.4CP2;<I-J$$&0CXFKJK#,C9X0Q6N2/\6L<4,JYH(C8[30;
M;3[KUW9ZEQ00$6,!XF6!0+\D2"I5 )80"%$^C"2FI0'L41L*].>(KC8@'VZW
MZMHN18@3,Y'$ J_;B>.A$UD/U[-1P2*>EQ14;SV! -[>L2#40>]-5K"56V-4
M%[['!<YT>U[HK]T>K7O(S3@B/F&YV_-(AK*H%O-(F357VE=>O,6&!CB%L 6'
MT) 3A>\V2P/!DPYG+?0XXY1K?$[!F,^HQN<R)!34I%KI,=6 A),+?UDPJJA!
M1FUUJ7.DS\-K/BU5J&9ON0+UV1LKB/X2&G:4C6\W[5IS31/^=&48RC:.O9%(
M@<F(=.@.5C+', A"5\;Y,:6+<8\8QR96^N8C^"1KI9FAC-88"0=.ZK,8&!)D
M&[OZR(/8&4_!187TKU&6YYBA=.FY2Y KQ]0NG'E>29*5@^ H?O!4*NE\MB51
M(N_Z!H;_+*X#_9E6,R^<2#^P@GAV)5RK"Q[<U5!/-C0TL1&,FY,O+S*]/U%$
M/YA'N,E1A4#MTK&OSGU-H6Y"P\U6TS)N&*-!MQ-Z.DV)$>, A";&VJN@"%JH
M964K%68O)$F\+;34G.$Q%MK@\IM>CQU)H?(M=L;'@B+ONPK63]F ]7KQS8F=
M@Y>_UWO>NH-_3O?RB*X0?#.VIWAVQ=;ZS\ 7E8TYV+X<[AT?LOW#X^.SX<'!
MRY.?7ZP,5OSWB[/A?OT][A'I95HI7EKP4G_:AHWE;D)G'OSC+GQQ>5[3 "9T
MA$AK"3I=+HM4B9%?<5"O:)%>".SR@-X7.:<?= +\ABSN$$L*W'O52RE=@)O2
MR[+]_L)SS][9LA3C*PR+MR>6J+=TLTK*"?KX"D3O@^VCCT3O.F C>R,@^JIF
MQ.L 5#^D^&*X?T.!DD&3*.H W&?GG)*.ST;4'EJFGW(JBF*X ? P5#&%?!ZC
M)'5UD/9',7RUXEDK9=3[(E<']MK1,*;[.@36J"#W$ZNB/1+C>SL,4V 4"&]Z
M>I/$;.*3:-QR$;R3Q0V57R215@-::H583GXQ#4W3Q<$CK3J!]=GP8Q"3LH@B
MJ!;KN[#:<WKCA=JZ<Y4%=<:HR2WM%26&#.$ P"QT<7WMZA$DY6J629-54VSD
MU7E;VF["0Q+/Y6@D,V0$WS"OP4OK]!:)T:,XWSSSU_"5%X17,DS0:$4-<13$
M%&11JB;^$<1%979,-TG;C *O=^0;@I+=#K$$G1"J K11R,'QZE)[U.YKZ!J+
MBH^(UE\98 E)RT;[:$GLHX"&I)'4^.P<!-@1#J2-K>%;"^W*J'=)G6^[N/'X
M]&5'\HE[4.! $)YJ2_<:F1=NO%89%@5)]US0O6US7;,VZ/V:L-\J;AQ!AOC8
MMI__%CT/5NSKBN"]ON7J-, @?(;)T5T:[':65'@W8O!RI%XQO68"2_7"^$B!
MM51:^!(ABC%Z -46))2TT3S +UUV?=K&/L"@WR>-QMJ@X$<7ZS^1HN[8_:^\
M9WEO; \+./@'[2%<64;'7B[6[2*[R,(KV6LS9AEZXZFYUO,O0%#A',-T[KOM
M=?O?UZ^1;+>#S[1GG_T17]EQ_(H" =.IJLMEHE?FL65/KUC9<#/QP6/X3J#/
M*]SW1+UY$C=4!;2XK^L70/A9*$SJJFXNJ>03UYDH*2O7)39=Y4E3O]1%K48%
MEZ S*SX/W-45R=>+A/MJ[84>-;UG@U"5N8?.\E)3_B$S^HJ;K-O9$P5!2DS?
M/SI]R.SNO-X]I*OIEB'\/W;3[]F[7A8S005)MW,N8BN%/1)'&]J)$H@+YSJ5
MA=7%0^:5@L)%)KN=88[T!1B;L./C_8?,,=R-&_.3 N,6""ZR_3?>8GVQ%M3Z
M-CL-5=@6.^: ]E\[4I_H2#WBGM$J_0U6^*,L^MNM?P-02P,$%     @ -(9$
M4V>-U;?1#0  %SH   H   !E>#DY+30N:'1M[5MM;QLW$OXN0/^!9_2"!%C)
MDAPG\4N-RF]M4"=Q;:=%[LN!NTM)C*GEAN1*UB$__IXAN=+:<9(6<')Q+P4:
MRRMR9CBOSPS7N[]<O#C9:[=V?SD:'N(GH_]V+YY?G!SM[:Z'G_AV/7Z]N__J
M\ T[OWAS<O3CVD@7;IOU>Z5C%W(J+'LIYNQ,3WF1A <).Q=&CM:P$5M/_^J^
M'3;E9BR+;49+>SO,B2O7X4J.\2@3A1-F;6_W^-7+BR;ESHA/I5IL?XZV7VOE
M?T0096WO09':<F=WG0CB[*=?0FHCQQ-WET+O[N\=74UD*EV[M;75?;R[OK_W
M98]P/Q5_]U+O/G_Q,SL_._AQ35QM;74>_[O7ZW??EN,U-CRY^'%MXEQIM]^_
MG\_G726NI+4BJXQT4MBIMEQFW4Q/WX^Y$W.^>(\O<^[X^T'_?0]T'F]M]#<'
MG4&_T^MO; P&[SV+_HI%/,!$D#]ML\?/RJL=-I>YFT"\)T_*J[7O7O!UO&!_
M[T2.Q(O#=FM8%+HJ,FP_-3*3Q9CI$3NM4B4S]FHT @$\ZB>/>[T$-F;G$VZP
M%FN>=9\]W?RG9X$'0W9032O%G9P)=BI,*5S%%6@*D# B9^=.9Y=?(L[OFS7?
M5M;)T>+NQ-YA*<\NQP9FS#N95MILL_E$.N'M_/+HCW;KS:NS7VE[Z<0T%88-
MMA(VZ WZ[,$TYW:RP[QA7D>G2-CS(NONKK_>8P\?J/Q=I7?<1+ #/2UYL7A@
M_)-'[.'+X?GA\+=M=G+\XO!1PC@SO)2Y6C#(,B>WR:41F>LXW2GA&/#B=LL)
M)2:"*S=A6: 7M<WNSHI.YWS!>'3LG)'PY<JYI;/M5FG$3.K*JN9"*%"8.=*=
M$P4S8BPMX@[/RQ .N@X'$%E%A%U&! C_Q:AHMWQ8)*SDALVXJ@3[H=>E7,I*
MF,F39@])_FB')=T;@54;)4$ZA6HY<]J!D9+O*HD4+74!#= .@8.2K#]L;)+T
M]'^WW7I>P!I% 6/12D_"3:1=GCAA#0=@$VYA8HZD%'2[5)LP%JPW>AW2ORX]
M,:>A/I-ACX"F&<]S2<\AW*!_0X'0QD>.Q[@+5KQA"+*J2)@2UJZD")YG,Q@5
M!N%%3IXV12D#6]ME%Q.Q(H SBJL2YZ:C:)8I;46[!;%?94Y3I#P.@9(P6Z5O
ML<ZO0@3#$<W"KR<R4%XXENW>L^1Q3W/>VA[,V&[5'BGABT5NR3@5_(Q<I1 .
M[J$S(7(?G-?\F1:.X#!^I15CQ#HG%\CE3.:@Q'CFW<=[#]8:45)&8:4VWJE!
M+Q/&<5F =2Y2["W@@TF[Q2-1(Z;XEEA=$V2D#9MK<^F=!MF2@I2VC$4A##YG
MVH '9*&@*>&,%@PR5>4^"-/*L4([A/54!H]-0'[.8G:-CBD,Q,@0^-:[I'?P
M@BCY4(A,_4/X;(70^^ZS7TGL?:3:,ZG$ BMJ6!V*;<)..!POK<P8"8HK4"O8
M SXM=Y!UNW')@59*4HY=[68G)P?>KD?'[)?*.0TAR(EM]-)]Y/L)#GD)$C-A
MW11N0F[JMZ&V\,RG2R3T5.O+CJD*[[-@S\?$B?S5-1)FEPVI++*#Z$8'\%=(
M1CEUQ2I&94+")6Q?BT T'.<\XRBO9JQUGE#A\0>;@%S!#CD$;PKJ3[;?/>BR
M?TDQ5DC'M4I"V,^E4BQMGB+3G5KV[U[]U3*Q!*!JEM14!"?*?1JS%: "95&4
M?X%5F4=#=B+4*((L$Q"*=4A\9'B&7XZUF;+SS@9@)@)@8V.C,]A\LM7O/_).
M 3!#2;"@(HSD:JF$5Y#"5F6I HT1 BVOL8Q@K[OGW6;@^*"Y BXIQA[91(!P
M'6T='=3 *N"&V]FR!E<LX.2,0+KZ6N2LG'7&I>*I$G1*6N&Y6.)BV5RDR-J"
M*9WY@@3<0RWY]OHZ=>3HM[MC/>M"WE**6-;^A%2KLD1US<=.0$_U6L#&"2#O
M4K0$QD.]4U:3Q#JE2@=I1D9/$8_L]AS&WN@*9M65RB/R9Q2D1KRK$-!4G-NM
MCVY.V)!0-_G!-M#?\A"'J+S&9X.$]3> %OM/8=!S9P3*ZDN4XPD<LR*5T;>@
M8A2.YO/@[Y*B0'(V& QZ:'C2!:/NHYSH M !FGWXM+?QB&WT!YVMS6<]AE2'
M)52W%>E]I1UA?TH-23V2!<T_OF>6KYI9X-Z ]_!Q03T$N@7$$:$@@&YP=)7S
MC86/,\HR5N#[6+:L1KN 0E6#MN:ZM%I$^+?,"2%O^14B![32)K+#.@.?H>B%
M1UNN1!U[']L-V!;64DXC<331@)*,M+D,?1:6H$_/)HA4_.,W)M=$3FBCYS;W
M4952KZ7X?%0I4HO4)H#31@[%HW=H,>5(9N&!;XMNB@H:-NAC$9A_0LSOWG[W
M<Z;=_;UAJBLDYC!Q^3X7^R*.$,=9 682,/D3(ZJ$?3BB2E95/.-VTJ%F<":-
MG^5,!>*$.K< IU$TP 8I8[,7@LIV61"CKO%A!N:WH:BR$GAA1%A'%%1Y[9(P
M2C7E/<)-(RS(/60(TPP@Y,(W?#5SE$/N NJA$HT,0AT?P21-#:WQ<*<N\B6>
M(GE MB0DU\S(,*L)Y/P<PW/2,V$Z2 @=WPPC+V!G7F6HY3D0Q\SGN:! :#3B
MG:C&):*9H"$%>-(,Z=N A39 %]2@.+;[>H]035 /%58:.7X/@SL/ V2; U[Y
MJ9M9M%LO-5+]F1AS0U,% MIS?&0G: #I]_,:A=LO?RMW;Y+_5X(ZA9BOD$X8
M_ C?A).%.BI::-DG6=_>R-!&3 4OXG#Z/ YR!T^'-4YI=#Y# '.:8&]M;"34
M,W.0RD6^4V]KMP;]HUOV+;NE%8''UPG478;E(\$FW*3:A!14CR.6C=BID3-"
M',U)!GZ, V8Y$Y01VZTEHZW-;NVGMVD!&3%V*%X72/37%$F]#* 33?9@-HEE
M:8!^-"L$_3FRJPTXB-OMNOE+D>+$3"2Q VRWXO,P+ZX?UZO1XB*?EY14;WP#
M!;R]94-HE#Y8K. K-YY1X_B!%#C3S75A"'KS*5HO.6V*A8Q/R.[F.M*A+*K5
M.C)F+97VK1EOB*$!5:%LP:$TU$3A;PBD@>+'X;9CB25GG&J-KREXYBNJ\;4,
M!05-JU9Z3$UBN)L@PXXJFDK2!8C4.<KGT16?EBJTNS=" 0W_R@MBO(0Q*57C
MFZ/2QEJS3'^Z,@Q]'0=O%%)@,B(=9K)T=5+0_0)L9<(L6.EBW"'!P<1*FOF2
MG.2MM#+TV1I/PH&3^BP&C@3=AJI*=1"<\2VDH,LAC;X]QPJERS"?0ZT<TXQV
MYF4E358.BJ/\P5.II//5EE2I%F'"X3^+JT!_IM7,*R?2#Z+0:$ZXQE5%"%=#
M@_,P1@8C.#>G6%Y5>G^BB'ZPCG"3HWZ!AM1CW[[[#D,MP@3.5M,R,HS9H-T*
M0Y]EPQ'S )0FQMJ;H A6J'5E*Q56KS1)LJVLM#S#WZ0W@>#_Z'38L10JWV:G
M?"PH&;^KZ+(.&UFG$]]QVCU\_GLM1I"[DVKG]'2;/?$7P<AD@&SULWW%LTO6
M[V[B:-17YCC)Q7#_Y(@=')V<G X/#Y^__/G'M=Z:__W\='A0_QYY1'J95HJ7
M%K+4GU:O;?1Z_[P-<ER<U30 $QV!U%JI3I?7M:S$R.\XK'<T2*\4=G%(;W:=
MT3]T OR$+FY12PHH?-E)J8) FM+K,JH*G+V>[H<6/GP#Y!J[/ZF9AE^MDV,%
M7[I?N/J6D Q$_L=B'W^B&-7U!V $^=TW:2->Y]/Z2TJ7AON7;ZBV+>M>74^Z
M[(Q3#?7%E69?U^FGG'J\F#V!HPPU@ &>Q*1/(RN@F%',QHWTW*B -5] CR!>
M,[E']%)G]!KDY'YA532?Q'+5K"J4YP6RM9XNXMUHP 21Y:H6):MK3K]) B4$
M\->H&)QB>AJ&Q*N#1UIU/>ZRX:<0,Q5%1<@SMJMAMY=TX97:N.>7!8W]:*@O
M[275N7CG&Z;6OA7W@)B@!\NDR:HI&'ESWM2VF_" 27(Y&LD,!<Y?$-18K'%Z
MBSKO0:F?#-(6%']?#,G(<$&C%5T H+^G H'.._%?05TT-8C5,VFZ49#UEO))
MR+C=(I%@$P*)0&H*D,(/$=Q$^R;$CP1J:"T^H5I_18(MI"T;_:.AL4_B,])&
M4L/-,Q!@QSB0-K9&HPWP+J/=)4WZ[>J&Y_.7.\EG+M,!:T%XJBW=XV1>N?$:
M:5@4I-TS06\ +*^G^KW.KPG[K>+&$0**7]OF][_%R(,7^S8I1*^?)SL-;(N8
M87)TFP7;K6LFO!T >3W2()Q>58*G>F5\HE^\UBGYCB>J,48 M4JDE'1I>6!Y
MNMS[O(]]1$#/)XW.N@3U]WC*\ZU6HV&!6/ZHZ<-M;(SAZV,&NRHDLO#V](:+
M!85>D%O>6/KW:ZCECQDY][<&]36&[[PCV78+GXEGE_T1WQ!S_))BGNE4U8T^
MT2OS>/5 ;^39<,/RT6/X&:8O(=Q/<[TGDC34OS2DKSLO-!^ST%+5_>A<4K,J
MKC)14@&NAP-T2RE-_0X@#4D5O)_.K/@\2%?W4O?9>;\!"6D:&<;J]/X6TE'F
MOO7KCVOW"-^RH"^XR=JM?5$0;,3R@^-7W[*XNZ_WCNBZO>$(_X\7 '<<7>$%
M*FW:K3,1IS_LG@3:T$Z40%XXTZDLK"Z^95DI*9QGLMT:YJA;@*K^?;=O66*$
M&S?F)P7!+5!:%/O+7;S5T7)WJJA)?6):-MAAKT+3M<U..)#\]^'9WW=$M$Y_
MV!G^TI/^(/2_4$L#!!0    ( #2&1%/K^_DV%0P  &DT   *    97@Y.2TU
M+FAT;>U;:V\;-Q;]+D#_@6MT@Q08R;(=;VI;,2J_VFP5V[&5%OFTH&8HB34U
MG) <R=Y?O^>2G-'8<=PNVB:K;@,$MCA\7-['N>?>D?O?C]X,#]NM_O>G@Q/\
M9/2O/WH]&IX>]C?#3SS=C(_[1Q<G[]GUZ/WP]-7&1.=NGVWU"L=&<BXL.Q=+
M=J7G/$_"0,*NA9&3#2S$TLO_=MT!FW,SE?D^HZGU_XW#_MG%^:BY6V?"YU+=
M[?_2?GZNE?\6X?B-PV?YV!8'_4W:$/>]?""I$[>NPY6<0@8CIS,7MOAMPA\=
MGM[.Y%@ZMK?7W>UO'CUR\&\\Y8 U)4]%[H3!R:_??,>NKXY?;8C;O;W.[K]Z
MO:WNS\5T@PV&HU<;&Y]+CDKIG^?2OYNOP'!#.1%O3MJM09[K,D^Q_%AI*_,I
MTQ-V68Z53-G%9((-PM"QGL]USJZ=3F\8SS-V>BM,*JV@AVXFV+L\$V9I)$2U
MSXS]4.H#=E$XJ?/@%Y_PR_]Q3?U"5/VNTO]<6B<G=[^SH<]/?VJWWE]<_9"P
MB]3IL3#L1<*V>]M;[%F><3L[8-Y [Z)+).QUGG;[F^\.V7.RZS.5D2UA_X+G
M=\^,__0U>WX^N#X9O-UGP[,W)U\GC#,E>$;.DDDC4M=QNE-P)V$17%*)F>#*
MS=JM-.R3,*<S?@=/"NZ7>1]*5RXHG66%$0NI2ZN:\\K*SYS(F1%3:6%RC!?!
M9W7#9W>2;W9VDIV=%\S.N('BXKZI]^5VRY(S)ZS@ABVX*@7[JM?M;;$"*O(+
M$K:<R73&9)ZJ,L/ZW5XOZ?5ZC>W"5LSOQ*2U)4E88(2N(ZH0D3F;E$I5H5*N
M0B5&BFVWM(\5J 4W,>F,8QG/,DF#7'WBQ.[:.N::Q]5H)MJM&!*P+EPQLV2Z
M$E8C"^?"P7MU*@3&^U>'? );LTQD9>K(.>]Y00@:F\+!X9R$K61C.!-,'SX+
M7&#.'7RK=F]Q6XC<"CA.P>_X6 DVOO/;'E<!-BX=&XN)-@)A@DES"D4X4";&
M+NEO7AW2!UY S%N_.:+LJ^VM[@L&E:CHBGXA8KO0QGMG#""9TR8BRX4- CK2
MAQ%S+G,2[M[U(0%;:G-##U)>2 =WIC53D0N#WU-ML#T$(,<O-.X4 PX+PBUR
M[9B2<TD*<#K!]DM684L*X^HYE,O3#Z6T/E[:K4H[09OQ4#^(B"H125VRRFBE
M+DQT,I78%8M*#T(/5+-;ZP5*N'?!6D_B%F!$2YOZZ9*JU];1USQ.C[KMUI54
MX@XSTI)BC693@H._D#MQZX/&:@H@K6\ZILR]"V-W/H5;D??2C"KP/C?D?A:&
M^4<AY+WLN.0V:+%*XDVXJO(@$IU0DYC7 0K2+T<(!O3*V9DV<W;=V:ER,^V:
MB51QVE9@>P#LH@;#E=7;K4!:D5GSJ3\V(BQ['AG.]>EQS6XP_,\R%VQ[.U"E
M+ALU?, ?.N<91G)  \Z:"Y[[[,S91%*^!CC8 K*4N%%9%"K(#Q':+9*+IY$'
MT6Z-N7S!I?)H'BF$%RJJ9BG&P#?!E$Y]+N".S9PK]C<WE\MEUXJT.]6++JY6
MR$ 5:(,GQ DJ>4J<.8&_LAIYA.FQ [KCV(G1<W;499^(J_>ZA!%UJ;+(!!G!
MJQ$?2F0Q#Y:/K6VW:''"!D3KR.K[['(EQPG@U3B2.6%;.R!@6R_=#+6($<#A
M<^2F&1RQ)-W04^QB%&[B--ST1TG>+SE,N=W;2[QC@(X6,PWS0H//7_9VOF8[
M6]N=O=UO>J!AAJ90)E/T>*4,8;\=&Q(;&NU"7>O+O5 45*CRN0JS/^86@[$N
MX<6A;EGWR_P)3!(+R!#+J(: A@;<*P-&3HU>/EH<)HWJD-7%88VT*0K4#G&K
MA32N!)+-12938HT ?. 6PA/'H+3:[84\ 687Q%A55G2 7P;X8H7B;D(Y1.2$
ML[;>&!A(;!;XQ">8D'D4#F0\7XC<D\WJ<  /]W 4P!!U)['-C-!B(9'9/.^D
M#(42U=/(PDC(!LV@I+6ID:'6"]NYFN;KA3 =X'''EP)(D%A)%0-E.(6L1BDN
M*! :A: $W5&-=9*8@0PC6VDJQPV.T%3&+H@8,Y3XE"B">@C"J,A?6V=;<V:*
MB#_FI:_NS5V[=:Z1O*[$E!O?0P'+6>)7-@0EI<_7%06R:PT0:VZST4P"3E!]
M6O 9Q)?O[,36T"18K*.BQ6K2"MXFW4P&.D<\,3:GKHFI @2V7PXJKK;B0VR0
M^EI]:V\'3!=LDV.K3&0'U;)V:WOK])%U-<%=;?#B_@85Y[-\(MB,F[$V ;=L
MK&U],[=[W04!DPLJRQO;#_%C&ECY%;46YNU6?=#>;K?RV\>T !B-!-+K MGA
MGB*):H)E CU!_R82TR*%+T.+>0E()O(*RL_M?M65' ,7Q4(DD;BW6W&<2OW4
M5</5[%6-__ )%/#S(PL"C_UHLH*O/!A;2J4^D@)W>C@O](H>CE;]G7H<:0*I
MX2-Y2(<R+U?SR)B55-HS9]X00YN$E"TXE(9$BD0 A4H#Q9,-427!]!I#U/ZD
M!.43$<9\&C8^ 2(+S66NE9X2AZ?B+4_)L).2VBC4*I4Z0\X]O>7S0H6RXT$H
M4)^U]H(8+Z&O0RG\86^G,=?4<*A+XPL9G(WL"])'6X<F4BDS#&-#V,KX"@OU
M43[MD. XQ$K?HX*<Y*TT,U0]&B/APDEU%P-'@FYCQPW)$R?C*:0HP1FTN4,6
M7@BE"R]=@@0[I:;2PLM*FBP=%$?XP<=22>=3-*D2R9H@(/PN;L/^"ZT67CEQ
M_R *<.T&)0WL'#J_L;MFJ+\8^EXX",[-*997],#?*%(FS".RA?-\ 8U"FD3R
M!;?R]1VWMIP7\<"Z>1=*YU##HEZKJD?0AZGV)LB#%2I=V5*%V2M-DFPK*]5W
M6-]":<W3U=D3<5B%'G 8KNU)[817KE0])$\QW+\<I+"N0[X*)=3QG.##XPI@
M^L'^8TZ<.#H.4H@APAR0.?I[N^4!?!(=L>&9C>"OSE4\AD/3KR-P5\Y<X7OF
M)Y9Y<R1&:C.@_$L:.*J>WR41%SP<QB-789BL6M)^D01 AKS7"!9.T3(/[8O5
MQ>->%11UV> ILD!XH"CI1GH?5GM)[[Q2;3FF"]-SF<^$UZF1]H9"/!6&4FQH
MQOC2Q7,!0EV62I.6<QSDS?E0VV[& QQG<C*1*6(;99.NTU#C]A80Y_.Q[[[1
M$N">QP$R,ES0:$4]*-1#'TH(IZB:*ZD][ZNL"!Q)TXV"K(\@!Y&"=HM$@DTH
M/R))*:"I+[K<3'O^Y4NHBE6()U3K>WA80MJRT3\:&GLR-9$VDBK37F$#=H8+
M:7K3'1)Q@[?(:'=)/:C _AZRM$^T(I-?>/&!C(Z-Y]K"Y"+URJ5C\'"0YZ3=
M*T$O:NHVZ5:O\T/"WI;<. +_^-@VG[^-D4=O0(@AANBE(!!.(ZTC9IB</&9!
MU+)-$SZ._5Z/^&3I+2T\U2OC":I\CR1ZLA?5&". 6"(I95Q;'C0&:GE40O9K
M!/3GC*.SUGSF2V/^K_LNTIKGIT&.Z/ZD,X0&>XSJ^S677:46F7L+>U/&%$/?
M%JC;Z/Z=+.-U.SPC;,7< %^^#(G;MELR-/6[[*?X<M;Q&T(!IL>JJGIHOR)L
M8H@QTMM]"IY/7L-W@7Q2X;X?YGTSO$)<-J6O:"B8V"+PRXJ<+R4Q=W&;BH)2
M<E4I44==KMZE\*)0B >ZL^++(%U%++^X._^?]T6IUQ,ZF_2E 2!<ZM;Z/FN.
M._?:U&M[BS?<I.W6D<B)@F/Z\=G%VMZE_^[PE-ZX-<+CK\[T%T2KU_E"4%W8
M;EV)V)M@?P'7%Q=_8&=*((=<Z;',+7VQ=DTO0@A\G<IV:Y"!0:&,2MAP>+RV
MUP%\<6.^5;B517D1[_3G?,.&"_RMTV%G4JALGUWRJ:!W$E0]I;2P^LZWW6=#
MCCJUTXE_B=$_>?UC)56X3F>LG=/S??:/PAVPL3:@L?78D>+I#=OJ[N*F5BN9
MX6*CP='PE!V?#H>7@Y.3U^??O=KH;?C/UY>#X^IS/"/NEVJE>&$A6O7; 8K0
MS,WHDKV_/V;,T56UQP(E +7&*AT[7=Q7NA(3O^*D6G%OZX_^Y&*ETM$)_4D*
M?2_07PH_H9Y*4PW];I*"@Q+7WG/61_R'@F_2GPJ%OQVB/S'Z#U!+ P04
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M,=I?RVE^+Q]YSZ#"X+S!^;N!#XHN29KD,TOD_"GDU"^:<CQ'/<>TAQA)?P\
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MVZMBN <IP2!U':N,5TB;D1F-E-975V[\^%P_9WY>,&XR/FRYTB)S:!8$95_
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M8_#-:)7X1<G9&EP6?GTS[H;E\H_"27F_?.+_*G4^?9)+\O]02P,$%     @
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M('*(IG("VJ2KRF@(>[6JC*><"[P8>#O+&3.790PS'R=^Z9@4:4N1P!TZ3<P
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M)EPJ1/\BZZK9J0W?'OV+M$$7'&7-R8@PMU&@95<Y2*.U+C(%Y764&IMKSH7
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M44HC0<(@W_;(R,)L)F9L).)'"5GBC(3B0$?B0)-_B /]D&^^QG,2#Y!0<C[
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MBH;2-A> 51T-3>85'69O(""EW"TC#PPG:20ZL$Y(FE+KEQN V<:EAZ;SBA/
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M)3@A[C0,^8E*\W^NHX1,P/H;M7;I:K%;9\H@](@DV!W 3ZY\5WQ (@;=)KY
M,]VCJE/WT$S[0C/U&IKI6Z!Y>*&>0'.X1U4/W4-SV!>:0Z^A.7P3-+SAG?8U
M9_SC+7N@+Z:'LT&E$V2:5HW [&3^X=+PU@6+"!#S&1'B$A,YL;IE=XP^1TD
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M=_TFDWKW7]5X@4"+L68J6R5%A=;%@H3=D+7LG@0LG4T"EAV3@*6/DX!EWTG
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MYIU_ 5!+ 0(4 Q0    ( #2&1%/H-3NVZET  %=; @ )              "
M 0    !E>#$M,2YH=&U02P$"% ,4    "  TAD13*LF=\<5L  "HW ( "0
M            @ $17@  97@Q+3(N:'1M4$L! A0#%     @ -(9$4]+JZ,"^
M00  $K !  D              ( !_<H  &5X,2TS+FAT;5!+ 0(4 Q0    (
M #2&1%.'&AT*7P<  %HA   )              "  >(, 0!E>#4M,2YH=&U0
M2P$"% ,4    "  TAD138M^+H4D(  !G+0  "0              @ %H% $
M97@U+3(N:'1M4$L! A0#%     @ -(9$4YKEN+%\#   (3H   H
M     ( !V!P! &5X.3DM,2YH=&U02P$"% ,4    "  TAD13OD.L4M@+   8
M,0  "@              @ %\*0$ 97@Y.2TR+FAT;5!+ 0(4 Q0    ( #2&
M1%.G\$@RW@P  ,(U   *              "  7PU 0!E>#DY+3,N:'1M4$L!
M A0#%     @ -(9$4V>-U;?1#0  %SH   H              ( !@D(! &5X
M.3DM-"YH=&U02P$"% ,4    "  TAD13Z_OY-A4,  !I-   "@
M    @ %[4 $ 97@Y.2TU+FAT;5!+ 0(4 Q0    ( #2&1%.@_VO_I T  -,Y
M   *              "  ;A< 0!E>#DY+38N:'1M4$L! A0#%     @ -(9$
M4_YI(\QQ(   !_\   L              ( !A&H! &9O<FTX+6LN:'1M4$L!
M A0#%     @ -(9$4U8Q?P[. P  X@X  !$              ( !'HL! &QF
M;60M,C R,3 Y,C@N>'-D4$L! A0#%     @ -(9$4Z^'K.C^"   N6@  !4
M             ( !&X\! &QF;60M,C R,3 Y,CA?9&5F+GAM;%!+ 0(4 Q0
M   ( #2&1%-&P4#,]0L  %R0   5              "  4R8 0!L9FUD+3(P
M,C$P.3(X7VQA8BYX;6Q02P$"% ,4    "  TAD13QT!&UT4(  !-8P  %0
M            @ %TI $ ;&9M9"TR,#(Q,#DR.%]P<F4N>&UL4$L%!@     0
- !  I ,  .RL 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
